Compositions and methods for organ transplantation

By tethering bioorthogonal azides to donor grafts for localized PD-L1 delivery, the method addresses the limitations of systemic immunosuppression, improving graft survival and function by mitigating ischemia-reperfusion injury and chronic rejection.

WO2026241231A1PCT designated stage Publication Date: 2026-11-19DUKE UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2026/027740
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-12
Filing Date
2026-05-12
Publication Date
2026-11-19

AI Technical Summary

Technical Problem

Current immunosuppressive therapies in organ transplantation lack spatial and antigenic specificity, leading to chronic rejection and limited graft longevity, while the shortage of donor organs complicates access to transplantation.

Method used

The method involves modifying donor grafts ex vivo by covalently tethering bioorthogonal azides to the vascular interface, enabling localized delivery of immunomodulatory therapies like PD-L1, thereby mitigating ischemia-reperfusion injury and reshaping local immune activation.

Benefits of technology

This approach enhances graft survival and function by reducing chronic rejection and preserving renal function, even under conditions of prolonged cold ischemia, while maintaining the integrity of the transplanted organ.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2026027740_19112026_PF_FP_ABST
    Figure US2026027740_19112026_PF_FP_ABST
Patent Text Reader

Abstract

Disclosed herein are compositions and methods for preparing a donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells for transplantation using the Surface Tethered Engineered Alloprotective Ligands for Transplant Health (STEALTH) protocol or using the Orthogonal Reactive Group Addition for Narrowed Immunosuppressant Capture (ORGANIC) protocol.
Need to check novelty before this filing date? Find Prior Art

Description

COMPOSITIONS AND METHODS FOR ORGAN TRANSPLANTATIONI. CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims priority to U.S. Provisional Application No. 63 / 804,029 filed 12 May 2025, which is incorporated herein in its entirety.II. BACKGROUND

[0002] Solid organ transplantation represents one of the most transformative achievements of modem medicine, converting once-fatal organ failure into a chronic, manageable condition. Yet despite remarkable advances in surgical technique, donor management, and immunosuppressive pharmacology, long-term graft survival has plateaued. In kidney transplantation, one-year graft survival now exceeds 93%, but median graft survival remains only 8-12 years (Lentine KL, et al. (2024) Am J Transplant. 24(2S 1): S 19-S 118; Poggio ED, et al. (2021) Am J Transplant.21(8)12824-2832). These gains in early outcomes have not translated into durable immune tolerance, and chronic allograft injury remains the principal cause of late graft loss. (Poggio ED, et al. (2021) Am J Transplant. 21(8)12824-2832; Alasfar S, et al. (2023) J Clin Med. 12(15)14927). At the same time, a persistent shortage of donor organs continues to limit access to transplantation, with over 90,000 patients awaiting kidney transplantation in the United States alone (Lentine KL, et al. (2024) Am J Transplant. 24(2S1):S 19-S 118).

[0003] These twin challenges: organ scarcity and limited graft longevity, are biologically linked. The same inflammatory and alloimmune processes that drive chronic rejection also compromise marginal organs, particularly extended criteria donors (ECD) kidneys, contributing to delayed graft function (DGF), discard, and inferior long-term outcomes. (Ahimark A, et al. (2024) Transpl Int. 37:12309). Contemporary immunosuppression has achieved potency, but not precision. Systemically administered agents prevent early rejection at the cost of nephrotoxicity, infection, malignancy, and metabolic complications (Poggio ED, et al. (2021) Am J Transplant. 21 (8)12824-2832; Farouk SS, et al. (2020) Adv Chronic Kidney Dis. 27(1)156-66; Szumilas K, et al. (2023) Int J Mol Sci. 24(12); Fishman JA. (2017) Am J Transplant. 17(4)1856-879). Thus, the central limitation of current transplant immunotherapy is not insufficient strength, but insufficient spatial and antigenic specificity.

[0004] What is needed are methods of addressing the limitations of systemic immunosuppression and improving long term graft outcomes. The compositions and methods disclosed herein advance the engineering of the transplanted graft itself, specifically its vascular interface, to be a therapeutic substrate. By directly modifying donor grafts ex vivo, it may be possible to mitigate ischemia-reperfusion injury (IRI), reshape local immune activation, and localize immunomodulatory therapies to the site of antigen exposure.III. BRIEF DESCRIPTION OF THE FIGURES

[0005] FIG. 1A - FIG. 1H show that mammalian cell surface functionalization with bioorthogonal azides preserved endothelial viability. FIG. 1A is a schematic illustrating NHS-ester-mediated covalent conjugation of PEG-azide tethers to primary' amines on mammalian cell surface proteins, enabling subsequent click-based capture of cyclooctyne-modified probes. FIG. IB shows a flow cytometry gating strategy used to assess cell viability and quantify DBCO probe capture on azide-modified HUVECs. FIG. 1C shows the viability of HUVECs following incubation with NHS-PEG4-azide (75 pM or 100 pM) for 0.5 hr - 1 hr. Data were analyzed by two-way ANOVA with Sidak’s multiple-comparisons test. FIG. ID show- the fold change in median fluorescence intensity (MFI) following incubation with DBCO-Alexa Fluor 488, normalized to unmodified controls, demonstrating dose- and time-dependent incorporation of bioorthogonal tethers. Data were analyzed by two-way ANOVA with Tukey’s multiplecomparisons test. FIG. IE shows the representative fluorescence microscopy images showing robust surface-associated DBCO-647 signal on azide-modified HUVECs (bottom) compared with negligible signal in unmodified controls (top). Scale bars are 50 pm. Each symbol represents an individual well of HUVECs (n = 3 independent wells per condition). FIG. IF shows a schematic of intra-arterial delivery' of NHS-PEG4-azide via the renal artery, with distribution through the segmental and interlobular arterioles, passage across the glomerular filtration barrier, and transit into Bowman’s space and tubular compartments, resulting in azide tether incorporation across endothelial, epithelial and collecting system surfaces throughout the kidney. FIG. 1G shows confocal microscopy of unmodified kidneys stained with DBCO-Cy5.5, demonstrating minimal background signal. FIG. 1H shows confocal microscopy of azide-modified kidneys following incubation with DBCO-Cy5.5, showing robust, homogenous labeling across glomerular, tubular, and vascular substructures, consistent with widespread biorthogonal functionalization.

[0006] FIG. 2A - FIG. 21 shows long-term persistence of covalently bound fluorophores on transplanted kidneys in vivo. FIG. 2A is a schematic illustrating amine-reactive NHS chemistry for covalent conjugation of fluorophores to donor kidney tissue. FIG. 2B shows a photographic overview of the experimental workflow, including donor kidney isolation, ex vivo fluorescent labeling, and orthotopic transplantation. FIG. 2C is a representative pre-transplant fluorescence imaging demonstrating robust graft-associated signal following 30 min ex vivo labeling with NHS-Alexa Fluor 647 (100 pM). FIG. 2D shows in vivo fluorescence imaging showing positional dependence of signal detection from the transplanted left (L) kidney, with maximal signal observed when recipients are imaged in the right lateral position. FIG. 2E shows the longitudinal in vivo imaging demonstrating graft-confined AF647 signal followingtransplantation. FIG. 2F shows the quantification of graft-associated fluorescence intensity compared with contralateral native kidney autofluorescence over time. FIG.2G shows quantified graft fluorescence at 5 weeks post-transplant, demonstrating significantly elevated signal relative to native kidneys (Welch’s t-test). Each symbol represents an individual transplanted animal (n = 4). FIG. 2H shows ex vivo fluorescence imaging of explanted organs at the terminal time point showing persistent labeling of transplanted kidneys compared with native contralateral kidneys. FIG. 21 shows representative images of non-target organs demonstrating absence of detectable fluorophore accumulation or evidence of tether shedding (Lu = lung, H = heart, T = thymus, L = liver, S = spleen, N = native kidney, asterisk = modified graft).

[0007] FIG. 3A - FIG. 3G show transplanted azide-functionalized kidneys selectively captured systemically administered probes in vivo. FIG. 3A shows a schematic illustrating azide tether installation on donor kidneys and subsequent bioorthogonal click conjugation with systemically administered DBCO-functionalized fluorophores. FIG.3B is an experimental timeline depicting transplantation of azide-functionalized (Az) kidneys at day 0 followed by intravenous administration of DBCO-Cy5.5 on post-operative day 2. FIG. 3C provides representative longitudinal in vivo fluorescence imaging demonstrating transient systemic circulation of DBCO-Cy5.5 with selective accumulation at the site of the transplanted Az graft and rapid clearance in recipients of unmodified grafts. FIG. 3D provides quantification of Cy5.5 average radiant efficiency measured from size-matched regions of interest over the left lateral flank, demonstrating graft-specific enrichment of DBCO probe signal over time. FIG.3E is a schematic illustrating dual graft labeling with NHS-Alexa Fluor 647 and NHS-azide prior to transplantation, enabling FIG. 3F shows the subsequent in vivo capture of DBCO-Cy7 administered i.v. on day 2. FIG. 3G show representative in vivo fluorescence images demonstrating organ-specific colocalization of pre-installed AF647 signal and captured DBCO-Cy7, supporting selective bioorthogonal capture at the graft.

[0008] FIG. 4A - FIG. 4E show azide-functionalized grafts supported replenishable capture of systemically administered probes. FIG. 4A shows an experimental timeline depicting transplantation of azide-functionalized (Az) kidneys followed by serial intravenous administration of DBCO-Cy5.5 (12 pM, 200 pL) at 5-day intervals. FIG. 4B shows serum creatinine measurements following transplantation and during the first week after initial probe administration, demonstrating preserved early graft function. FIG. 4C shows representative in vivo fluorescence images of Az grafts following zero, one, or three sequential injections of DBCO-Cy5.5, illustrating progressive graft-specific probe accumulation. FIG. 4D shows the longitudinal quantification of graft associated Cy5.5 signal demonstrating stepwise increases insignal following each injection in transplanted animals, compared with probe washout in nontransplanted controls. FIG. 4E shows that cumulative graft-associated fluorescence measured immediately prior to injections on day 0, day 5, day 10, and day 15, demonstrating a linear relationship between repeated dosing and retained signal (linear regression, R2= 0.74, P < 0.0001).

[0009] FIG. 5A - FIG. 5G shows the clinically compatible functionalization of porcine kidneys under standard cold storage conditions. FIG. 5A is a representation of a kidney maintained on ice in standard cold storage conditions, as used for donor organ preservation in clinically deployed solutions such as UW Belzer. FIG.5B show that gravity-driven perfusion setup used to flush and chemically functionalize intact kidneys ex vivo without active pumping or supraphysiologic pressures. FIG.5C shows an experimental workflow depicting organ procurement and immediate flush with UW Belzer (to-ti), removal of preservation solution using Plasmalyte (250 ml; ti-t2), infusion of NHS-PEGi-azide (ORGANIC) for a 15 min reaction period (t2-ts), and final Plasmalyte flush to remove unreacted reagent 03-t4). FIG. 5D provides the quantification of primary amine content in serially collected outflow during the Plasmalyte flush (ti-t2), measured by TNBSA assay, demonstrating efficient removal of amine-containing components from preservation solution and residual blood proteins. FIG.5E shows the introduction of NHS-PEG4-azide during the ORGANIC reaction phase (t2-ts) under cold storage conditions. FIG. 5F shows a schematic of the strain-promoted azide-alkyne cycloaddition (SPAAC) reaction between azide groups and DBCO, with inset showing representative UV-Vis spectra illustrating loss of characteristic DBCO absorbance peaks at 292 nm and 309 nm following reaction. FIG.5G shows an approximation of azide tether content in inflow vs outflow solutions following the 15-minute reaction period (t2-ts) shows that most tethers remain graft bound (n = 3 organs).

[0010] FIG.6A - FIG.6H shows the protein-level and spatial validation of ORGANIC-mediated azide installation and macromolecular capture in porcine kidneys. FIG. 6A shows photographs of kidneys during gravity perfusion with interval wedge biopsies before and after closing the biopsy defect (biopsy site indicated by white asterisk). FIG. 6B shows representative 5 pm sections of fixed porcine kidney tissue from unmodified control kidneys and kidneys modified with NHS-PEG4-azide under cold storage conditions, stained with DBCO-647 to detect tissuebound azide groups. Unmodified kidneys exhibit minimal background signal, whereas ORGANIC -modified kidneys display robust and homogeneous DBCO-647 fluorescence across renal substructures, including tubules (T), glomeruli (G), and vascular structures (V). Notably, glomeruli characterized by low autofluorescence in control tissue show ubiquitous DBCO-647 signal in modified kidneys with clearly defined luminal spaces, consistent with uniform surface functionalization. DBCO-647 signal localizes broadly to cellular membranes throughout thesection. Scale bar =100 pm. FIG. 6C shows Coomassie-stained SDS-PAGE gel showing total protein content of tissue lysates collected prior to modification (Pre) and after azide installation (Az). FIG.6D provides in-gel fluorescence demonstrating DBCO-488 binding to azide-modified proteins in tissue lysates. FIG. 6E shows quantification of integrated fluorescent intensity showing significantly increased DBCO-488 signal in azide-modified lysates compared to unmodified controls. FIG. 6F shows Coomassie-stained SDS-PAGE gel showing total protein content of lysates collected azide installation (Az) and following perfusion with DBCO-mTet.FIG. 6G provides the in-gel fluorescence of mTet. FIG. 6H shows the quantitative analysis of integrated fluorescence intensity demonstrating significantly increased TCO-488 signal in mTet-perfused samples, confirming functional azide-DBCO ligation and macromolecular capture within porcine kidney tissue.

[0011] FIG.7A - FIG. 7G show the optimization of near-infrared probe detection parameters for IVIS imaging. FIG. 7A shows serial dilutions of fluorescent probes prepared in 1 x DPBS over a concentration range of 100 pM to 0.78125 pM (100 pM, 50 pM. 25 pM, 12.5 pM. 6.25 pM, 3.125 pM, 1.5625 pM, and 0.78125 pM) in 10 pL volumes, plated in triplicate and imaged using an IVIS Spectrum system. FIG. 7B shows total photon flux measured from regions of interest (ROIs) over AF647-NHS probe droplets plotted as a function of probe concentration. FIG. 7C shows the corresponding signal-to-noise ratio (SNR) for AF647-NHS across concentrations. FIG.7D shows total photon flux measured from ROIs over Cy7-DBCO probe droplets plotted as a function of probe concentration. FIG. 7E shows the corresponding SNR for Cy7-DBCO across concentrations. FIG. 7F shows total radiant efficiency measured from ROIs over sCy5.5-DBCO probe droplets across excitation and emission filter settings. FIG. 7G shows corresponding SNR for sCy5.5-DBCO across filter settings.

[0012] FIG. 8A - FIG. 8D show the identification and mitigation of diet-associated autofluorescence in near-infrared in vivo imaging. FIG. 8A shows the in vivo IVIS imaging of a representative kidney transplant recipient bearing a donor graft pre-labeled with NHS-AF647 and NHS-azide before and after systemic administration of DBCO-Cy7. Top row: imaging at Ex 640nm / Em Cy5.5 to detect graft-bound AF647 signal before and after probe injection. Bottom row: imaging at Ex 745 nm / Em ICG to detect captured DBCO-Cy7 signal. Notably, detectable signal is observed superior to the transplanted kidney in the DBCO-Cy7 channel prior to probe injection. FIG. 8B shows the anatomical schematic of rat abdominal organs highlighting the relative superior position of the stomach with respect to the transplanted kidney, alongside ex vivo IVIS imaging of explanted tissues. The stomach exhibits pronounced autofluorescence compared to the AF647-labeled graft and unmodified contralateral native kidney. FIG. 8C shows the IVISimaging of standard rodent chow (LabDiet 5001; bottom row) and an alfalfa-free, imaging-optimized diet (LabDiet 5V75; top row) across relevant excitation and emission filter sets, demonstrating robust near-infrared autofluorescence associated with standard chow. FIG. 8D shows longitudinal whole-body IVIS imaging of a representative animal transitioned from standard chow to the alfalfa-free diet (5V75), imaged daily across fluorophore settings. Quantification and representative images demonstrate a marked reduction in background autofluorescence by four days following dietary switch.

[0013] FIG. 9A - FIG. 9D shows that gravity -driven perfusion achieved uniform distal cortical delivery in porcine kidneys. FIG. 9A is a schematic of the gravity perfusion setup and flush sequence used to assess distal cortical perfusion using filtered Alcian blue (<1% w / v). FIG. 9B shows a gross photograph of a porcine kidney following procurement, vascular cannulation, and ex vivo flushing on ice with 250 mL UW Belzer solution followed by 250 mL Plasmalyte. FIG.9C shows a cross photograph of a porcine kidney following gravity perfusion with 40 mL of filtered Alcian blue solution, demonstrating macroscopic dye distribution. FIG. 9D shows a histologic assessment of cortical perfusion. Top row: representative images from a bisected control kidney that did not receive Alcian blue, sectioned and counterstained with periodic acid-Schiff (PAS), with 12 randomly selected glomeruli from the outer cortex evaluated for dye presence. Middle and bottom rows: representative gross and histologic images from two kidneys perfused with the Alcian blue sequence, similarly sectioned, PAS-counterstained, and analyzed with 12 randomly selected outer cortical glomeruli per kidney. Alcian blue was detectable to varying degrees in all analyzed glomeruli from perfused kidneys, whereas no Alcian blue signal was observed in glomeruli from unperfused controls, indicating effective delivery of perfusate to distal cortical microvasculature under gravity -driven conditions.

[0014] FIG. 10A - FIG. 10D show a quantitative UV-Vis analysis of residual NHS-PEG-azide in perfusate during ORGANIC modification of porcine kidneys. FIG. 10A shows UV-Vis spectra of DBCO following reaction with the initial NHS-PEG4-azide inflow solution (500 pM) for 15 min, 30 min, or 60 min, compared with outflow solution alone, confirming time-dependent consumption of DBCO in the presence of azide. FIG. 10B shows UV-Vis spectra of DBCO reacted with outflow collected after the 15 min ORGANIC reaction period, demonstrating markedly reduced DBCO consumption relative to inflow, consistent with extensive binding of NHS-PEG4-azide to the kidney and minimal residual azide in the effluent. Quantification of DBCO absorbance at 292 nm (FIG. 10C) and 309 nm (FIG. 10D) following reaction of DBCO with samples collected from either the ORGANIC inflow perfusate or outflow perfusate before and after the 15 min NHS-PEG-azide incubation period. DBCO absorbance provides a readout ofresidual, unreacted azide groups capable of undergoing SPAAC chemistry. Samples were incubated with DBCO and absorbance measured at 15 min, 30 min, and 60 min to assess timedependent reaction kinetics. Quantitative analysis demonstrates robust loss of DBCO signal when reacted with inflow NHS-PEG-azide solution, whereas outflow samples collected after the 15 min reaction period exhibit significantly reduced DBCO consumption, consistent with depletion of free NHS-PEG-azide due to graft binding. Data represent mean± SEM from n = 3 porcine kidneys. Statistical significance was assessed by two-way ANOVA with Sidak multiplecomparisons correction at each time point.

[0015] FIG. 11A - FIG. 11B shows the engineering and characterization of bioorthogonally tethered murine PD-L1 for graft-localized immune modulation. FIG. 11A shows a mechanistic schematic illustrating PD-1 / PD-L1 signaling at the graft cell-T cell interface. Engagement of PD-1 on activated T cells by PD-L1 expressed on graft cells attenuated T cell receptor (TCR) signaling, suppressed effector T cell proliferation and cytokine production, and promoted regulatory T cell (Treg) activity, providing the physiological basis for localized immune modulation at the graft surface. FIG. 11B shows an overview of the STEALTH two-step bioorthogonal surface-tethering strategy for graft-directed checkpoint presentation. Step 1: azide functional groups are introduced onto accessible primary amines of cell-surface glycoproteins and proteoglycans using NHS-ester chemistry, generating a chemically addressable graft surface.Step 2: an engineered PD-L1 ligand bearing a dibenzocyclooctyne (DBCO) moiety is covalently attached through strain-promoted azide-alkyne cycloaddition (SPAAC), enabling rapid and stable immobilization under physiological conditions without genetic modification.

[0016] FIG. 12A - FIG. 12H show the generation of clickable PD-L1 fusion proteins. FIG. 12A - FIG. 12B show one-pot synthesis of a DBCO-PEG-modified PD-L1 ectodomain (FIG. 12A) followed by (FIG. 12B) ultracentrifugation to remove unreacted linker groups. FIG. 12C provides a schematic representation of the human PD-L1 (hPD-Ll) fusion protein used for surface tethering. The construct comprised the extracellular domain of PD-L1, which contains the IgV and IgC immunoglobulin-like domains responsible for PD-1 engagement (RCSB PDB: 3BIS). PEG-linked DBCO moiety provided the reactive handle for bioorthogonal conjugation to azi demodified cell surfaces. FIG. 12D shows the UV-Vis absorbance spectra of unmodified PD-L1 and DBCO-conjugated PD-L1 (DBCO-hPDLl). The modified protein retained the characteristic protein absorbance peak at 280 nm and exhibited an additional peak at 309 nm corresponding to the cyclooctyne group, confirming successful DBCO conjugation. FIG. 12E shows a dynamic light scattering analysis demonstrating a monodisperse size distribution of DBCO-PDL1 with a hydrodynamic diameter centered at ~8.7 nm (normalized intensity), consistent with successfulchemical modification while preserving protein solubility and preventing aggregation. FIG. 12F shows a schematic representation of the murine PD-L1 ectodomain fusion protein used for surface tethering fused to an Fc region to enhance stability’ and dimerization (RCSB PDB: 3BIS). A biotin handle enabled dow nstream detection. FIG. 12G - FIG. 12H show' a spectroscopic confirmation of DBCO modification (FIG. 12G) and protein size near 12 nm for the modified protein (FIG.12H)

[0017] FIG. 13A - FIG. 13K shows that surface-presented PD-L1 suppressed T cell proliferation and enhances FoxP3+regulatory' T cell differentiation in vitro. FIG. 13A shows the flow' cytometric characterization of murine splenocytes before and after magnetic sorting for naive CD4+T cells, demonstrating effective depletion of CD8+cells and enrichment of the CD4+population (gated on BV570-anti-CD4 and PE-Cy5-anti-CD8a). FIG. 13B shows cell viability before (Pre-Sort) and after sorting (Sorted), showdng preserved viability' following enrichment.FIG. 13C - FIG. 13D shows the quantification of CD4+and CD8+lymphocyte frequencies pre-and post-sorting, confirming selective isolation of CD4+cells. FIG. 13E shows the percentage of FoxP3+cells within the CD4+compartment before and after sorting. FIG. 13F provides a schematic of the in vitro T cell activation assay using surface-bound anti-CD3 and soluble anti-CD28 to induce T cell activation and proliferation. FIG. 13G shows representative CMFDA dilution profiles demonstrating robust T cell proliferation from Day 0 to Day 5 following stimulation; unstained controls are shown for reference. FIG. 13H shows a schematic of the modified activation assay incorporating surface-presented DBCO-PDL1 concurrent with anti-CD3 and anti-CD28 stimulation, with the expected outcome of attenuated T cell activation and enhanced regulatory T cell differentiation (n = 3 independent wells per treatment condition). FIG.131 shows CMFDA fluorescence profiles at Day 5 for unstimulated cells, stimulated untreated cells, stimulated cells with soluble PD-L1, and stimulated cells with surface-presented DBCO-PDL1. FIG. 13J show' the percentage of CD45+CD8"CD4+T cells expressing FoxP3, demonstrating a significant increase in FoxP3+cells in PD-Ll-treated conditions compared with unstimulated controls. FIG. 13K shows the mean fluorescence intensity (MFI) of FoxP3 expression within the FoxP3+CD4+population, showing the highest FoxP3 signal in the DBCO-PD-L1 condition, significantly exceeding all other groups, including soluble PD-L1. A one-w ay ANOVA with Tukey’s multiple comparisons were performed, n = 3 independent wells studied.

[0018] FIG. 14A - FIG. 14J show that prolonged cold ischemia sensitized rat kidney transplants to early dysfunction and graft failure. FIG. 14A is a schematic of the rat kidney transplant workflow illustrating periods of warm ischemia during donor procurement and recipient implantation separated by a cold preservation interval during which grafts are stored on ice.During this preservation phase, grafts received sequential vehicle saline injections to replicate the procedural timing used in subsequent STEALTH modification studies involving NHS-azide and PD-L1-DBCO delivery. FIG. 14B shows post-implantation vascular and ureteral anatomy. The renal artery (a.) is anastomosed using a short 24-gauge catheter stent (1.5 mm - 2 mm), the renal vein (v.) is connected using a cuff technique with a 14-gauge catheter (2.5 mm - 3 mm), and the ureter (u.) is reconstructed via uretero-ureteral anastomosis supported by a MicroLumen stent with an inner diameter of 0.55 mm. Representative photograph of a transplanted kidney with corresponding anatomical landmarks is shown. FIG. 14C shows vehicle-controlled syngeneic (iso* ) and allogeneic (allo* ) grafts subjected to the extended preservation workflow experienced significantly prolonged cold ischemia times (iso* mean = 129 min; allo* mean = 127.5 min) relative to standard isograft (83 min) and allograft (61.5 min) procedures. FIG. 14D shows warm ischemia times were not significantly different between experimental groups. FIG. 14E - FIG.14F show longitudinal assessment of renal function following transplantation showing elevated serum creatinine (FIG. 14E) and blood urea nitrogen (BUN) (FIG. 14F) in iso* and allo* recipients compared with standard transplant controls. FIG. 14G - FIG. 14H show severe renal dysfunction is detectable in allo* recipients by post-transplant day 2, as reflected by significantly increased creatinine levels (FIG. 14G) and BUN levels (FIG. 14H). FIG. 141 - FIG. 14J are Kaplan-Meier survival analysis demonstrating accelerated graft failure in allo* recipients, with all animals reaching humane endpoints by post-transplant day 3. and reduced survival in iso* recipients relative to standard isografts. Groups evaluated by one-way ANOVA with Tukey’s multiple comparisons, n = 3-4 independent transplants per group.

[0019] FIG. 15A - FIG. 15C provide histopathologic evidence of graft injury following prolonged cold ischemia. FIG. 15A shows representative hematoxylin and eosin (H&E)-stained sections comparing native kidney tissue with iso and allo grafts subjected to extended cold preservation. Pathologic features include endothelial cell swelling and occlusion of glomerular capi 11 ary loops (white arrows)' , interstitial leukocyte infiltration (black asterisk), and tubular inj ury characterized by epithelial atrophy and eosinophilic casts within tubules (black arrows). FIG.15B show a blinded quantitative Banff-style scoring demonstrating increased glomerulitis (g), peritubular capillaritis (ptc), interstitial fibrosis (ci), and tubular atrophy (ct) in iso* grafts compared with standard isografts. Allo* grafts exhibited heterogeneous but frequently severe injury', with some specimens displaying extensive necrosis that precluded formal Banff scoring.FIG. 15C shows representative macroscopic images of whole-kidney tissue sections illustrating marked variability in injury severity across experimental groups, ranging from preserved renal architecture to widespread necrosis and tissue autolysis. Together, these findings demonstratethat prolonged cold ischemia under non-optimal preservation conditions markedly exacerbates renal graft injury, establishing a stringent platform for evaluating graft-directed immunomodulatory rescue strategies.

[0020] FIG. 16A - FIG. 16F show graft-localized PD-L1 delivery' preserved renal function and survival in a fully mismatched rat kidney transplant model. FIG. 16A is a schematic of the STEALTH graft modification and transplantation workflow. Donor kidneys were procured and maintained on ice while undergoing sequential intra-arterial delivery of an azide tether (100 pM, 250 pL), followed by PBS washout and conjugation of PD-L1-DBCO (5 pg or 25 pg in 250 pL PBS). Each modification step included a 30-min incubation interval to permit surface conjugation prior to implantation. Here, shown is an overview of experimental groups including syngeneic Lewis-to-Lewis transplants, untreated allogeneic Lewis-to-Brown Norway transplants, and allogeneic grafts modified using STEALTH to display surface-bound PD-L1 at two doses (PDL1_5 or PDL1_25). FIG. 16B - FIG. 16C provide serum creatinine levels (FIG. 16B) and BUN levels (FIG. 16C) measured longitudinally following transplantation. Untreated allogeneic recipients exhibited rapid loss of renal function, reaching humane endpoints by post-transplant day 3. In contrast, recipients of PD-L1 -modified grafts maintained creatinine levels comparable to syngeneic controls during the acute post-transplant period. FIG. 16D and FIG. 16E show that surface-tethered PD-L1 preserves renal function in a cold-ischemia-sensitized allogeneic transplant model. Recipients of PD-L1 -modified grafts maintained renal function during the acute post-transplant period, with the 5 pg cohort exhibiting serum creatinine values comparable to syngeneic controls and the 25 pg cohort supporting preserved graft function through the planned early analysis window. These data demonstrate that graft-localized PD-L1 provides functional protection under stringent transplant conditions. Consistent with these findings, improved graft survival is observed in FIG. 16F. FIG. 16F show a Kaplan-Meier survival analysis demonstrating accelerated graft failure in untreated allogeneic recipients, with 0% survival by day 3. Recipients of PD-L1 -modified grafts showed prolonged survival, with 75% survival through day 7 in the PDL1 5 cohort. Two animals in the PDL1 25 cohort were sacrificed on day 3 for planned tissue analysis and therefore were not included in survival analysis.

[0021] FIG. 17A - FIG. 17G show that STEALTH-mediated PD-L1 delivery preserved renal tissue integrity despite dense immune infiltration. FIG. 17A shows representative H&E and PAS images of PD-L1 -treated grafts (5 pg and 25 pg) illustrating tissue architecture, immune cell infiltrates, and preservation of tubular and vascular structures. FIG. 17B is a heat map of blinded Banff-inspired scoring for interstitial inflammation (i), peritubular capillaritis (ptc), tubular injury / atrophy (ct), and tubulitis (ti), highlighting that conventional metrics alone did notdistinguish PD-Ll-treated grafts from untreated allografts despite preserved function. FIG. 17C shows representative TUNEL staining of native, iso*, allo*, PDL1-5, and PDL1-25 grafts. Allo* kidneys exhibited widespread TUNEL positivity, consistent with severe cellular injury. FIG. 17D shows quantification of TUNEL -positive area across treatment groups, demonstrating significantly higher injury in allo* grafts compared with all other groups. FIG. 17E is a schematic of renal zones (papilla, inner medulla, outer medulla, cortex) overlaid on H&E images, used for subsequent zonal TUNEL quantification. FIG. 17F is a zonal analysis of TUNEL-positive area reveals that the inner medulla is particularly sensitive to cold ischemia, whereas cortical and papillary injury' is more prominent in alloimmune-mediated damage. PDL1-5 grafts show residual injury patterns partially resembling allo*, whereas PDL1-25 grafts exhibited markedly reduced TUNEL staining across all zones, indicating combined protection against ischemia and alloimmune injury'. FIG. 17G is a comparison of TUNEL-positive area across renal zones for all groups, emphasizing that allo* kidneys have higher injury' than other groups in most zones, while inner medullary injury in iso* and PD-Ll-treated grafts reflects sensitivity to cold ischemia rather than alloimmune rejection. Each data point represents the average of 3 high-powered fields per zone per biological replicate. A mixed effects model with Tukey ’s correction was used to compare regions while accounting for repeated measures within samples.

[0022] FIG. 18A - FIG. 18Q show that high-dimensional flow cytometry revealed local Treg enrichment in PD-Ll-treated grafts. FIG. 18A provides a gating strategy applied to kidney’ and spleen single-cell suspensions. FIG. 18B - FIG. 181 shows kidney-infiltrating cells: (FIG. 18B) %CD45+ of live cells, (FIG. 18C) %CD45R+ B cells of CD45+, (FIG. 18D) %CD3+ T cells of CD45+, (FIG. 18E - FIG. 18F) %CD8+ cytotoxic T cells (CTLs) of CD3+, (FIG. 18G) %CD4+Foxp3+CD25+ Tregsof CD4+, (FIG. 18H) Foxp3 MFI, (FIG. 181) CD25 MFI. PDL1-treated grafts exhibited increased immune infiltration and higher Tregpercentages and CD25 expression relative to allo* controls. FIG. 18J - FIG. 18Q shows a splenocyte analysis: (FIG.18J) %CD45+ of live cells, (FIG. 18K) %CD45R+ B cells of CD45+, (FIG. 18L) %CD3+ of CD45+, (FIG. 18M - FIG. 18N) %CD8+ of CD3+, (FIG. 180) %CD4+Foxp3+CD25+ of CD4+, (FIG. 18P) Foxp3 MFI. (FIG. 18Q) CD25 MFI. No significant differences in Tregpercentages were observed systemically, indicating localized immunomodulation. Data are mean ± SD; n = 3-4 per group. Statistical significance determined by one-way ANOVA with Tukey's post hoc test.

[0023] FIG. 19A - FIG. 19F shows that a spatial proteomic profiling of using CODEX revealed regulatory immune niches and tertiary lymphoid structure-like organization. FIG. 19A shows PD-L1 staining across graft conditions demonstrating strong PD-L1 signal in PD-L1 -modifiedallografts consistent with successful STEALTH tethering. Native and iso* grafts show minimal endogenous PD-L1, whereas untreated allogeneic grafts (allo*) exhibit moderate PD-L1 expression likely reflecting inflammation-induced checkpoint upregulation during rejection. FIG.19B shows that multiplex CODEX imaging highlighting structural and immune markers including DAPI, P-catenin, smooth muscle actin (SMA), FoxP3, CD56 (NCAM), and CD20. -catenin delineates renal tubular epithelium, while SMA outlines vascular structures. CD56 localizes to cells lining Bowman’s capsule surrounding glomeruli, consistent with renal progenitor-like epithelial populations involved in injury repair. FIG. 19C provides that FoxP3+ regulatory' T cells distributed throughout the graft parenchyma with clustering near vascular structures and hilar regions. FIG. 19D provides that FoxP3+ cells observed near arteriolar structures associated with glomeruli, including regions corresponding to the juxtaglomerular apparatus. FIG. 19E provides a representative image of a FoxP3+ cell undergoing diapedesis across vascular endothelium, indicating active recruitment of regulatory' cells into graft tissue. FIG. 19F provides that Ki67 staining that highlights proliferative activity’ surrounding glomeruli, consistent with activation of reparative cellular programs following transplant injury. Spatial clustering of FoxP3+ T cells with CD20+ B cells in the hilar region forms structures resembling tertiary lymphoid structures (TLSs), which have been implicated in both graft rejection and tolerance depending on cellular composition and regulatory signaling.

[0024] FIG.20A - FIG.20H shows that spatial proteomic analysis defined zonal immune niches.FIG. 20A shows CODEX-derived Leiden clustering based on marker expression and spatial proximity, demonstrating alignment with manually-assigned anatomical renal zones. FIG. 20B shows protein expression profiles by renal zone highlighting region-specific marker signatures.FIG.20C shows PD-L1 signal intensity across zones showing relatively uniform distribution with reduced signal in the papillary region. FIG.20D - FIG.20H show representative markers (TIM1, CD1 lb, FoxP3, CD20, Ki67) demonstrating enrichment within the renal hilum, consistent with localized immune organization. Combined clustering and marker distribution indicate formation of organized immune niches within the hilar region.

[0025] FIG. 21A - FIG. 21B show exemplary DBCO-modifi cation of PDL1. FIG. 21A shows the degree of labeling of human PD-L1 following modification with DBCO-PEG-NHS at molar ratios of 7:1 and 15:1, demonstrating increased incorporation of DBCO w th higher reagent excess. FIG. 21B provides an SDS-PAGE analysis of unmodified human PD-L1 and DBCO-modified PD-L1 (7:1 reaction), stained with Coomassie blue. Both conditions exhibited a dominant band at the expected molecular weight of approximately 36 kDa, consistent with glycosylated PD-L1. The comparable band pattern and absence of higher molecular w eightspecies indicated preservation of protein integrity without detectable aggregation following bioorthogonal modification.

[0026] FIG.22 shows that TUNEL correlated with PDL1 Localization. Side-by-side comparison of PD-L1 immunofluorescence and TUNEL staining in untreated and PD-L1 -treated allografts. Regions lacking PD-L1 signal correspond to areas of increased TUNEL positivity, consistent with an association between PD-L1 localization and preserved tissue viability.

[0027] FIG. 23 shows that Z-Score normalized spatial proteomics in PDL1 -treated graft. Normalized protein expression across marker classes, including immune, stromal, activation, and injury -associated markers, illustrating coordinated changes in the graft microenvironment.

[0028] FIG. 24 shows that PD-1 localization in kidney grafts revealed papillary and urothelial-specific expression. Multiplex CODEX imaging of PD-1 expression across native (upper left), ischemia-sensitized isograft (iso*) (upper right), ischemia-sensitized allograft (allo*) (bottom left), and PD-L1 -modified (PDL1-5) (bottom right) kidney sections. Across all conditions, PD-1 staining demonstrated consistent and spatially restricted localization to the renal papilla and urothelial lining of the calyx, independent of alloimmune status or PD-L1 modification. Minimal PD-1 signal was observed within the cortical and medullary parenchyma. This conserved distribution pattern indicates that, in the rat kidney, PD-1 may mark papillary and urothelial cell populations rather than exclusively reflecting infiltrating immune cells.

[0029] FIG.25 shows CODEX validation of germinal center and lymphoid architecture markers in rat spleen. Multiplex CODEX imaging of rat spleen demonstrating spatial localization and coexpression of immune and stromal markers used for kidney tissue analysis. Whole-spleen overview highlighting white pulp and red pulp organization. Co-localization of CD 19, TIM-1 (KIM-1), and Ki67 within germinal center regions of the white pulp, indicating proliferative B cell niches and validating marker performance for identifying lymphoid aggregates. Podoplanin (PDPN) staining delineating stromal reticular networks within T cell zones and along follicular boundaries, consistent with fibroblastic reticular and marginal reticular cell populations. CD27 expression identify ing activated and memory lymphocyte populations localized to the white pulp and follicular periphery. Together, these staining patterns recapitulate canonical splenic microarchitecture and support the specificity and spatial interpretability of the CODEX marker panel applied to kidney graft tissue.

[0030] FIG.26A - FIG. 26D shows spatial clustering and regional marker expression in PD-L1-treated and untreated allograft kidneys. FIG. 26A provides the Leiden clustering of multiplex CODEX data from a PD-L1 -modified (PDL1-5) kidney section based on marker expression and spatial proximity, demonstrating concordance with manually defined renal anatomical regions.FIG. 26B shows corresponding heatmap of z-score-normalized marker expression across segmented renal zones, highlighting region-specific enrichment of immune and structural markers. FIG. 26C provides the Leiden clustering of an untreated ischemia-sensitized allograft (allo*) section showing reduced cluster definition consistent with disrupted tissue architecture.FIG. 26D provides an associated heatmap demonstrating globally diminished marker signal across regions in allo* tissue, consistent with widespread apoptosis and loss of viable cellular structure.

[0031] FIG. 27 A - FIG. 27D show a concurrent porcine kidney allotransplant operating room workflow. FIG.27A - FIG. 27B shows recipient animals were cared for by dedicated anesthesia and husbandry staff and operations were performed by teams of surgeons moving between the donor pig table (FIG. 27C) where organ procurement was performed and the recipient tables for preparation and implantation. FIG. 27D shows the ex vivo modifications were performed in sterile fashion at a dedicated work bench within the operating room.

[0032] FIG. 28A - FIG. 28C show a clinically compatible functionalization of porcine kidneys under standard cold storage conditions. FIG. 28A shows a representation of a kidney maintained on ice in standard cold storage conditions, as used for donor organ preservation in clinically deployed solutions such as University of Wisconsin (UW) Belzer. FIG. 28B shows a gravity-driven perfusion setup used to flush and chemically functionalize intact kidneys ex vivo without active pumping or supraphysiologic pressures. FIG.28C show experimental workflow depicting organ procurement and immediate flush with UW Belzer (to-ti), removal of preservation solution using Plasmalyte (250 ml; ti-t2), infusion of NHS-PEG4-azide (Step 1 of STEALTH) for a 15 min reaction period (t2-ts), and final Plasmalyte flush to remove unreacted reagent (ty-14) before introducing PDL1-DBCO for an additional 15 min reaction period.

[0033] FIG.29 provides an exemplary explantation, STEALTH modification, and transplantation workflow. Shown herein are the step-wise organ procurement, preservation solution exchange, and sequential STEALTH modification with azide tethers and DBCO-PDL1 prior to recipient implantation.

[0034] FIG.30 A - FIG. 30F show post-transplant renal function and PD-L1 detection in porcine kidney transplantation. FIG. 30A - FIG. 30E show a longitudinal assessment of renal function in autotransplant and allotransplant recipients. Metrics include serum creatinine (FIG. 30A), blood urea nitrogen (FIG. 30B), 24-hr. urine output (FIG. 30C), sodium (FIG. 30D), and potassium (FIG. 30E). Data are presented as mean and SEM values for n = 2 animals per group.FIG. 30F shows ELISA detection of human PD-L1 (hPD-Ll) in urine and serum. Detectable hPD-Ll is observed in urine on postoperative day 1, likely representing unbound protein, with nodetectable signal at later timepoints or in serum. Data for ELISA shown for n = 1 autotransplant; follow-up studies are ongoing.IV. BRIEF SUMMARY

[0035] Disclosed herein is a method of preparing a donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells for transplantation, the method comprising subjecting the donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells to the Orthogonal Reactive Group Addition for Narrowed Immunosuppressant Capture (ORGANIC) protocol.

[0036] Disclosed herein is a method of preparing a donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells for transplantation, the method comprising functionalizing a donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells ex vivo by installing reactive groups on the donor organ.

[0037] Disclosed herein is a method of preparing a donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells for transplantation, the method comprising functionalizing a donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells by installing azide tethers or azide handles on the donor organ.

[0038] Disclosed herein is a method of preparing a donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells for transplantation, the method comprising installing reactive groups on a donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells ex vivo, thereby functionalizing the donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells for subsequent capture of circulating therapeutic payloads or therapeutic molecules.

[0039] Disclosed herein is a method of preparing a donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells for transplantation, the method comprising installing azide tethers or azide handles on a donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells, thereby functionalizing the donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells for subsequent capture of circulating therapeutic payloads or therapeutic molecules.

[0040] Disclosed herein is a method of preparing a donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells for transplantation, the method comprising installing reactive groups on a donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells ex vivo, thereby functionalizing the donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells for subsequent capture of circulating payloads or circulating molecules.

[0041] Disclosed herein is a method of preparing a donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells for transplantation, the method comprising installing azide tethers or azide handles on a donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells, thereby functionalizing the donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells for subsequent capture of circulating payloads or circulating molecules.

[0042] Disclosed herein is a method of preparing a donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells for transplantation, the method comprising procuring an organ from a donor; and subjecting the donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells to the Orthogonal Reactive Group Addition for Narrowed Immunosuppressant Capture (ORGANIC) protocol.

[0043] Disclosed herein is a method of preparing a donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells for transplantation, the method comprising procuring an organ from a donor; and functionalizing a donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells ex vivo by installing reactive groups on the donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells.

[0044] Disclosed herein is a method of preparing a donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells for transplantation, the method comprising procuring an organ from a donor; and functionalizing a donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells by installing azide tethers or azide handles on the donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells.

[0045] Disclosed herein is a method of preparing a donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells for transplantation, the method comprising procuring an organ from a donor; and installing reactive groups on a donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells ex vivo, thereby functionalizing the donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells for subsequent capture of circulating therapeutic payloads or therapeutic molecules.

[0046] Disclosed herein is a method of preparing a donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells for transplantation, the method comprising procuring an organ from a donor; and installing azide tethers or azide handles on a donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells, thereby functionalizing the donor organ, portion of a donor organ, donor tissue, connective tissue, orpopulation of cells for subsequent capture of circulating therapeutic payloads or therapeutic molecules.

[0047] Disclosed herein is a method of preparing a donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells for transplantation, the method comprising procuring an organ from a donor; and installing reactive groups on a donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells ex vivo, thereby functionalizing the donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells for subsequent capture of circulating payloads or circulating molecules.

[0048] Disclosed herein is a method of preparing a donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells for transplantation, the method comprising procuring an organ from a donor; and installing azide tethers or azide handles on a donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells, thereby functionalizing the donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells for subsequent capture of circulating payloads or circulating molecules.

[0049] Disclosed herein is a method of prepanng a donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells for transplantation, the method comprising procuring an organ from a donor; subjecting the donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells to the Orthogonal Reactive Group Addition for Narrowed Immunosuppressant Capture (ORGANIC) protocol; and transplanting into a recipient a disclosed functionalized donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells.

[0050] Disclosed herein is a method of preparing a donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells for transplantation, the method comprising procuring an organ from a donor; functionalizing a donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells ex vivo by installing reactive groups on the donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells; and transplanting into a recipient a disclosed functionalized donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells.

[0051] Disclosed herein is a method of preparing a donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells for transplantation, the method comprising procuring an organ from a donor; functionalizing a donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells by installing azide tethers or azide handles on the donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells; andtransplanting into a recipient a disclosed functionalized donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells.

[0052] Disclosed herein is a method of preparing a donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells for transplantation, the method comprising procuring an organ from a donor; installing reactive groups on a donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells ex vivo, thereby functionalizing the donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells for subsequent capture of circulating therapeutic pay loads or therapeutic molecules; and transplanting into a recipient a disclosed functionalized donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells.

[0053] Disclosed herein is a method of preparing a donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells for transplantation, the method comprising procuring an organ from a donor; installing azide tethers or azide handles on a donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells, thereby functionalizing the donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells for subsequent capture of circulating therapeutic payloads or therapeutic molecules; and transplanting into a recipient a disclosed functionalized donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells.

[0054] Disclosed herein is a method of preparing a donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells for transplantation, the method comprising procuring an organ from a donor; installing reactive groups on a donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells ex vivo, thereby functionalizing the donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells for subsequent capture of circulating payloads or circulating molecules; and transplanting into a recipient a disclosed functionalized donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells.

[0055] Disclosed herein is a method of preparing a donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells for transplantation, the method comprising procuring an organ from a donor; installing azide tethers or azide handles on a donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells, thereby functionalizing the donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells for subsequent capture of circulating payloads or circulating molecules; and transplanting into a recipient a disclosed functionalized donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells.

[0056] Disclosed herein is a method of preparing a donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells for transplantation, the method comprising subjecting the donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells to the Surface Tethered Engineered Alloprotective Ligands for Transplant Health (STEALTH) protocol.

[0057] Disclosed herein is a method of preparing a donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells for transplantation, the method comprising functionalizing a donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells ex vivo by installing reactive groups on the donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells; and using the installed reactive groups to immobilize one or more immunomodulatory ligands.

[0058] Disclosed herein is a method of preparing a donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells for transplantation, the method comprising functionalizing a donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells by installing azide tethers or azide handles on the donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells; and using the installed azide tethers or azide handles to immobilize one or more immunomodulatory' ligands.

[0059] Disclosed herein is a method of preparing a donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells for transplantation, the method comprising installing reactive groups on a donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells ex vivo, thereby functionalizing the donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells for subsequent capture of circulating therapeutic payloads or therapeutic molecules: and using the installed reactive groups to immobilize one or more immunomodulatory ligands.

[0060] Disclosed herein is a method of preparing a donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells for transplantation, the method comprising installing azide tethers or azide handles on a donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells, thereby’ functionalizing the donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells for subsequent capture of circulating therapeutic payloads or therapeutic molecules; and using the installed azide tethers or azide handles to immobilize one or more immunomodulatory ligands.

[0061] Disclosed herein is a method of preparing a donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells for transplantation, the method comprising installing reactive groups on a donor organ, portion of a donor organ, donor tissue, connectivetissue, or population of cells ex vivo, thereby functionalizing the donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells for subsequent capture of circulating payloads or circulating molecules; and using the installed reactive groups to immobilize one or more immunomodulatory ligands.

[0062] Disclosed herein is a method of preparing a donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells for transplantation, the method comprising installing azide tethers or azide handles on a donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells, thereby functionalizing the donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells for subsequent capture of circulating payloads or circulating molecules; and using the installed azide tethers or azide handles to immobilize one or more immunomodulatory ligands.

[0063] Disclosed herein is a method of preparing a donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells for transplantation, the method comprising procuring an organ from a donor; and subjecting the donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells to the Surface Tethered Engineered Alloprotective Ligands for Transplant Health (STEALTH) protocol.

[0064] Disclosed herein is a method of preparing a donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells for transplantation, the method comprising procuring an organ from a donor; functionalizing a donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells ex vivo by installing reactive groups on the donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells; and using the installed reactive groups to immobilize one or more immunomodulatory ligands.

[0065] Disclosed herein is a method of preparing a donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells for transplantation, the method comprising procuring an organ from a donor; functionalizing a donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells by installing azide tethers or azide handles on the donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells; and using the installed azide tethers or azide handles to immobilize one or more immunomodulatory ligands.

[0066] Disclosed herein is a method of preparing a donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells for transplantation, the method comprising procuring an organ from a donor: and installing reactive groups on a donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells ex vivo, thereby functionalizing the donor organ, portion of a donor organ, donor tissue, connective tissue, orpopulation of cells for subsequent capture of circulating therapeutic payloads or therapeutic molecules; and using the installed reactive groups to immobilize one or more immunomodulatory ligands.

[0067] Disclosed herein is a method of preparing a donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells for transplantation, the method comprising procuring an organ from a donor; and installing azide tethers or azide handles on a donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells, thereby functionalizing the donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells for subsequent capture of circulating therapeutic payloads or therapeutic molecules; and using the installed azide tethers or azide handles to immobilize one or more immunomodulatory ligands.

[0068] Disclosed herein is a method of preparing a donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells for transplantation, the method comprising procuring an organ from a donor; installing reactive groups on a donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells ex vivo, thereby functionalizing the donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells for subsequent capture of circulating payloads or circulating molecules; and using the installed reactive groups to immobilize one or more immunomodulatory ligands.

[0069] Disclosed herein is a method of preparing a donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells for transplantation, the method comprising procuring an organ from a donor; installing azide tethers or azide handles on a donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells, thereby functionalizing the donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells for subsequent capture of circulating payloads or circulating molecules; and using the installed azide tethers or azide handles to immobilize one or more immunomodulatory ligands.

[0070] Disclosed herein is a method of preparing a donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells for transplantation, the method comprising procuring an organ from a donor; subjecting the donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells to the Surface Tethered Engineered Alloprotective Ligands for Transplant Health (STEALTH) protocol; and transplanting into a recipient a disclosed functionalized donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells.

[0071] Disclosed herein is a method of preparing a donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells for transplantation, the method comprisingprocuring an organ from a donor; functionalizing a donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells ex vivo by installing reactive groups on the donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells; using the installed reactive groups to immobilize one or more immunomodulatory' ligands; and transplanting into a recipient a disclosed functionalized donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells.

[0072] Disclosed herein is a method of preparing a donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells for transplantation, the method comprising procuring an organ from a donor; functionalizing a donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells by installing azide tethers or azide handles on the donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells; using the installed azide tethers or azide handles to immobilize one or more immunomodulatory' ligands; and transplanting into a recipient a disclosed functionalized donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells.

[0073] Disclosed herein is a method of prepanng a donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells for transplantation, the method comprising procuring an organ from a donor; installing reactive groups on a donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells ex vivo, thereby functionalizing the donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells for subsequent capture of circulating therapeutic payloads or therapeutic molecules; using the installed reactive groups to immobilize one or more immunomodulatory' ligands; and transplanting into a recipient a disclosed functionalized donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells.

[0074] Disclosed herein is a method of prepanng a donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells for transplantation, the method comprising procuring an organ from a donor; installing azide tethers or azide handles on a donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells, thereby functionalizing the donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells for subsequent capture of circulating therapeutic payloads or therapeutic molecules; using the installed azide tethers or azide handles to immobilize one or more immunomodulatory' ligands; and transplanting into a recipient a disclosed functionalized donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells.

[0075] Disclosed herein is a method of preparing a donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells for transplantation, the method comprisingprocuring an organ from a donor; installing reactive groups on a donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells ex vivo, thereby functionalizing the donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells for subsequent capture of circulating payloads or circulating molecules; using the installed reactive groups to immobilize one or more immunomodulatory ligands: and transplanting into a recipient a disclosed functionalized donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells.

[0076] Disclosed herein is a method of preparing a donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells for transplantation, the method comprising procuring an organ from a donor; installing azide tethers or azide handles on a donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells, thereby functionalizing the donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells for subsequent capture of circulating payloads or circulating molecules; using the installed azide tethers or azide handles to immobilize one or more immunomodulatory ligands; and transplanting into a recipient a disclosed functionalized donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells.V. DETAILED DESCRIPTION

[0077] The present disclosure describes formulations, compounded compositions, kits, capsules, containers, and / or methods thereof. It is to be understood that the inventive aspects of which are not limited to specific synthetic methods unless otherwise specified, or to particular reagents unless otherwise specified, as such may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular aspects only and is not intended to be limiting. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, example methods and materials are now described.

[0078] All publications mentioned herein are incorporated herein by reference to disclose and describe the methods and / or materials in connection with which the publications are cited. The publications discussed herein are provided solely for their disclosure prior to the filing date of the present application. Nothing herein is to be construed as an admission that the present invention is not entitled to antedate such publication by virtue of prior invention.A. Abbreviations

[0079] In an aspect, the following definitions are relevant: ACK (Ammonium-Chloride-Potassium red blood cell lysis buffer); AF (Alexa Fluor); ANOVA (Analysis of variance); BN (Brown Norway); BSA (Bovine serum albumin); CODEX (CO-Detection by indEXing); CTLA4-Ig (Cytotoxic T-lymphocyte-associated protein 4 immunoglobulin fusion); DBCO (Dibenzocyclooctyne); DC (Dendritic cell); DCD (Donation after circulatory death); DGF (Delayed graft function); DSA (Donor-specific antibody); ECD (Extended criteria donor); ELISA (Enzyme-linked immunosorbent assay); FMO (Fluorescence minus one); GC (Germinal Center); GFP (Green fluorescent protein); GMP (Good manufacturing practice); HA (Hyaluronic acid); HA-NB (Norbomene-functionalized hyaluronic acid); HMP (Hydrogel microparticle); IgG (Immunoglobulin G); IVIS (In vivo imaging system); LAP (Lithium phenyl-2,4,6-trimethylbenzoylphosphinate photoinitiator); Lew (Lewis); Luc (Luciferase); MAP (Microporous annealed particle hydrogel); MFI (Median fluorescence intensity); MHC (Major histocompatibility complex); NB (Norbomene); NHS (N-hydroxysuccinimide); OCT (Optimal cutting temperature compound); PBS (Phosphate-buffered saline); PD-1 (Programmed cell death protein 1); PD-L1 (Programmed death-ligand 1); PEG (Polyethylene glycol)); PMMA (Polymethyl methacrylate); POD (Post-operative day); RBC (Red blood cell); RGD (Arginine-glycine-aspartate cell adhesion peptide); SCS (Static cold storage); SEM (Standard error of the mean); SPAAC (Strain-promoted azide-alkyne cycloaddition); TCR (T cell receptor); TEA (Triethylamine); TLS (Tertiary Lymphoid Structure); TNBSA (Trinitrobenzene sulfonic acid amine quantification assay); Treg / TRegs (Regulatory T cell(s)); TUNEL (Terminal deoxynucleotidyl transferase dUTP nick end labeling); UW (University of Wisconsin preservation solution); NoGlow (Genetically tolerant reporter mouse system); ORGANIC (Orthogonal Reactive Group Addition for Narrowed Immunosuppressant Capture); STEALTH (Surface-Tethered Engineered Alloprotective Ligands for Transplant Health).B. Definitions

[0080] Before the present compounds, compositions, articles, systems, devices, and / or methods are disclosed and described, it is to be understood that they are not limited to specific synthetic methods unless otherwise specified, or to particular reagents unless otherwise specified, as such may, of course, vary7. It is also to be understood that the terminology used herein is for the purpose of describing particular aspects only and is not intended to be limiting. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, example methods and materials are now described.

[0081] This disclosure describes inventive concepts with reference to specific examples. However, the intent is to cover all modifications, equivalents, and alternatives of the inventive concepts that are consistent with this disclosure.

[0082] In an aspect, the singular forms “a”, '‘an”, and “the’’ include plural referents unless the context clearly dictates otherwise.

[0083] The phrase “consisting essentially of’ limits the scope of a claim to the recited components in a composition or the recited steps in a method as well as those that do not materially affect the basic and novel characteristic or characteristics of the claimed composition or claimed method. The phrase “consisting of’ excludes any component, step, or element that is not recited in the claim. The phrase “comprising’’ is synonymous with “including’’, “containing’’, or “characterized by”, and is inclusive or open-ended. “Comprising” does not exclude additional, unrecited components or steps.

[0084] In an aspect, when referring to any numerical value, the term “about” means a value falling within a range that is ± 10% of the stated value.

[0085] Ranges can be expressed herein as from “about” one particular value, and / or to “about” another particular value. When such a range is expressed, a further aspect includes from the one particular value and / or to the other particular value. Similarly, when values are expressed as approximations, by use of the antecedent “about,” it will be understood that the particular value forms a further aspect. It will be further understood that the endpoints of each of the ranges are significant both in relation to the other endpoint and independently of the other endpoint. It is also understood that there are a number of values disclosed herein, and that each value is also herein disclosed as “about” that particular value in addition to the value itself. For example, if the value “10” is disclosed, then “about 10” is also disclosed. It is also understood that each unit between two particular units are also disclosed. For example, if 10 and 15 are disclosed, then 11, 12, 13, and 14 are also disclosed.

[0086] References in the specification and concluding claims to parts by weight of a particular element or component in a composition denotes the weight relationship between the element or component and any other elements or components in the composition or article for which a part by weight is expressed. Thus, in a compound containing 2 parts by weight component X and 5 parts by weight component Y, X and Y are present at a weight ratio of 2:5, and are present in such ratio regardless of whether additional components are contained in the compound.

[0087] In an aspect, the terms “optional” or “optionally” means that the subsequently described event or circumstance can or cannot occur, and that the description includes instances where said event or circumstance occurs and instances where it does not. In an aspect, a disclosed method can optionally comprise one or more additional steps, such as, for example, repeating an administering step or altering an administering step.

[0088] In an aspect, the term “subject” can refer to either the donor or the recipient in a disclosed method, e.g., a human being. The term “subject” also includes domesticated animals (e.g., cats, dogs, etc.), livestock (e.g., cattle, horses, pigs, sheep, goats, etc.), and laboratory animals (e.g.,mouse, rabbit, rat, guinea pig. fruit fly, etc.). Thus, the subject of the herein disclosed methods can be a vertebrate, such as a mammal, a fish, a bird, a reptile, or an amphibian. Alternatively, the subject of the herein disclosed methods can be a human, non-human primate, horse, pig, rabbit, dog, sheep, goat, cow, cat, guinea pig, or rodent. The term does not denote a particular age or sex, and thus, adult and child subjects, as well as fetuses, whether male or female, are intended to be covered. In an aspect, a recipient can be a human patient in need of one or more solid organ transplants (such as, for example, a kidney).

[0089] In an aspect, the term “diagnosed” means having been subjected to an examination by a person of skill, for example, a physician, and found to have a condition that can be diagnosed or treated with a disclosed functionalized donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells or a disclosed functionalized donor kidney, by one or more of the disclosed methods, or the combination thereof. For example, “diagnosed with a need for an organ transplant” means having been subjected to an examination by a person of skill, for example, a physician, and found to have a condition (such as, for example, an absent immune system) that can be treated with a disclosed functionalized donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells or a disclosed functionalized donor kidney, by one or more of the disclosed methods, or the combination thereof. In an aspect, an examination can be physical, can involve various tests (e.g., blood tests, genotyping, biopsies, etc.), scans (e.g., CT scans, PET scans, etc.), and assays (e.g., enzymatic assay), or a combination thereof.

[0090] A “patient” refers to a recipient needing an organ transplant. In an aspect, a patient can refer to a recipient that has been diagnosed with an absent immune system and is seeking treatment. For example, a recipient can be identified as having a need for an organ transplant based upon an earlier diagnosis by a person of skill and thereafter subjected to treatment for this need. In an aspect, the identification can be performed by a person different from the person making the diagnosis.

[0091] In an aspect, “inhibit,” “inhibiting”, and “inhibition” mean to diminish or decrease an activity, response, condition, severity, disease, or other biological parameter. This can include, but is not limited to. the complete ablation of the activity, response, condition, severity, disease, or other biological parameter. This can also include, for example, a 10% inhibition or reduction in the activity', expression level, response, condition, severity, disease, or other biological parameter as compared to the native or control level (e g., a recipient not needing a disclosed functionalized donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells or a disclosed functionalized donor kidney). Thus, in an aspect, the inhibition or reduction can be a 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, or any amountof reduction in between as compared to native or control levels. In an aspect, the inhibition or reduction can be 10-20%, 20-30%, 30-40%, 40-50%, 50-60%, 60-70%, 70-80%, 80-90%, or 90-100% as compared to a native or control level (e.g., a recipient not needing a disclosed functionalized donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells or a disclosed functionalized donor kidney). In an aspect, the inhibition or reduction can be 0-25%. 25-50%, 50-75%, or 75-100% as compared to native or control levels.

[0092] In an aspect, “allogeneic” refers to tissues or cells from another body that in a natural setting are immunologically incompatible or capable of being immunologically incompatible, although from one or more individuals of the same species. For example, a disclosed functionalized donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells or a disclosed functionalized donor kidney of patient A is allogeneic to patient B.

[0093] In an aspect, the terms “allostimulatory” and “alloreactive” refer to stimulation and reaction of the immune system in response to an allologous antigens, or “alloantigens” or cells expressing a dissimilar HLA haplotype.

[0094] In an aspect, the term “autoimmunity” refers to the system of immune responses of an organism against its own healthy cells and tissues.

[0095] In an aspect, “autologous” refers to tissues or cells that are derived or transferred from the same individual's body (e.g., autologous blood donation or an autologous bone marrow transplant).

[0096] The term “fibrosis” means the formation of excessive fibrous connective tissue in an organ or tissue. Fibrosis occurs in normal physiology' to act as a deposit of connective tissue. In pathology, fibrosis can be used to describe an excess state of deposition of extracellular material and proteins that can result in scarring, thickening of the afflicted tissue, and interfere with the normal function of the tissue or organ.

[0097] In an aspect, “matching” refers to the degree of similarity between the genetic makeup of a cell product or unit to be used for therapeutic and / or prophylactic purpose (including vaccination or inducing an immune response) into an individual and the individual’s genetic makeup. For the purposes of this disclosure, when two individuals share a type, they are said to be a match, meaning that their tissues are immunologically compatible with each other. The degree to which blood parameters need be identical will vary from patient to patient, and from year to year depending on the current state of technology. Matching then refers to providing the desired degree of match. For example, bone marrow and peripheral blood stem cell transplantation requires a greater degree of matching than blood cord stem cell transplantation. Matching can refer to amatch with about 90%, 80%, 70%, 60%, 50%, or 40% similarity based on HLA matching; HLA matching refers to the number of HLA alleles that are similar between the donor and the recipient. A matching fibroblast unit is one that is from a donor not related to the potential recipient.

[0098] In an aspect “ty pe or “ty ping” In an aspect refers to characteristics of a sample that might be of relevance or importance for any potential use of the sample. The term and the corresponding testing conducted to determine the “type” of the sample is thus not limited to any particular tests mentioned herein, e.g., HLA typing. Determination of tests that are relevant and how to perform them may be entirely conventional and may change with technological developments. Thus, the term “type identifier” refers to any characteristic that can be used for identification purposes.

[0099] In an aspect, the term “transplantation” refers to the process of taking living tissue or cells (such as a disclosed functionalized donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells or a disclosed functionalized donor kidney) and implanting it in another part of the body or into another body.

[0100] The words “treat” or “treating” or “treatment” include palliative treatment, that is, treatment designed for the relief of symptoms rather than the curing of the infection, disease, pathological condition, or disorder; preventative treatment, that is, treatment directed to minimizing or partially or completely inhibiting the development of the associated infection, disease, pathological condition, or disorder; and supportive treatment, that is, treatment employed to supplement another specific therapy directed toward the improvement of the associated infection, disease, pathological condition, or disorder. In an aspect, the terms cover any treatment of a recipient, including a mammal (e.g., a human), and includes: (i) preventing the undesired infection, physiological change, disease, pathological condition, or disorder from occurring in a recipient that can be predisposed to the disease but has not yet been diagnosed as having it; (ii) inhibiting the infection, physiological change, disease, pathological condition, or disorder, z.e., arresting its development; or (iii) relieving the infection, physiological change, disease, pathological condition, or disorder, i.e., causing regression of the disease. For example, in an aspect, treating can reduce the severity' of an established infection, physiological change, disease, pathological condition, or disorder in a recipient by 1%- 100% as compared to a control (such as, for example, an individual not having the infection, physiological change, disease, pathological condition, or disorder). In an aspect, treating can refer to a 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% reduction in the severity of the infection, physiological change, disease, pathological condition, or disorder. For example, treating an infection can reduce one or more symptoms of a disease or disorder in a recipient by 1 %-l 00% as compared to a control (such as, for example, an individual not having the infection,physiological change, disease, pathological condition, or disorder). It is understood that treatment does not necessarily refer to a cure or complete ablation or eradication of the infection, physiological change, disease, pathological condition, or disorder. However, in an aspect, treatment can refer to a cure or complete ablation or eradication of the infection, physiological change, disease, pathological condition, or disorder.

[0101] In an aspect, ‘"click chemistry” was as first articulated by Sharpless and colleagues in 2001, and was bom of a desire to harness the power of molecular assembly for the widest possible range of applications. The logic behind click chemistry' is simple: (i) new molecular properties are needed every' where; (ii) such properties can emerge from the joining of small molecular building blocks; (iii) scientists and engineers not trained in synthetic chemistry often lack the skills and equipment needed to perform such connecting operations reliably; and (iv) chemical methods exist, and more can be developed, that make molecular connections easily. The “click” in click chemistry' was meant to convey the ty pe of convenience and satisfaction one is afforded by snapping objects together with a luggage strap connector. It does not matter what the pieces are; if the two ends of the buckle can reach each other, the linkage is made.

[0102] In an aspect, a disclosed bioorthogonal process can involve two steps. First, a bioorthogonal handle (such as an azide group) is incorporated into biomolecules using methods such as metabolic labeling. Next, a probe bearing a functional group (such as an alkyne moiety) which reacts rapidly and selectively with the bioorthogonal handle is introduced exogenously, attaching the probe to a biomolecule.

[0103] In an aspect, the term “prevent” or “preventing” or “prevention” refers to precluding, averting, obviating, forestalling, stopping, or hindering something from happening, especially by advance action. It is understood that where reduce, inhibit, or prevent are used herein, unless specifically indicated otherwise, the use of the other two words is also expressly disclosed. In an aspect, preventing complete organ failure or death intended. The words “prevent”, “preventing”, and “prevention” also refer to prophylactic or preventative measures for protecting or precluding a recipient (e.g., an individual) not having the infection, physiological change, disease, pathological condition, or disorder or related complication from progressing to that complication.

[0104] In an aspect, the terms “administering” and “administration” refer to any method of providing to a recipient one or more of the disclosed immunosuppressive agents, pharmaceutical formulations, or therapeutic agents. Such methods are well know n to those skilled in the art and include, but are not limited to, the following: oral administration, transdermal administration, administration by inhalation, nasal administration, topical administration, in utero administration, intratumoral administration, intrahepatic administration, intravaginal administration, ophthalmicadministration, intraaural administration, otic administration, intracerebral administration, rectal administration, sublingual administration, buccal administration, and parenteral administration, including injectable such as intravenous administration, intra-CSF administration, intra-arterial administration, intramuscular administration, and subcutaneous administration. Administration can be continuous or intermittent. Administration can comprise a combination of routes.

[0105] In an aspect, the skilled person can determine an efficacious dose, an efficacious schedule, and an efficacious route of administration of one or more of the disclosed biotherapeutics, the disclosed pharmaceutical formulations, or any combination thereof to deplete T cells and / or to suppress a recipient's immune system. In an aspect, the skilled person can also alter, change, or modify an aspect of an administering step to improve efficacy of any disclosed immunosuppressive agents, pharmaceutical formulations, or therapeutic agents.

[0106] By “determining the amount” is meant both an absolute quantification of a particular analyte (e.g., biomarker for functionalization of a donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells or donor kidney) or a determination of organ rejection or organ functionality.

[0107] In an aspect, “modifying the method” can comprise modifying or changing one or more features or aspects of one or more steps of a disclosed method. In an aspect, a method can be altered by changing the amount of a disclosed immunosuppressive agent, pharmaceutical formulation, or therapeutic agent administered to a recipient, or by changing the frequency of administration of the disclosed immunosuppressive agent, pharmaceutical formulation, or therapeutic agent, by changing the duration of time that the disclosed immunosuppressive agent, pharmaceutical formulation, or therapeutic agent is administered, or by substituting for one or more of the disclosed immunosuppressive agent, pharmaceutical formulation, or therapeutic agent with a similar or equivalent component and / or reagent. The same applies to all disclosed immunosuppressive agents, pharmaceutical formulations, or therapeutic agents, or any combination thereof. In an aspect, a method can be modified following the review or analysis of data.

[0108] In an aspect, “type” or “typing” refers to characteristics of a sample, e.g.. endothelial or endothelial progenitor cell product sample, which might be of relevance or importance for any potential use of the sample. The term and the corresponding testing conducted to determine the “type” of the sample is thus not limited to any test mentioned herein, e.g., HLA typing. Determination of which tests are relevant and how to perform them may be entirely conventional and may change with technological developments. Thus, the term “type identifier” refers to any characteristic that can be used for identification purposes.

[0109] In an aspect, PD-L1 (aka CD274 or Programmed Cell Death Ligand 1) can be identified by HGNC 17635; NCBI Gene 29126; Ensembl ENSG00000120217; OMIM 605402; and / or UniProtKB / Swiss-Prot Q9NZQ7. In an aspect, the checkpoint regulator PD-L1 (programmed death-ligand 1) can regulate T-cell activity and promote immune tolerance by binding PD-1 receptors on T cells. PD-1:PD-L1 interactions are thought to contribute to peripheral tolerance by limiting alloreactive T-cell expansion via cell cycle arrest, increasing apoptosis of T-cells, or by increasing CD4+CD25+ regulatory T-cell activity.

[0110] In an aspect, CTLA-4 (aka cytotoxic T-lympopycte Associated Protein 4 or CD152) can be identified by HGNC 2505; NCBI Gene 1493; Ensembl ENSG00000163599; OMIM 123890; and / or UniProtKB / Swiss-Prot P16410. In an aspect, CTLA4-Ig (belatacept / abatacept) can be an alternative to calcineurin inhibitors (CNIs). CTLA4-Ig can function to selectively block T-cell activation by targeting a key costimulatory pathway rather than the more generalized immune suppression seen with CNIs. Belatacept blocks the CD28-B7 costimulation pathway that is required for full T-cell activation and subsequent effector cell differentiation. By preventing the interaction of CD28 on T-cells with B7 (CD80 / CD86) on antigen-presenting cells (APCs), belatacept induces T-cell anergy and prevents rejection while avoiding the nephrotoxicity associated with CNIs.

[0111] In an aspect, the major histocompatibility complex (MHC) is a set of cell surface molecules encoded by a large gene family which controls a major part of the immune system in all vertebrates. The major function of major histocompatibility complexes is to bind to peptide fragments derived from pathogens and display them on the cell surface for recognition by the appropriate T-cells. The major histocompatibility complex (MHC) contains two types of polymorphic MHC genes, the class I and class II genes, which encode two groups of structurally distinct but homologous proteins, and other nonpolymorphic genes whose products are involved in antigen presentation. The human WIC is called human leukocyte antigen (HLA). HLA proteins are encoded by genes of the MHC. HLA class I antigens include HLA- A, HLA-B, and HLA-C. HLA class II antigens include HLA-DR. HLA-DQ, HLA-DP, HLA-DM, HLA-DOA. HLA-DOB. HLA’s corresponding to MHC class I (A, B, and C) present peptides from inside the cell. HLA’s corresponding to MHC class II (DP, DM, DOA, DOB, DQ, and DR) present antigens from outside of the cell to T-lymphocytes. MHC molecules mediate the binding of a given T cell receptor to a given antigen, so MHC polymorphism across individuals modulates the T cell response to a given antigen. Clinical applications of HLA typing include vaccine trials, disease associations, adverse drug reactions, platelet transfusion, and transplantation of organs and stem cells.

[0112] There are numerous alleles at each HLA gene locus (AL A2, A3, etc.). Each person inherits one complete set of HLA alleles (haplotype) from each parent, and this combination of encoded proteins constitutes a person’s HLA type (e.g., different antigens of A23, A31, B7, B44, C7, C8, DR4, DR7, DQ2, DQ7, DP2, DP3). There are more than 50,000 different known HLA types.

[0113] In an aspect, adaptive immune receptor (AIR) refers to an immune cell receptor, e.g., a T cell receptor (TCR) or an Immunoglobulin (Ig) receptor found in mammalian cells. In certain embodiments, the adaptive immune receptor is encoded by a TCRB, TCRG, TCRA, TCRD, IGH, IGK, and IGL gene or gene segment.

[0114] In an aspect, the term “pharmaceutically acceptable carrier” refers to sterile aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, as well as sterile powders for reconstitution into sterile inj ectable solutions or dispersions just prior to use. Examples of suitable aqueous and nonaqueous carriers, diluents, solvents, or vehicles include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol and the like), carboxymethylcellulose and suitable mixtures thereof, vegetable oils (such as olive oil) and injectable organic esters such as ethyl oleate. In an aspect, a pharmaceutical carrier employed can be a solid, liquid, or gas. In an aspect, examples of solid carriers can include lactose, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, and stearic acid. In an aspect, examples of liquid carriers can include sugar syrup, peanut oil. olive oil. and water. In an aspect, examples of gaseous carriers can include carbon dioxide and nitrogen. In preparing a disclosed composition for oral dosage form, any convenient pharmaceutical media can be employed. For example, water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents and the like can be used to form oral liquid preparations such as suspensions, elixirs and solutions; while carriers such as starches, sugars, microcrystalline cellulose, diluents, granulating agents, lubricants, binders, disintegrating agents, and the like can be used to form oral solid preparations such as powders, capsules and tablets. Because of their ease of administration, tablets and capsules are the preferred oral dosage units whereby solid pharmaceutical carriers are employed. Optionally, tablets can be coated by¬ standard aqueous or nonaqueous techniques. Proper fluidity can be maintained, for example, by the use of coating materials such as lecithin, by the maintenance of the required particle size in the case of dispersions and by the use of surfactants. These compositions can also contain adjuvants such as preservatives, wetting agents, emulsifying agents and dispersing agents. Prevention of the action of microorganisms can be ensured by the inclusion of various antibacterial and antifungal agents such as paraben, chlorobutanol, phenol, sorbic acid and the like. It can also be desirable to include isotonic agents such as sugars, sodium chloride and the like. Prolongedabsorption of the injectable pharmaceutical form can be brought about by the inclusion of agents, such as aluminum monostearate and gelatin, which delay absorption. Injectable depot forms are made by forming microencapsule matrices of the drug in biodegradable polymers such as polylactide-polyglycolide, poly(orthoesters) and poly (anhydrides). Depending upon the ratio of drug to polymer and the nature of the particular polymer employed, the rate of drug release can be controlled. Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions that are compatible with body tissues. The injectable formulations can be sterilized, for example, by filtration through a bacterial -retaining filter or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable media just prior to use. Suitable inert carriers can include sugars such as lactose. Desirably, at least 95% by weight of the particles of the active ingredient have an effective particle size in the range of 0.01 to 10 micrometers.

[0115] In an aspect, the term “excipient” refers to an inert substance which is commonly used as a diluent, vehicle, preservative, binder, or stabilizing agent, and includes, but is not limited to, proteins (e.g., serum albumin, etc.), amino acids (e.g., aspartic acid, glutamic acid, lysine, arginine, glycine, histidine, etc ), fatty acids and phospholipids (e.g., alkyl sulfonates, caprylate, etc.), surfactants (e.g., SDS, polysorbate, nonionic surfactant, etc.), saccharides (e.g., sucrose, maltose, trehalose, etc.) and polyols (e.g., mannitol, sorbitol, etc.). See, also, for reference, Remington’s Pharmaceutical Sciences, (1990) Mack Publishing Co., Easton, Pa., which is hereby incorporated by reference in its entirety.

[0116] In an aspect, “concurrently” means (1) simultaneously in time, or (2) at different times during the course of a common treatment schedule.

[0117] In an aspect, “contacting” refers to bringing one or more of the disclosed immunosuppressive agents, pharmaceutical formulations, or therapeutic agents, or any combination thereof together w ith a target area or intended target area (e.g., such as a disclosed functionalized donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells or a disclosed functionalized donor kidney) in such a manner that the disclosed immunosuppressive agents, pharmaceutical formulations, or therapeutic agents, or any combination thereof can exert an effect on the intended target or targeted area either directly or indirectly.

[0118] In an aspect, “effective amount” and “amount effective” can refer to an amount that is sufficient to achieve the desired result such as. for example, the treatment and / or prevention of organ rejection. In an aspect, the terms “effective amount” and “amount effective” can refer to an amount that is sufficient to achieve the desired an effect on an undesired condition (e.g. , GVHD).For example, a 'therapeutically effective amount” refers to an amount that is sufficient to achieve the desired therapeutic result or to have an effect on undesired symptoms, but is generally insufficient to cause adverse side effects. In an aspect, “therapeutically effective amount” means an amount of a disclosed immunosuppressive agent, pharmaceutical formulation, or therapeutic agent, or any combination thereof that (i) treats the particular infection, disease, condition, or disorder, (ii) attenuates, ameliorates, or eliminates one or more symptoms of the particular infection, disease, condition, or disorder, or (iii) delays the onset of one or more symptoms of the particular infection, disease, condition, or disorder described herein. The specific therapeutically effective dose level for any particular patient will depend upon a variety of factors including the particular infection, disease, condition, or disorder being treated and the severity of the particular infection, disease, condition, or disorder; the disclosed biotherapeutics, the disclosed pharmaceutical formulations, or any combination thereof employed in the disclosed methods; the age, body weight, general health, sex and diet of the patient; the time of administration; the route of administration; the rate of excretion of the disclosed biotherapeutics, the disclosed pharmaceutical formulations, or any combination thereof employed; the duration of the treatment; other drugs used in combination or coincidental with the disclosed biotherapeutics, the disclosed pharmaceutical formulations, or any combination thereof, and other like factors well known in the medical arts. For example, it is well within the skill of the art to start doses of the disclosed biotherapeutics, the disclosed pharmaceutical formulations, or any combination thereof at levels lower than those required to achieve the desired therapeutic effect and to gradually increase the dosage until the desired effect is achieved. If desired, then the effective daily dose can be divided into multiple doses for purposes of administration. Consequently, a single dose of the disclosed biotherapeutics, the disclosed pharmaceutical formulations, or any combination thereof can contain such amounts or submultiples thereof to make up the daily dose. The dosage can be adjusted by the individual physician in the event of any contraindications. Dosage can vary, and can be administered in one or more dose administrations daily, for one or several days. Guidance can be found in the literature for appropriate dosages for given classes of pharmaceutical products. In further various aspects, a preparation can be administered in a “prophylactically effective amount”; that is, an amount effective for prevention of an infection.

[0119] In an aspect, the term “package insert” is used to refer to instructions customarily included in commercial packages of therapeutic products, that contain information about the indications, usage, dosage, administration, contraindications and / or warnings concerning the use of such therapeutic products.

[0120] In an aspect, MLR can be used to quantitate the response of T cells to alloantigens. The MLR is a relatively easy and inexpensive assay, and this technique has produced a great deal of invaluable basic information on various aspects of the immune response, including the nature of the antigens recognized, the specificity of CD4+ and CD8+ cells and the features of APCs.

[0121] In an aspect, the term "in combination’' in the context of the administration of other therapies (e.g., other agents) includes the use of more than one therapy (e.g., drug therapy). Administration “in combination with” one or more further therapeutic agents includes simultaneous (e.g., concurrent) and consecutive administration in any order. The use of the term “in combination” does not restrict the order in which therapies are administered to a recipient. By way of non-limiting example, a first therapy (e.g., a disclosed immunosuppressive agent or a disclosed pharmaceutical formulation) may be administered prior to (e.g., 1 minute, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 12 hours, 24 hours, 48 hours, 72 hours, 96 hours, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 8 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, or 12 weeks), concurrently, or after (e.g., 1 minute, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 3 hours. 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 12 hours, 24 hours, 48 hours, 72 hours, 96 hours, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, or 12 weeks or longer) the administration of a second therapy (e.g., a disclosed immunosuppressive agent or a disclosed pharmaceutical formulation) to a recipient needing one or more solid organ transplants.

[0122] Disclosed are the components to be used to prepare the disclosed immunosuppressive agents or the disclosed pharmaceutical formulations used within the methods disclosed herein. These and other materials are disclosed herein, and it is understood that when combinations, subsets, interactions, groups, etc. of these materials are disclosed that while specific reference of each various individual and collective combinations and permutation of these compounds cannot be explicitly disclosed, each is specifically contemplated and described herein. For example, if a particular compound is disclosed and discussed and a number of modifications that can be made to a number of molecules including the compounds are discussed, specifically contemplated is each and every combination and permutation of the compound and the modifications that are possible unless specifically indicated to the contrary. Thus, if a class of molecules A, B, and C are disclosed as well as a class of molecules D, E, and F and an example of a combination molecule, A-D is disclosed, then even if each is not individually recited each is individually and collectively contemplated meaning combinations, A-E, A-F. B-D, B-E, B-F. C-D, C-E, and C-F are considered disclosed. Likewise, any subset or combination of these is also disclosed. Thus, for example, the sub-group of A-E, B-F, and C-E would be considered disclosed. This concept applies to all aspectsof this application including, but not limited to, steps in methods of making and using the compositions of the invention. Thus, if there are a variety of additional steps that can be performed it is understood that each of these additional steps can be performed with any specific embodiment or combination of embodiments of the methods of the invention.C. Methods of Preparing a Donor Organ (ORGANIC)

[0123] Disclosed herein is a method of preparing a donor organ for transplantation, the method comprising subjecting a donor organ or a portion thereof to the Orthogonal Reactive Group Addition for Narrowed Immunosuppressant Capture (ORGANIC) protocol. Disclosed herein is a method of preparing a donor organ for transplantation, the method comprising functionalizing a donor organ or a portion thereof ex vivo by installing reactive groups on the donor organ or the portion thereof. Disclosed herein is a method of preparing a donor organ for transplantation, the method comprising functionalizing a donor organ or a portion thereof by installing azide tethers or azide handles on the donor organ or the portion thereof. Disclosed herein is a method of preparing a donor organ for transplantation, the method comprising installing reactive groups on a donor organ or a portion thereof ex vivo, thereby functionalizing the donor organ or the portion thereof for subsequent capture of circulating therapeutic payloads or therapeutic molecules. Disclosed herein is a method of preparing a donor organ for transplantation, the method comprising installing azide tethers or azide handles on a donor organ or a portion thereof, thereby functionalizing the donor organ or the portion thereof for subsequent capture of circulating therapeutic payloads or therapeutic molecules. Disclosed herein is a method of preparing a donor organ for transplantation, the method comprising installing reactive groups on a donor organ or a portion thereof ex vivo, thereby functionalizing the donor organ or the portion thereof for subsequent capture of circulating payloads or circulating molecules. Disclosed herein is a method of preparing a donor organ for transplantation, the method comprising installing azide tethers or azide handles on a donor organ or a portion thereof, thereby functionalizing the donor organ or the portion thereof for subsequent capture of circulating payloads or circulating molecules.

[0124] Disclosed herein is a method of preparing a donor organ for transplantation, the method comprising procuring an organ or a portion thereof from a donor; and subjecting the donor organ to or the portion thereof the Orthogonal Reactive Group Addition for Narrowed Immunosuppressant Capture (ORGANIC) protocol. Disclosed herein is a method of preparing a donor organ for transplantation, the method comprising procuring an organ or a portion thereof from a donor; and functionalizing a donor organ or a portion thereof ex vivo by installing reactive groups on the donor organ or the portion thereof. Disclosed herein is a method of preparing a donor organ for transplantation, the method comprising procuring an organ or a portion thereoffrom a donor; and functionalizing a donor organ or a portion thereof by installing azide tethers or azide handles on the donor organ or the portion thereof. Disclosed herein is a method of preparing a donor organ for transplantation, the method comprising procuring an organ or a portion thereof from a donor; and installing reactive groups on a donor organ or a portion thereof ex vivo, thereby functionalizing the donor organ or the portion thereof for subsequent capture of circulating therapeutic pay loads or therapeutic molecules. Disclosed herein is a method of preparing a donor organ for transplantation, the method comprising procuring an organ or a portion thereof from a donor; and installing azide tethers or azide handles on the donor organ or the portion thereof, thereby functionalizing the donor organ or the portion thereof for subsequent capture of circulating therapeutic pay loads or therapeutic molecules. Disclosed herein is a method of preparing a donor organ for transplantation, the method comprising procuring an organ or a portion thereof from a donor; and installing reactive groups on the donor organ or the portion thereof ex vivo, thereby functionalizing the donor organ for subsequent capture of circulating payloads or circulating molecules. Disclosed herein is a method of preparing a donor organ for transplantation, the method comprising procuring an organ or a portion thereof from a donor; and installing azide tethers or azide handles on the donor organ or the portion thereof, thereby functionalizing the donor organ or the portion thereof for subsequent capture of circulating payloads or circulating molecules.

[0125] Disclosed herein is a method of preparing a donor organ for transplantation, the method comprising procuring an organ or a portion thereof from a donor; subjecting the donor organ or the portion thereof to the Orthogonal Reactive Group Addition for Narrowed Immunosuppressant Capture (ORGANIC) protocol; and transplanting into a recipient a disclosed functionalized donor organ or portion thereof. Disclosed herein is a method of preparing a donor organ for transplantation, the method comprising procuring an organ or a portion thereof from a donor; functionalizing a donor organ or a portion thereof ex vivo by installing reactive groups on the donor organ or the portion thereof; and transplanting into a recipient the disclosed functionalized donor organ or the portion thereof. Disclosed herein is a method of preparing a donor organ for transplantation, the method comprising procuring an organ or a portion thereof from a donor; functionalizing the donor organ by installing azide tethers or azide handles on the donor organ or the portion thereof; and transplanting into a recipient the disclosed functionalized donor organ or the portion thereof. Disclosed herein is a method of preparing a donor organ for transplantation, the method comprising procuring an organ or a portion thereof from a donor; installing reactive groups on the donor organ or the portion thereof ex vivo, thereby functionalizing the donor organ or the portion thereof for subsequent capture of circulating therapeutic payloads or therapeuticmolecules; and transplanting into a recipient a disclosed functionalized donor organ or the portion thereof. Disclosed herein is a method of preparing a donor organ for transplantation, the method comprising procuring an organ or a portion thereof from a donor; installing azide tethers or azide handles on the donor organ or the portion thereof, thereby functionalizing the donor organ or the portion thereof for subsequent capture of circulating therapeutic payloads or therapeutic molecules; and transplanting into a recipient a disclosed functionalized donor organ or the portion thereof. Disclosed herein is a method of preparing a donor organ for transplantation, the method comprising procuring an organ or a portion thereof from a donor; installing reactive groups on a donor organ or the portion thereof ex vivo, thereby functionalizing the donor organ or the portion thereof for subsequent capture of circulating payloads or circulating molecules; and transplanting into a recipient the functionalized donor organ or the portion thereof. Disclosed herein is a method of preparing a donor organ for transplantation, the method comprising procuring an organ or a portion thereof from a donor; installing azide tethers or azide handles on the donor organ or the portion thereof, thereby functionalizing the donor organ or the portion thereof for subsequent capture of circulating payloads or circulating molecules; and transplanting into a recipient a disclosed functionalized donor organ or the portion thereof.

[0126] Disclosed herein is a method of preparing a donor organ for transplantation, the method comprising subjecting the donor organ or a portion thereof to the Orthogonal Reactive Group Addition for Narrowed Immunosuppressant Capture (ORGANIC) protocol. Disclosed herein is a method of preparing a donor organ for transplantation, the method comprising functionalizing a donor organ or a portion thereof ex vivo by installing reactive groups on the donor organ or the portion thereof. Disclosed herein is a method of preparing a donor organ for transplantation, the method comprising functionalizing a donor organ or a portion thereof by installing azide tethers or azide handles on the donor organ or the portion thereof. Disclosed herein is a method of preparing a donor organ for transplantation, the method comprising installing reactive groups on a donor organ or a portion thereof ex vivo, thereby functionalizing the donor organ or a portion thereof for subsequent capture of circulating therapeutic payloads or therapeutic molecules. Disclosed herein is a method of preparing a donor organ for transplantation, the method comprising installing azide tethers or azide handles on a donor organ or a portion thereof, thereby functionalizing the donor organ or the portion thereof for subsequent capture of circulating therapeutic pay loads or therapeutic molecules. Disclosed herein is a method of preparing a donor organ for transplantation, the method comprising installing reactive groups on a donor organ or a portion thereof ex vivo, thereby functionalizing the donor organ or the portion thereof for subsequent capture of circulating payloads or circulating molecules. Disclosed herein is a methodof preparing a donor organ for transplantation, the method comprising installing azide tethers or azide handles on a donor organ or a portion thereof, thereby functionalizing the donor organ or the portion thereof for subsequent capture of circulating payloads or circulating molecules.

[0127] Disclosed herein is a method of preparing a donor organ for transplantation, the method comprising procuring an organ or a portion thereof from a donor; and subjecting the donor organ or the portion thereof to the Orthogonal Reactive Group Addition for Narrowed Immunosuppressant Capture (ORGANIC) protocol. Disclosed herein is a method of preparing a donor organ for transplantation, the method comprising procuring an organ or a portion thereof from a donor; and functionalizing a donor organ or the portion thereof ex vivo by installing reactive groups on the donor organ. Disclosed herein is a method of preparing a donor organ for transplantation, the method comprising procuring an organ or a portion thereof from a donor; and functionalizing a donor organ or the portion thereof by installing azide tethers or azide handles on the donor organ or the portion thereof. Disclosed herein is a method of preparing a donor organ for transplantation, the method comprising procuring an organ or a portion thereof from a donor; and installing reactive groups on a donor organ or the portion thereof ex vivo, thereby functionalizing the donor organ or the portion thereof for subsequent capture of circulating therapeutic pay loads or therapeutic molecules. Disclosed herein is a method of preparing a donor organ for transplantation, the method comprising procuring an organ from a donor or a portion thereof; and installing azide tethers or azide handles on a donor organ or the portion thereof, thereby functionalizing the donor organ or the portion thereof for subsequent capture of circulating therapeutic payloads or therapeutic molecules. Disclosed herein is a method of preparing a donor organ for transplantation, the method comprising procuring an organ or a portion thereof from a donor; and installing reactive groups on the donor organ or the portion thereof ex vivo, thereby functionalizing the donor organ or the portion thereof for subsequent capture of circulating payloads or circulating molecules. Disclosed herein is a method of preparing a donor organ for transplantation, the method comprising procuring an organ or a portion thereof from a donor; and installing azide tethers or azide handles on the donor organ or the portion thereof, thereby- functionalizing the donor organ or the portion thereof for subsequent capture of circulating payloads or circulating molecules.

[0128] In an aspect, a disclosed donor organ can be a portion of that donor organ or a part of that donor organ (e.g., a heart valve, an intestinal segment, a lung lobe, a part of the liver, a part of the pancreas, etc.).

[0129] Disclosed herein is a method of preparing a donor tissue, a donor connective tissue, or a donor population of cells for transplantation, the method comprising procuring a donor tissue, adonor connective tissue, or a donor population of cells from a donor; subjecting the donor tissue, donor connective tissue, or donor population of cells to the Orthogonal Reactive Group Addition for Narrowed Immunosuppressant Capture (ORGANIC) protocol; and transplanting into a recipient the functionalized donor tissue, donor connective tissue, or donor population of cells. Disclosed herein is a method of preparing a donor tissue, a donor connective tissue, or a donor population of cells for transplantation, the method comprising procuring a tissue, a connective tissue, or a population of cells from a donor; functionalizing the donor tissue, donor connective tissue, or donor population of cells ex vivo by installing reactive groups on the donor tissue, donor connective tissue, or donor population of cells; and transplanting into a recipient the functionalized donor tissue, donor connective tissue, or donor population of cells. Disclosed herein is a method of preparing a donor tissue, a donor connective tissue, or a donor population of cells for transplantation, the method comprising procuring a donor tissue, a donor connective tissue, or a donor population of cells from a donor; functionalizing the donor tissue, donor connective tissue, or donor population of cells by installing azide tethers or azide handles on the donor tissue, donor connective tissue, or donor population of cells; and transplanting into a recipient the functionalized donor tissue, donor connective tissue, or donor population of cells. Disclosed herein is a method of preparing a donor tissue, a donor connective tissue, or a donor population of cells for transplantation, the method comprising procuring a donor tissue, a donor connective tissue, or a donor population of cells from a donor; installing reactive groups on the donor tissue, donor connective tissue, or donor population of cells ex vivo, thereby functionalizing the donor tissue, donor connective tissue, or donor population of cells for subsequent capture of circulating therapeutic payloads or therapeutic molecules; and transplanting into a recipient the functionalized donor tissue, donor connective tissue, or donor population of cells. Disclosed herein is a method of preparing a donor tissue, a donor connective tissue, or a donor population of cells for transplantation, the method comprising procuring a donor tissue, a donor connective tissue, or a donor population of cells from a donor; installing azide tethers or azide handles on the donor tissue, donor connective tissue, or donor population of cells, thereby functionalizing the donor tissue, donor connective tissue, or a donor population of cells for subsequent capture of circulating therapeutic payloads or therapeutic molecules; and transplanting into a recipient the functionalized donor tissue, donor connective tissue, or donor population of cells. Disclosed herein is a method of preparing a donor tissue, a donor connective tissue, or a donor population of cells for transplantation, the method comprising procuring a donor tissue, a donor connective tissue, or a donor population of cells from a donor; installing reactive groups on the donor tissue, donor connective tissue, or donor population of cells ex vivo, thereby functionalizing the donor tissue,donor connective tissue, or donor population of cells for subsequent capture of circulating payloads or circulating molecules; and transplanting into a recipient the functionalized donor tissue, donor connective tissue, or a donor population of cells. Disclosed herein is a method of preparing a donor tissue, a donor connective tissue, or a donor population of cells for transplantation, the method comprising procuring a donor tissue, a donor connective tissue, or a donor population of cells from a donor; installing azide tethers or azide handles on the donor tissue, donor connective tissue, or donor population of cells, thereby functionalizing the donor tissue, donor connective tissue, or donor population of cells for subsequent capture of circulating payloads or circulating molecules; and transplanting into a recipient the functionalized donor tissue, donor connective tissue, or donor population of cells.

[0130] In an aspect, ORGANIC can comprise installing tethers or handles onto a disclosed donor organ, a disclosed portion of a donor organ, a disclosed donor tissue, a disclosed donor connective tissue, or a disclosed donor population of cells during standard preservation workflows. In an aspect, a disclosed method can transform a disclosed donor organ, a disclosed portion of a donor organ, a disclosed donor tissue, a disclosed donor connective tissue, or a disclosed donor population of cells into a chemically programmable interface. In an aspect, a disclosed method can establish a disclosed donor organ, a disclosed portion of a donor organ, a disclosed donor tissue, a disclosed donor connective tissue, or a disclosed donor population of cells itself as a reloadable platform for targeted drug delivery’ following transplantation. In an aspect, disclosed tethers or disclosed handles can be conjugated to primary amines belonging to proteins on the cell surface. This conjugation can be covalent. This conjugation can be NHS-ester-mediated. Following the NHS-ester-mediated conjugation, a disclosed tether or a disclosed handle can be used for subsequent click-based capture of a cyclooctyne-modified payload or cyclooctyne-modified molecule.

[0131] In an aspect, disclosed connective tissue can comprise fascia, tendons, ligaments, or any type of connective tissue known to the art.

[0132] In an aspect, a disclosed functionalized donor organ, a disclosed functionalized portion of a donor organ, a disclosed functionalized donor tissue, a disclosed functionalized donor connective tissue, or a disclosed functionalized donor population of cells can comprise surface-exposed azide handles or surface-exposed azide tethers capable of participating in SPAAC reactions. In an aspect, a disclosed donor organ, a disclosed portion of a donor organ, a disclosed donor tissue, a disclosed donor connective tissue, or a disclosed donor population of cells can comprise surface-exposed azide handles or tethers capable of participating in SPAAC reactions. In an aspect, a disclosed method can incorporate principles of bioorthogonal chemistry.

[0133] In an aspect, the installation of azide tethers or azide handles can comprise steps of the process set forth in FIG. 5E.

[0134] In an aspect, installing azide tethers or azide handles can comprise use of a bioorthogonal reaction. In an aspect, bioorthogonal reactions can comprise a Staudinger ligation (in which azides and phosphines are biocompatible and which stable amide linkages are produced), a CuAAC reaction (which is a fast reaction with well-established chemistry and good regioselectivity), a SPAAC reaction (which does not use copper catalysts), a tetrazine ligation (which has very fast reactions with tunable kinetics / stability tunable), a metal-catalyzed biorthogonal reactions, a native chemical ligation, an oxime and hydrazone ligation, a light-catalyzed biorthogonal reaction, and an IEDDA reaction. In an aspect, a disclosed bioorthogonal reaction can comprise an oximehydrazone ligation. In an aspect, oximes and hydrazones can be formed through the condensation of carbonyl groups with alkoxy amines and hydrazines, respectively. In an aspect, a disclosed Staudinger ligation reaction can comprise azide and triphenylphosphine. In an aspect, a disclosed CuAAC reaction, Cu(I) can react with the sulfhydryl group in the organism. In an aspect, a disclosed Staudinger ligation can comprise an in vivo formation of amide bonds. In an aspect, a disclosed photoinducible bioorthogonal chemistry can comprise spatio-temporal control with light. In an aspect, a disclosed oxime and hydrazone ligation can be enabled by ketone and aldehyde tags. In an aspect, a disclosed strain-promoted [3+2] cycloaddition can comprise copper-free coupling with 1,3-dipoles. In an aspect, a disclosed tetrazine ligation can comprise exceptionally rapid kinetics. In an aspect, a disclosed palladium and ruthenium-catalyzed coupling can comprise unique tags for biomolecule modification. In an aspect, a disclosed copper-catalyzed azide-alkyne cycloaddition can comprise minimal size, can be readily accessible, and can be broadly useful. In an aspect, a disclosed native chemical ligation can comprise protein synthesis from synthetic or expressed fragments.

[0135] In an aspect, procuring a disclosed donor organ, a disclosed portion of a donor organ, a disclosed donor tissue, a disclosed donor connective tissue, or a disclosed donor population of cells and functionalizing a disclosed donor organ, a disclosed portion of a donor organ, a disclosed donor tissue, a disclosed donor connective tissue, or a disclosed donor population of cells can be performed in a singular location (e g., one hospital or clinic). In an aspect, procuring a disclosed donor organ and functionalizing a disclosed donor organ, a disclosed portion of a donor organ, a disclosed donor tissue, a disclosed donor connective tissue, or a disclosed donor population of cells can be performed in different locations (e.g., two hospitals or clinics). In an aspect, procuring a disclosed donor organ, a disclosed portion of a donor organ, a disclosed donor tissue, a disclosed donor connective tissue, or a disclosed donor population of cells and installing azide tethers orazide handles on a disclosed donor organ, a disclosed portion of a donor organ, a disclosed donor tissue, a disclosed donor connective tissue, or a disclosed donor population of cells can be performed in a singular location (e.g., one hospital or clinic). In an aspect, procuring a disclosed donor organ, a disclosed portion of a donor organ, a disclosed donor tissue, a disclosed donor connective tissue, or a disclosed donor population of cells and installing azide tethers or azide handles on a disclosed donor organ, a disclosed portion of a donor organ, a disclosed donor tissue, a disclosed donor connective tissue, or a disclosed donor population of cells can be performed in different locations (e.g., two hospitals or clinics).

[0136] In an aspect, procuring a disclosed donor kidney and functionalizing a disclosed donor kidney can be performed in a singular location (e.g., one hospital or clinic). In an aspect, procuring a disclosed donor kidney and functionalizing a disclosed donor kidney can be performed in different locations (e.g., two hospitals or clinics). In an aspect, procuring a disclosed donor kidney and installing azide tethers or azide handles on a donor kidney can be performed in a singular location (e.g., one hospital or clinic). In an aspect, procuring a disclosed donor kidney and installing azide tethers or azide handles on a donor kidney can be performed in different locations (e g., two hospitals or clinics).

[0137] In an aspect, a disclosed method can further comprise procuring an organ, a portion of a donor organ, a tissue, a connective tissue, or a population of cells from a donor. In an aspect, a donor can be a living donor that has consented to making a live organ donation. In an aspect, a donor can be a donor that has been declared brain dead. In an aspect, a donor can be a donor that has experienced cardiac death. In an aspect, a disclosed method can further comprise transplanting into a recipient a disclosed functionalized donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells.

[0138] In an aspect, a disclosed method can comprise preserving a procured disclosed donor organ, disclosed portion of a donor organ, disclosed donor tissue, disclosed donor connective tissue, or disclosed donor population of cells, flushing a procured disclosed donor organ, disclosed portion of a donor organ, disclosed donor tissue, disclosed donor connective tissue, or disclosed donor population of cells to deplete amines, installing azide tethers or azide handles via a perfusion pump or gravity perfusion, and flushing the procured disclosed donor organ, the disclosed portion of a donor organ, the disclosed donor tissue, the disclosed donor connective tissue, or the disclosed donor population of cells to remove unreacted azide tethers or azide handles.

[0139] In an aspect, a disclosed method can comprise preserving a procured organ, portion of a donor organ, donor tissue, connective tissue, or population of cells, flushing a procured organ, portion of a donor organ, donor tissue, connective tissue, or population of cells to deplete amines,installing azide tethers or azide handles via a perfusion pump or gravity perfusion, and flushing the procured organ, portion of a donor organ, donor tissue, connective tissue, or population of cells to remove unreacted azide tethers or azide handles; and then transplanting the functionalized donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells.

[0140] In an aspect, a disclosed method can comprise preserving a procured organ, portion of a donor organ, donor tissue, connective tissue, or population of cells flushing a procured organ to deplete amines, installing azide tethers or azide handles via a perfusion pump or gravity perfusion, and flushing the procured organ, portion of donor organ, donor tissue, connective tissue, or population of cells to remove unreacted azide tethers or azide handles; then transplanting the functionalized donor organ, portion of donor organ, donor tissue, connective tissue, or population of cells; and then administering to the recipient one or more payloads or one or more molecules.

[0141] In an aspect, a disclosed method can comprise preserving a procured organ, flushing a procured organ, portion of a donor organ, donor tissue, connective tissue, or population of cells to deplete amines, installing azide tethers or azide handles via a perfusion pump or gravity perfusion, and flushing the procured organ, portion of a donor organ, donor tissue, connective tissue, or population of cells to remove unreacted azide tethers or azide handles; then transplanting the functionalized donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells; and then administering one or more times to the recipient one or more pay loads or one or more molecules.

[0142] In an aspect, a disclosed method can comprise preserving a procured kidney, flushing a procured kidney to deplete amines, installing azide tethers or azide handles via a perfusion pump or gravity perfusion, and flushing the procured kidney to remove unreacted azide tethers or azide handles.

[0143] In an aspect, a disclosed method can comprise preserving a procured kidney, flushing a procured kidney to deplete amines, installing azide tethers or azide handles via a perfusion pump or gravity perfusion, and flushing the procured kidney to remove unreacted azide tethers or azide handles; and then transplanting the functionalized donor kidney.

[0144] In an aspect, a disclosed method can comprise preserving a procured kidney, flushing a procured kidney to deplete amines, installing azide tethers or azide handles via a perfusion pump or gravity perfusion, and flushing the procured kidney to remove unreacted azide tethers or azide handles; then transplanting the functionalized donor kidney; and then administering to the recipient one or more payloads or one or more molecules.

[0145] In an aspect, a disclosed method can comprise preserving a procured kidney, flushing a procured kidney to deplete amines, installing azide tethers or azide handles via a perfusion pumpor gravity perfusion, and flushing the procured kidney to remove unreacted azide tethers or azide handles; then transplanting the functionalized donor kidney; and then administering one or more times to the recipient one or more payloads or one or more molecules.

[0146] In an aspect, a disclosed method comprising preserving a procured organ, flushing a procured organ to deplete amines, installing azide tethers or azide handles via a perfusion pump or gravity perfusion, and flushing the procured organ to remove unreacted azide tethers or azide handles can comprise about 45 minutes - 75 minutes.

[0147] In an aspect, a disclosed method comprising preserving a procured organ, portion of a donor organ, donor tissue, connective tissue, or population of cells, flushing a procured organ, portion of a donor organ, donor tissue, connective tissue, or population of cells to deplete amines, installing azide tethers or azide handles via a perfusion pump or gravity perfusion, and flushing the procured organ, portion of a donor organ, donor tissue, connective tissue, or population of cells to remove unreacted azide tethers or azide handles can comprise about 60 minutes. In an aspect, a disclosed method comprising preserving a procured kidney, flushing a procured kidney to deplete amines, installing azide tethers or azide handles via a perfusion pump or gravity perfusion, and flushing the procured kidney to remove unreacted azide tethers or azide handles can comprise about 45 minutes - 75 minutes. In an aspect, a disclosed method comprising preserving a procured kidney, flushing a procured kidney to deplete amines, installing azide tethers or azide handles via a perfusion pump or gravity perfusion, and flushing the procured kidney to remove unreacted azide tethers or azide handles can comprise about 60 minutes.

[0148] In an aspect, upon procurement, flushing a procured donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells can ensure that high concentrations of amino acids and other nucleophilic compounds designed to protect cellular metabolism during cold storage (but can also interfere with a disclosed bioorthogonal reaction such as, for example, a CuAAC reaction, a IEDDA reaction, or a SPAAC reaction) are removed from the donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells. In an aspect, upon procurement, flushing a procured donor kidney can ensure that high concentrations of amino acids and other nucleophilic compounds designed to protect cellular metabolism during cold storage (but can also interfere with a disclosed bioorthogonal reaction such as, for example, a CuAAC reaction, a IEDDA reaction, or a SPAAC reaction) are removed from the donor kidney.

[0149] In an aspect, gravity perfusion can be obtained by controlling or modifying the height of the infusion bag relative to the donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells. In an aspect, an arterial pressure of about 60 mmHg can be achieved in a donor organ by gravity perfusion. In an aspect, an arterial pressure of about 60 mmHg canbe achieved in a donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells by gravity perfusion, wherein the infusion bag is about 70 cm to about 100 cm higher than the donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells. In an aspect, an arterial pressure of about 60 mmHg can be achieved in a donor organ by gravity perfusion, wherein the infusion bag is about 75 cm to about 90 cm higher than the donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells. In an aspect, an arterial pressure of about 60 mmHg can be achieved in a donor organ by gravity perfusion, wherein the infusion bag is about 80 cm to about 85 cm higher than the donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells. In an aspect, a disclosed infusion bag can be mounted on an adjustable IV pole and moved up and down to generate a difference in pressures in the disclosed donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells.

[0150] In an aspect, gravity perfusion can be obtained by controlling or modifying the height of the infusion bag relative to the donor kidney. In an aspect, an arterial pressure of about 60 mmHg can be achieved in a donor kidney by gravity perfusion. In an aspect, an arterial pressure of about 60 mmHg can be achieved in a donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells by gravity perfusion, wherein the infusion bag is about 70 cm to about 100 cm higher than the donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells. In an aspect, an arterial pressure of about 60 mmHg can be achieved in a donor organ by gravity perfusion, wherein the infusion bag is about 75 cm to about 90 cm higher than the donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells. In an aspect, an arterial pressure of about 60 mmHg can be achieved in a donor organ by gravity’ perfusion, wherein the infusion bag is about 80 cm to about 85 cm higher than the donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells. In an aspect, a disclosed infusion bag can be mounted on an adjustable IV pole and moved up and down to generate a difference in pressures in the disclosed donor kidney. In an aspect, using gravity-based perfusion can confer one or more advantages including, for example, simplifying the perfusion setup and / or reducing the risk of pressure-induced vascular injury. In an aspect, using gravity-based can enable uniform perfusion of a donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells or a donor kidney.

[0151] In an aspect, a disclosed azide tether or a disclosed azide handle can persist longer than a systemically administered payload or systemically administered molecule. In an aspect, a disclosed azide tether or a disclosed azide handle can persist longer than a systemically administered therapeutic payload or systemically administered therapeutic molecule.

[0152] In an aspect, upon procurement, a disclosed procured organ can be transferred to cold preservation for ORGANIC modification. In an aspect, upon procurement, a disclosed procured kidney can be transferred to cold preservation for ORGANIC modification.

[0153] In an aspect, following procurement, one or more steps of a disclosed method can be performed under cold storage conditions. In an aspect, following procurement, one or more steps of a disclosed method can be performed on ice.

[0154] In an aspect, upon procurement, a disclosed donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells can be flushed with a UW Belzer solution or another standard preservation solution. In an aspect, upon procurement, a disclosed procured kidney can be flushed with a UW Belzer solution or another standard preservation solution. In an aspect, flushing a disclosed donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells or a disclosed donor kidney can remove residual blood. In an aspect, a disclosed kidney can be flushed with an amine-free solution. In an aspect, a disclosed kidney can be flushed with an amine-free solution via the renal artery. In an aspect, a disclosed kidney can be flushed via the renal artery with cold PBS or cold Belzer University of Wisconsin (UW) solution or another disclosed standard preservation solution. In an aspect, following an initial flushing with PBS or UW Belzer or another standard preservation solution, a disclosed organ can be transitioned to PlasmaLyte or an analogous physiologically compatible saline substitute. In an aspect. PlasmaLyte or an analogous physiologically compatible saline substitute can be used to remove preservation solution components and / or endogenous amine-containing species. In an aspect, PlasmaLyte or an analogous physiologically compatible saline substitute can be used prior to chemical modification. In an aspect, PlasmaLyte or an analogous physiologically compatible saline substitute can be used prior to ORGANIC modification. In an aspect, PlasmaLyte or an analogous physiologically compatible saline substitute can be used prior to installing the disclosed azide tethers or the disclosed azide handles. In an aspect, PlasmaLyte can be used prior to functionalizing the donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells ex vivo. In an aspect, PlasmaLyte or an analogous physiologically compatible saline substitute can be delivered by gravity perfusion on ice.

[0155] In an aspect, upon procurement, a disclosed donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells can be flushed with a UW Belzer solution or another standard preservation solution and transferred to cold preservation for ORGANIC modification. In an aspect, upon procurement, a disclosed donor kidney can be flushed with a UW Belzer solution or another standard preservation solution transferred to cold preservation for ORGANIC modification.

[0156] As known to the skilled person, Belzer UW or UW Belzer solution is a sterile non-pyrogenic solution and comprises Pentafraction (50 g / L); Lactobionic Acid (as Lactone) (35.83 g / L); Potassium Phosphate monobasic (3.4 g / L); Magnesium Sulfate heptahydrate (1.23 g / L); Raffinose pentahydrate (17.83 g / L); Adenosine (1.34 g / L); Allopurinol (0.136 g / L); Total Glutathione (0.922 g / L); Potassiuim Hydroxide (5.61 g / L); Sodium Hydroxide, 5N (5.0 mL / L); and Water for Injection (q.s.); and with an osmolarity of approximately 320 mOsm; a sodium concentration of approximately 29 mEq / L; a potassium concentration of approximately 125 mEq / L; and a pH of approximately 7.4 at 20 °C.

[0157] In an aspect, another standard preservation solution can be any solution known to the art and used to preserve an organ, portion of a donor organ, donor tissue, connective tissue, or population of cells following procurement from a donor. In an aspect, another standard preservation solution can be one that is commonly used for cold storage (e.g., Celsior Solution, Euro-Collins Solution, Institut Georges Lopez-1 (IGL-1) Solution, Perfadex Solution, Stanford Solution, Collins Solution, SPS-1 (Static Preservation Solution-1), KPS-1 (Kidney Preservation Solution-1), ET-Kyoto Solution, Servator B. Servator H, Servator C, Servator P, Sevartor M, SCOT Solution (Solution de Conservation des Organes et des Tissus), Polysol Solution, Biolasol Solution, Lifor Solution, Unisol Solution, Custodiol-N Solution, Somah Solution, etc.).

[0158] In an aspect, other standard preservation solution can comprise histidine-tryptophan-ketoglutarate solution (HTK).

[0159] In an aspect, another standard preservation solution can comprise CoStorSol (University of Wisconsin). In an aspect, CoStorSol can comprise Pentafraction (50 g / L); Lactobionic Acid (as Lactone) 935.83 g / L); Potassium Phosphate monobasic (3.4 g / L);Magnesium Sulfate heptahydrate (1.23 g / L): Raffinose pentahydrate (17.83 g / L); Adenosine (1.34 g / L): Allopurinol (0.136 g / L); Total Glutathione (0.922 g / L); Potassium Hydroxide (5.61 g / L); Sodium Hydroxide / Hydrochloric Acid (Adjust to pH 7.4); Water for Injection (q.s.).

[0160] In an aspect, another standard preservation solution can comprise Celsior (manufactured by IGL). In an aspect, Celsior can comprise Glutathione (0.921 g (3 mmol)); Mannitol : 10.930 g (60 mmol)); Lactobionic acid : 28.664 g (80 mmol)); Glutamic acid : 2.942 g (20 mmol)); Sodium hydroxide : 4.000 g (100 mmol)); Calcium chloride dihydrate : 0.037 g (0.25 mmol)); Potassium chloride : 1.118 g (15 mmol)); Magnesium chloride hexahydrate (2.642 g (13 mmol)); Histidine (4.650 g (30 mmol)); Water for injection; and Sodium hydroxide (4% (pH adjustment)).

[0161] In an aspect, another standard preservation solution can comprise SPS-1. In an aspect, SPS-1 can compnse Hydroxyethyl Starch (HES) (50 g); Lactobionic Acid (as Lactone) (35.83 g); Potassium Phosphate monobasic (3.4 g); Magnesium Sulfate heptahydrate (1.23 g); RaffinosePentahydrate (17.83 g); Adenosine (1.34 g); Allopurinol (0.136 g); Glutathione (reduced form) (0.922 g); and Potassium Hydroxide (5.61 g).

[0162] In an aspect, another standard preservation solution can comprise KPS-1. In an aspect, KPS-1 can comprise Calcium chloride (dihydrate) (0.068 g); Sodium hydroxide (0.70 g); HEPES (free acid) (2.38 g); Potassium phosphate (monobasic) (3.4 g); Mannitol (USP) (5.4 g); Glucose, beta D (+) (1.80 g); Sodium gluconate (17.45 g); Magnesium gluconate D (-) gluconic acid, hemimagnesium salt (1.13 g); Ribose, D (-) (0.75 g); Hydroxyethyl Starch (HES) (50.0 g); Glutathione (reduced form) (0.92 g); Adenine (free base) (0.68 g).

[0163] In an aspect, another standard preservation solution can comprise Servator B. In an aspect, Servator B can comprise Pentafraction (50 g / L); Lactobionic Acid (as Lactone) (35.83 g / L); Potassium Phosphate monobasic (3.4 g / L); Magnesium Sulfate heptahydrate (1.23 g / L); Raffinose pentahydrate (17.83 g / L); Adenosine (1.34 g / L); Allopurinol (0.136 g / L); Total Glutathione (0.922 g / L); Potassium Hydroxide (5.61 g / L); and Sodium Hydroxide / Hydrochloric Acid (adjust to pH 7.4). In an aspect, another standard preservation solution can comprise Servator H. In an aspect, Servator H can comprise Sodium Chloride (0.8766 g / L); Potassium Chloride (0.6710 g / L); Magnesium Chloride (0.8132 g / L); Histidine Hydrochloride (3.7733 g / L); Histidine Tryptophan (27.9289 g / L); Mannitol (5.4651 g / L); Calcium Chloride (0.0022 g / L); and Potassium Hydrogen 2-oxopentandioate (0.1842 g / L). In an aspect, another standard preservation solution can comprise Servator C. In an aspect. Servator C can comprise Glutathione (0.922 g / L); Mannitol (10.931 g / L); Lactobionic acid (28.660 g / L); Glutamic acid (2.943 g / L); Sodium hydroxide (4.000 g / L); Calcium chloride (0.037 g / L); Potassium chloride (1.12 g / L); Magnesium chloride (2.645 g / L); Histidine (4.655 g / L); and Water for injection (q.s. to 1000 mL). In an aspect, another standard preservation solution can comprise Servator P. In an aspect, Servator P can comprise Dextran 40 (50 g / L); Glucose Monohydrate (1 g / L); Potassium Chloride (0.4 g / L); Sodium Chloride (8 g / L); Potassium Phosphate monobasic (0.063 g / L); Sodium phosphate dibasic dehydrate or Disodium phosphate (0.0576 g / L); Magnesium Sulphate Heptahydrate or Magnesium Sulphate (0.201 g / L); and Water for injection (q.s. to 1000 ml). In an aspect, another standard preservation solution can comprise Servator M. In an aspect. Servator M can comprise Adenine (free base) (0.68 g / L); Calcium Chloride dihydrate (0.068 g / L); Dextrose (1.80 g / L); Glutathione (reduced) (0.92 g / L); HEPES (free acid) (2.38 g / L); Hydroxy ethyl Starch (50.0 g / L); Magnesium Gluconate (anhydrous) (1.13 g / L); Mannitol (5.4 g / L); Potassium Phosphate (monobasic) (3.4 g / L); Ribose, D-(-) (0.75 g / L); Sodium Gluconate (17.45 g / L); Sodium Hydroxide (0.70 g / L); and Water for injection (q.s. to 1000 mL).

[0164] In an aspect, a disclosed flushing with a UW Belzer solution or another standard preservation solution can be continued for at least 5 minutes, at least 6 minutes, at least 7 minutes, at least 8 minutes, at least 9 minutes, at least 10 minutes, at least 11 minutes, at least 12 minutes, at least 13 minutes, at least 14 minutes, at least 15 minutes, at least 16 minutes, at least 17 minutes, at least 19 minutes, at least 19 minutes, at least 20 minutes, at least 25 minutes, at least 30 minutes, at least 35 minutes, at least 40 minutes, at least 45 minutes, at least 50 minutes, at least 55 minutes, at least 60 minutes, or more than 60 minutes. In an aspect, a disclosed flushing with a UW Belzer solution or another standard preservation solution can be continued for at least 5 minutes to at least 30 minutes. In an aspect, a disclosed flushing with a UW Belzer solution or another standard preservation solution can be continued for at least 15 minutes to at least 30 minutes.

[0165] In an aspect, a disclosed flushing with a UW Belzer solution or another standard preservation solution can comprise at least 20 mL, at least 30 rnL, at least 40 rnL, at least 50 mL, at least 60 mL, at least 70 mL, at least 80 mL, at least 90 mL, at least 100 mL, at least 110 mL, at least 120 mL, at least 130 mL. at least 140 mL, at least 150 rnL, at least 160 mL, at least 170 mL, at least 180 mL, at least 190 mL, at least 200 mL, at least 210 mL, at least 220 mL, at least 240 mL, at least 250 mL, at least 260 mL, at least 270 mL, at least 280 mL, at least 290 mL, at least 300 mL, at least 310 mL, at least 320 mL, at least 330 mL, at least 340 mL, at least 350 mL, at least 360 rnL, at least 370 mL, at least 380 mL, at least 390 rnL, at least 400 mL, at least 410 mL, at least 420 mL. at least 430 mL, at least 440 mL, at least 450 mL, at least 460 mL, at least 470 mL, at least 480 mL, at least 490 rnL, at least 500 rnL, or more than 500 mL. In an aspect, a disclosed flushing can comprise at least 0.1 L, at least 0.2 L, at least 0.3 L, at least 0.4 L, at least 0.5 L, at least 0.6 L, at least 0.7 L, at least 0.8 L, at least 0.9 L, at least 1.0 L, or more than 1.0 L. In an aspect, a disclosed flushing with a UW Belzer solution or another standard preservation solution can comprise about 200 mL to about 500 mL.

[0166] In an aspect, the volume and / or the duration of a flushing with a UW Belzer solution or another standard preservation solution can be modified in view of one or more considerations (including, for example, vascular resistance, flow rate, perfusion pump v. gravity' perfusion, etc.) or any combination thereof.

[0167] In an aspect, a disclosed method can comprise (i) flushing the donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells with a first solution; (ii) removing the first solution by flushing a second solution; (iii) infusing the donor organ with the azide solution or solution comprising azide tethers or azide handles; and (iv) flushing the donor organ with another solution (e.g., the second solution) to remove the unreacted azide solution.

[0168] In an aspect a disclosed method can comprise (i) flushing the donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells with a UW Belzer solution or another standard preservation solution; (ii) removing the UW Belzer solution or the other standard preservation solution by flushing with PlasmaLyte or an analogous physiologically compatible saline substitute; (iii) infusing the donor organ with the azide solution or solution comprising azide tethers or azide handles; and (iv) flushing the donor organ with PlasmaLyte or an analogous physiologically compatible saline substitute to remove the unreacted azide solution.

[0169] In an aspect, upon procurement, a disclosed procured organ, portion of a donor organ, donor tissue, connective tissue, or population of cells can be flushed with cold phosphate buffered saline (PBS) or a UW Belzer solution or another standard preservation solution. In an aspect, a disclosed PBS-flushed or a disclosed UW Belzer solution-flushed or another standard preservation solution-flushed organ, portion of a donor organ, donor tissue, connective tissue, or population of cells can be injected with a solution comprising a disclosed azide handle or a disclosed azide tether. In an aspect, a disclosed PBS-flushed or a disclosed UW Belzer-flushed organ or another standard preservation solution-flushed organ, portion of a donor organ, donor tissue, connective tissue, or population of cells can be injected with a solution comprising NHS-azide. In an aspect, a disclosed PBS-flushed or a disclosed UW Belzer solution-flushed or another standard preservation solution-flushed organ, portion of a donor organ, donor tissue, connective tissue, or population of cells can be injected with a solution comprising NHS-PEG4-azide. In an aspect, a disclosed PBS-flushed or a disclosed UW Belzer solution-flushed or another standard preservation solution-flushed organ, portion of a donor organ, donor tissue, connective tissue, or population of cells can be injected with a solution comprising NHS-azide tethers or handles. In an aspect, a disclosed PBS-flushed or a disclosed UW Belzer solution-flushed or another standard preservation solution-flushed organ, portion of a donor organ, donor tissue, connective tissue, or population of cells can be injected with a solution comprising NHS-PEG4-azide tethers or handles.

[0170] In an aspect, a disclosed PBS-flushed or a disclosed UW Belzer solution-flushed or another standard preservation solution-flushed organ, portion of a donor organ, donor tissue, connective tissue, or population of cells can be injected with a solution comprising a disclosed azide handle or a disclosed azide tether via an artery. In an aspect, a disclosed PBS-flushed or a disclosed UW Belzer solution-flushed or another standard preservation solution-flushed organ, portion of a donor organ, donor tissue, connective tissue, or population of cells can be injected with a solution comprising NHS-PEGi-azide an artery. In an aspect, a disclosed solution comprising a disclosed azide handle or a disclosed azide tether can comprise a PBS solution or a UW Belzer solution or another standard preservation solution.

[0171] As known to the skilled person, PlasmaLyte comprises sodium chloride (5.26 g / L), potassium chloride (0.37 g / L), magnesium chloride hexahydrate (0.30 g / L), sodium acetate trihydrate (3.68 g / L), sodium gluconate (5.02 g / L) as well as water for injections and sodium hydroxide.

[0172] In an aspect, upon procurement, a disclosed procured kidney can be transferred to cold preservation for ORGANIC modification. In an aspect, a disclosed procured kidney can be flushed with cold phosphate buffered saline (PBS) or a disclosed UW Belzer solution or another disclosed standard preservation solution. In an aspect, a disclosed PBS-flushed or a disclosed UW Belzer solution-flushed or another standard preservation solution-flushed kidney can be injected with a solution comprising a disclosed azide handle or a disclosed azide tether. In an aspect, a disclosed PBS-flushed or a disclosed UW Belzer solution-flushed or another standard preservation solution-flushed kidney can be injected with a solution comprising NHS-azide. In an aspect, a disclosed PBS-flushed or a disclosed UW Belzer solution-flushed or another standard preservation solution-flushed kidney can be injected with a solution comprising NHS-PEGt-azide. In an aspect, a disclosed PBS-flushed or a disclosed UW Belzer solution-flushed or another standard preservation solution-flushed kidney can be injected w ith a solution comprising NHS-azide tethers or handles. In an aspect, a disclosed PBS-flushed or a disclosed UW Belzer solution-flushed or another standard preservation solution-flushed kidney can be injected with a solution comprising NHS-PEG4-azide tethers or handles.

[0173] In an aspect, a disclosed PBS-flushed or a disclosed UW Belzer solution-flushed or another standard preservation solution-flushed kidney can be injected with a solution comprising a disclosed azide handle or a disclosed azide tether via the renal artery7. In an aspect, a disclosed PBS-flushed or a disclosed UW Belzer solution-flushed or another standard preservation solutionflushed kidney can be injected with a solution comprising NHS-PEGt-azide via the renal artery. In an aspect, a disclosed solution comprising a disclosed azide handle or a disclosed azide tether can comprise a PBS solution or a disclosed UW Belzer solution or another disclosed standard preservation solution.

[0174] In an aspect of a disclosed method, a disclosed solution can be introduced in a donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells via an artery. In an aspect of a disclosed method, a disclosed solution can be introduced in a donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells via an artery while one or more veins in the donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells are clamped or occluded. In an aspect of a disclosed method, the clamping or occlusion of the veins in the organ donor, portion of a donor organ, donor tissue, connective tissue,or population of cells can facilitate the interaction between the tethers or handles and the cells and / or tissues of the organ donor, portion of a donor organ, donor tissue, connective tissue, or population of cells. In an aspect of a disclosed method, the interaction between the NHS esters and accessible primary' amines of proteins in the cells and / or tissue can be facilitated.

[0175] In an aspect of a disclosed method, adisclosed solution can be introduced in a donor kidney¬ via the renal artery. In an aspect of a disclosed method, a disclosed solution can be introduced in a donor kidney via the renal artery while renal vein in the donor kidney is clamped or occluded. In an aspect of a disclosed method, the clamping or occlusion of the renal vein in the donor kidney can facilitate the interaction between the tethers or handles and the cells and / or tissues of the donor kidney. In an aspect of a disclosed method, the interaction between the NHS esters and accessible primary amines of proteins in kidney cells and / or kidney tissue can be facilitated.

[0176] In an aspect of a disclosed method, perfusion of a disclosed donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells can be performed using gravity-driven flow. In an aspect of a disclosed method, perfusion of a disclosed donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells can be performed using a pump or a perfusion pump.

[0177] In an aspect of a disclosed method, following the injection of a disclosed azide solution, the donor organ can be stored and / or incubated on ice for at least 5 minutes, at least 6 minutes, at least 7 minutes, at least 8 minutes, at least 9 minutes, at least 10 minutes, at least 11 minutes, at least 12 minutes, at least 13 minutes, at least 14 minutes, at least 15 minutes, at least 16 minutes, at least 17 minutes, at least 19 minutes, at least 19 minutes, at least 20 minutes, at least 25 minutes, at least 30 minutes, at least 35 minutes, at least 40 minutes, at least 45 minutes, at least 50 minutes, at least 55 minutes, at least 60 minutes, or more than 60 minutes. In an aspect of a disclosed method, following the injection of a disclosed azide solution, the donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells can be stored and / or incubated on ice for at least 1 hour, at least 1.5 hours, at least 2 hours, at least 2.5 hours, at least 3 hours, at least 3.5 hours, at least 4 hours, at least 4.5 hours, or at least 5 hours.

[0178] In an aspect of a disclosed method, following the injection of a disclosed azide solution, the donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells can be stored and / or incubated on ice for between 10 minutes and 20 minutes prior to a flush to remove the unreacted azide. In an aspect of a disclosed method, following the injection of a disclosed azide solution, the donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells can be stored and / or incubated on ice for between 30 min and 60 min prior to a flush to remove the unreacted azide.

[0179] In an aspect, the volume of a disclosed azide solution delivered to a disclosed donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells can comprise at least 5 rnL, at least 10 mL, at least 15 rnL, at least 20 mL, at least 25 mL, at least 30 mL, at least 35 mL, at least 40 mL, at least 45 mL, at least 50 mL, at least 55 mL, at least 60 mL, at least 65 mL, at least 70 mL, at least 75 mL, at least 80 mL, at least 85 mL, at least 90 mL, at least 95 mL, at least 100 mL, or more than at least 100 mL. In an aspect, the volume of a disclosed azide solution delivered to a disclosed donor kidney can comprise at least 5 mL, at least 10 mL, at least 15 mL, at least 20 rnL, at least 25 mL, at least 30 mL, at least 35 mL, at least 40 mL, at least 45 mL, at least 50 mL, at least 55 mL, at least 60 mL, at least 65 mL, at least 70 mL, at least 75 mL, at least 80 mL, at least 85 mL, at least 90 mL, at least 95 mL, at least 100 mL. or more than at least 100 rnL.

[0180] In an aspect, a disclosed solution can comprise at least 50 pM azide, at least 60 pM azide, at least 70 pM azide, at least 80 pM azide, at least 90 pM azide, at least 100 pM azide, at least 110 pM azide, at least 120 pM azide, at least 130 pM azide, at least 140 pM azide, at least 150 pM azide, at least 160 pM azide, at least 170 pM azide, at least 180 pM azide, at least 190 pM azide, at least 200 pM azide, at least 210 pM azide, at least 220 pM azide, at least 230 pM azide, at least 240 pM azide, at least 250 pM azide, at least 260 pM azide, at least 270 pM azide, at least 280 pM azide, at least 290 pM azide, at least 300 pM azide, at least 310 pM azide, at least 320 pM azide, at least 330 pM azide, at least 340 pM azide, at least 350 pM azide, at least 360 pM azide, at least 370 pM azide, at least 380 pM azide, at least 390 pM azide, at least 400 pM azide, at least 410 pM azide, at least 420 pM azide, at least 430 pM azide, at least 440 pM azide, at least 450 pM azide, at least 460 pM azide, at least 470 pM azide, at least 480 pM azide, at least 490 pM azide, at least 500 pM azide, or more than 500 pM azide.

[0181] In an aspect, after being stored and / or incubated, a disclosed functionalized donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells can be flushed one or more times with PBS or PlasmaLyte or an analogous physiologically compatible saline substitute prior to transplantation into a recipient. In an aspect of a disclosed method, after being stored and / or incubated, unreacted reagent can be removed with one or more PBS flushes or one or more or PlasmaLyte flushes or flushes with an analogous physiologically compatible saline substitute prior to transplantation. In an aspect, after being stored and / or incubated, a disclosed donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells can be flushed one or more times with PlasmaLyte or an analogous physiologically compatible saline substitute prior to transplantation into a recipient. In an aspect of a disclosed method, after being stored and / or incubated, unreacted reagent can be removed with one or more PlasmaLyte flushesor flushes with an analogous physiologically compatible saline substitute prior to transplantation. In an aspect, after being stored and / or incubated, a disclosed functionalized donor kidney can be flushed one or more times with PBS prior to transplantation into a recipient. In an aspect of a disclosed method, after being stored and / or incubated, unreacted reagent can be removed with one or more PBS flushes prior to transplantation. In an aspect, after being stored and / or incubated, a disclosed functionalized donor kidney can be flushed one or more times with PlasmaLyte or an analogous physiologically compatible saline substitute prior to transplantation into a recipient. In an aspect of a disclosed method, after being stored and / or incubated, unreacted reagent can be removed with one or more PlasmaLyte flushes or flushes with an analogous physiologically compatible saline substitute prior to transplantation.

[0182] In an aspect, after being stored and / or incubated, a disclosed functionalized donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells can be flushed one or more times with an appropriate solution prior to transplantation into a recipient. In an aspect of a disclosed method, after being stored and / or incubated, unreacted reagent can be removed from the functionalized donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells with one or more flushes with an appropriate solution prior to transplantation. In an aspect, after being stored and / or incubated, a disclosed functionalized kidney organ can be flushed one or more times with an appropriate solution prior to transplantation into a recipient. In an aspect of a disclosed method, after being stored and / or incubated, unreacted reagent can be removed from the functionalized donor kidney with one or more flushes with an appropriate solution prior to transplantation.

[0183] In an aspect, a disclosed handle or a disclosed tether can withstand cold storage ex vivo, reperfusion on implantation, post-implantation vascular shear stress, early immune remodeling, or any combination thereof.

[0184] In an aspect, a disclosed handle or a disclosed tether can support durable post-transplant therapeutic capture. In an aspect, one or more steps of a disclosed method can be conducted and / or performed under sterile conditions using clinically relevant preservation solutions. In an aspect, a disclosed donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells can be maintained under static cold storage unless otherwise specified.

[0185] In an aspect, a disclosed donor kidney can be maintained under static cold storage unless otherwise specified. In an aspect, a disclosed method can minimize supraphysiologic stress and / or can preserve kidney tissue integrity. In an aspect of a disclosed method, perfusion and / or flushing of a disclosed donor kidney can be performed using gravity-driven flow. In an aspect of a disclosed method, perfusion and / or flushing of a disclosed donor kidney can be performed usinga pump or a perfusion pump. In an aspect, a disclosed perfusion can achieve uniform delivery throughout a disclosed donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells. In an aspect, a disclosed perfusion can achieve uniform delivery throughout distal cortical cells of a disclosed donor kidney.

[0186] In an aspect, a disclosed flushing can be continued for a pre-determined time. In an aspect, a disclosed flushing with a disclosed solution can be continued for at least 5 minutes, at least 6 minutes, at least 7 minutes, at least 8 minutes, at least 9 minutes, at least 10 minutes, at least 1 1 minutes, at least 12 minutes, at least 13 minutes, at least 14 minutes, at least 15 minutes, at least 16 minutes, at least 17 minutes, at least 19 minutes, at least 19 minutes, at least 20 minutes, at least 25 minutes, at least 30 minutes, at least 35 minutes, at least 40 minutes, at least 45 minutes, at least 50 minutes, at least 55 minutes, at least 60 minutes, or more than 60 minutes.

[0187] In an aspect, a disclosed flushing with a disclosed solution can comprise at least 20 mL, at least 30 mL, at least 40 mL, at least 50 mL, at least 60 mL, at least 70 mL, at least 80 mL, at least 90 mL, at least 100 mL, at least 110 mL. at least 120 mL, at least 130 mL. at least 140 mL, at least 150 mL, at least 160 mL, at least 170 mL, at least 180 mL, at least 190 mL, at least 200 mL, at least 210 mL, at least 220 mL, at least 240 mL, at least 250 mL, at least 260 mL, at least 270 mL, at least 280 mL, at least 290 mL, at least 300 mL, at least 310 mL, at least 320 mL, at least 330 mL, at least 340 mL, at least 350 mL. at least 360 mL, at least 370 mL, at least 380 mL, at least 390 mL. at least 400 mL, at least 410 mL, at least 420 mL, at least 430 mL, at least 440 mL, at least 450 mL, at least 460 mL, at least 470 mL, at least 480 mL, at least 490 mL, at least 500 mL, or more than 500 mL. In an aspect, a disclosed flushing can comprise at least 0.1 L, at least 0.2 L, at least 0.3 L, at least 0.4 L, at least 0.5 L, at least 0.6 L, at least 0.7 L, at least 0.8 L, at least 0.9 L, at least 1.0 L. or more than 1.0 L. In an aspect, a disclosed flushing can comprise about 200 mL to about 500 mL.

[0188] In an aspect, a disclosed PlasmaLyte flushing or flushing with an analogous physiologically compatible saline substitute can be continued for at least 5 minutes, at least 6 minutes, at least 7 minutes, at least 8 minutes, at least 9 minutes, at least 10 minutes, at least 11 minutes, at least 12 minutes, at least 13 minutes, at least 14 minutes, at least 15 minutes, at least 16 minutes, at least 17 minutes, at least 19 minutes, at least 19 minutes, at least 20 minutes, at least 25 minutes, at least 30 minutes, at least 35 minutes, at least 40 minutes, at least 45 minutes, at least 50 minutes, at least 55 minutes, at least 60 minutes, or more than 60 minutes.

[0189] In an aspect, a disclosed PlasmaLyte flushing or flushing with an analogous physiologically compatible saline substitute can comprise at least 20 mL, at least 30 mL, at least 40 mL, at least 50 mL, at least 60 mL, at least 70 mL, at least 80 mL, at least 90 mL, at least 100mL, at least 110 mL, at least 120 mL. at least 130 mL, at least 140 mL, at least 150 mL, at least 160 mL, at least 170 mL, at least 180 mL, at least 190 mL, at least 200 mL, at least 210 mL, at least 220 mL, at least 240 mL, at least 250 mL, at least 260 mL, at least 270 mL, at least 280 mL, at least 290 mL, at least 300 mL, at least 310 mL, at least 320 mL, at least 330 mL, at least 340 mL, at least 350 mL, at least 360 mL. at least 370 mL, at least 380 mL, at least 390 mL, at least 400 mL. at least 410 mL, at least 420 mL, at least 430 mL, at least 440 mL, at least 450 mL, at least 460 mL, at least 470 mL, at least 480 mL, at least 490 mL, at least 500 mL, or more than 500 mL. In an aspect, a disclosed PlasmaLyte flushing or flushing with an analogous physiologically compatible saline substitute can comprise at least 0.1 L, at least 0.2 L, at least 0.3 L, at least 0.4 L, at least 0.5 L. at least 0.6 L, at least 0.7 L, at least 0.8 L, at least 0.9 L, at least 1.0 L. or more than 1.0 L.

[0190] In an aspect, a disclosed ORGANIC protocol can comprise one or more steps of the process set forth in FIG. 5C.

[0191] In an aspect, during a perfusion, effluent can be collected at one or more defined intervals. In an aspect, effluent can be collected one or more times to evaluate the presence of remaining, unreacted azide tethers or azide handles. In an aspect, a disclosed effluent can be subjected to an analysis. In an aspect, a disclosed effluent can be evaluated for amine content. In an aspect of a disclosed method, evaluating a disclosed effluent for amine content can be quantified using the 2,4,6-trinitrobenzene sulfonic acid (TNBSA) assay according to the manufacturer's instructions. In an aspect, one or more aliquots of a disclosed effluent can be reacted with TNBSA reagent under alkaline conditions. In an aspect, absorbance can be measured by UV-Vis spectroscopy. In an aspect, glycine standards can be used to generate a calibration curve. In an aspect, amine content can be calculated. In an aspect, amine content can be calculated to ascertain the effectiveness of a disclosed flushing. In an aspect, amine content can be calculated to ascertain the effectiveness of one or more disclosed flushings.

[0192] In an aspect, strain-promoted azide-alkyne cycloaddition (SPAAC) reactivity can be quantified by monitoring the spectral signature of DBCO prior to and / or during a reaction with one or more effluent samples. In an aspect, effluent samples can be incubated with excess DBCO, and UV-Vis absorbance spectra can be acquired over time. In an aspect, loss of characteristic DBCO absorbance peaks at 292 nm and 309 nm can be used as a readout of azide-alkyne reaction. In an aspect, reduced absorbance loss in post-reaction effluent relative to inflow controls can be interpreted as evidence of azide consumption by tissue binding.

[0193] In an aspect, a disclosed method can further comprise generating a standard value or control value for each expressed biomarker detected in a disclosed effluent. In an aspect, adisclosed method can further comprise generating a standard value or control value for each expressed biomarker detected in a disclosed effluent over time so that the standard value or control value represents the entirety of functionalizing process.

[0194] In an aspect, a disclosed functionalized donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells can comprise programmable capture sites. In an aspect, a disclosed functionalized donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells can function as a selective chemical sink for circulating therapeutic payloads and / or circulating therapeutic molecules. In an aspect, a disclosed functionalized donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells can function as a selective chemical sink for circulating molecule. In an aspect, a disclosed functionalized donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells can sequester a circulating therapeutic payload and / or circulating therapeutic molecule. In an aspect, a disclosed functionalized donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells can sequester a circulating molecule.

[0195] In an aspect, disclosed surface-exposed azide handles or disclosed surface-exposed azide tethers can be stable. In an aspect, disclosed surface-exposed azide handles or disclosed surface-exposed azide tethers can be durable. In an aspect, disclosed surface-exposed azide handles or surface-exposed azide tethers can persist and can be functional for at least 2 weeks, at least 3 weeks, at least 4 weeks, at least 5 weeks, at least 6 weeks, at least 7 weeks, at least 8 weeks, at least 9 weeks, at least 10 weeks, at least 11 weeks, at least 12 weeks, at least 13 weeks, at least 14 weeks, at least 15 weeks, at least 16 weeks, at least 17 weeks, at least 18 weeks, at least 19 weeks, at least 20 weeks, or more than 20 weeks.

[0196] In an aspect, disclosed surface-exposed azide handles or disclosed surface-exposed azide tethers can persist and can be functional for at least 1 month, at least 2 months, at least 3 months, at least 4 months, at least 5 months, at least 6 months, at least 7 months, at least 8 months, at least 9 months, at least 10 months, at least 11 months, at least 12 months, at least 13 months, at least 14 months, at least 15 months, at least 16 months, at least 17 months, at least 18 months, at least 19 months, at least 20 months, at least 21 months, at least 22 months, at least 23 months, at least 24 months, at least 25 months, at least 26 months, at least 27 months, at least 28 months, at least 29 months, at least 30 months, at least 31 months, at least 32 months, at least 33 months, at least 35 months, at least 34 months, or more than 36 months. In an aspect, disclosed surface-exposed azide handles or disclosed surface-exposed azide tethers can persist and can be functional for at least 1 year, at least 2 years, at least 3 years, at least 4 years, at least 5 years, at least 6 years, at least 7 years, at least 8 years, at least 9 years, at least 10 years, or more than 10 years.

[0197] In an aspect, a disclosed method can further comprise repeated captures or serial captures of a disclosed therapeutic payload or a disclosed therapeutic molecule by engineered donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells or by a functionalized donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells. In an aspect, disclosed repeated captures or disclosed serial captures of a disclosed therapeutic payload or a disclosed therapeutic molecule by engineered donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells or by a functionalized donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells can comprise differing payloads or differing molecules.

[0198] In an aspect, a first disclosed therapeutic pay load can be the same as a second disclosed therapeutic payload. In an aspect, a first disclosed therapeutic payload can be the same as one or more subsequent therapeutic payloads. In an aspect, a first disclosed therapeutic payload can be different than as a second disclosed therapeutic payload. In an aspect, a first disclosed therapeutic pay load can be different than one or more subsequent therapeutic pay loads. In an aspect, a first disclosed therapeutic molecule can be the same as a second disclosed therapeutic molecule. In an aspect, a first disclosed therapeutic molecule can be the same as one or more subsequent therapeutic molecules. In an aspect, a first disclosed therapeutic molecule can be different than as a second disclosed therapeutic molecule. In an aspect, a first disclosed therapeutic molecule can be different than one or more subsequent therapeutic molecule.

[0199] In an aspect, a disclosed functionalized donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells can comprise a reloadable platform for targeted drug delivery following transplantation. In an aspect, a disclosed engineered donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells can comprise a reloadable platform for targeted drug delivery following transplantation.

[0200] In an aspect, a disclosed functionalized donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells can improve localizations of targeted drug delivery following transplantation. In an aspect, a disclosed engineered donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells can improve localizations of targeted drug delivery following transplantation.

[0201] In an aspect, disclosed circulating payloads or disclosed circulating molecules can comprise any payload or any molecule that has a DBCO modification, an ODIBO modification, a DIBO modification, or a BCN modification. In an aspect, disclosed circulating payloads or disclosed circulating molecules can comprise a DBCO modification, an ODIBO modification, a DIBO modification, or a BCN modification.

[0202] In an aspect, a disclosed method can enable the selective capture of one or more molecules at the transplanted organ, portion of a donor organ, donor tissue, connective tissue, or population of cells. In an aspect, a disclosed molecule can comprise a therapeutic molecule. In an aspect, a disclosed molecule can comprise a DBCO modification, an ODIBO modification, a DIBO modification, or a BCN modification. In an aspect, a disclosed molecule can comprise a therapeutic molecule having a DBCO modification, an ODIBO modification, a DIBO modification, or a BCN modification.

[0203] In an aspect, a disclosed circulating payload or a disclosed circulating molecule can comprise an oligonucleotide therapeutic agent. In an aspect, a disclosed oligonucleotide therapeutic agent can comprise a single-stranded or double-stranded DNA, iRNA, shRNA, siRNA, mRNA, non-coding RNA (ncRNA), an antisense molecule, miRNA, a morpholino, a peptide-nucleic acid (PNA), or an analog or conjugate thereof. In an aspect, a disclosed oligonucleotide therapeutic agent can be an ASO or an RNAi. In an aspect, a disclosed oligonucleotide therapeutic agent can comprise one or more modifications at any position applicable. In an aspect, a disclosed oligonucleotide therapeutic agent can comprise a CR1SPR-based endonuclease. In an aspect, a disclosed endonuclease can be Cas9. CRISPR / Cas9 systems and methods are known to the art.

[0204] In an aspect, a disclosed circulating payload or a disclosed circulating molecule can comprise any biologically active agent, pharmaceutically active agent, anti-bacterial agent, antifungal agent, anti-viral agent, corticosteroid, analgesic, immunostimulant, immunomodulatory agent, immune-based product, antibody, antibody fragment, antibody derivative, immune modulator, proteosome inhibitor, small molecule, cytokine, nucleic acid, or any combination thereof. In an aspect, a disclosed circulating payload or a disclosed circulating molecule can comprise nanoparticles. In an aspect, a disclosed circulating payload or a disclosed circulating molecule can comprise any payload or any molecule so long that it can be modified with a DBCO modification, an ODIBO modification, a DIBO modification, or a BCN modification.

[0205] In an aspect, a disclosed circulating payload or a disclosed circulating molecule can comprise one or more immune checkpoint ligands. In an aspect, a disclosed immune checkpoint ligand can serve to deter immune cells from interacting with and / or attacking a transplanted donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells or transplanted donor kidney. In an aspect, a disclosed immune checkpoint can be PD-L1 or CTLA-4.

[0206] In an aspect, a disclosed method can further comprise administering to the recipient one or more times a pharmaceutical formulation comprising complementary reactive groups thatselectively ligate to the transplanted donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells. In an aspect, a disclosed selective ligation can comprise strain-promoted azide-alkyne cycloaddition (SPAAC). In an aspect, a disclosed selective ligation can enable covalent and spatially confined capture within transplanted donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells.

[0207] In an aspect, a disclosed method can enable selective covalent bond formation between mutually reactive molecular partners (e.g., a therapeutic payload or a therapeutic molecule with a tether or a handle) and under physiological conditions. In an aspect, a disclosed method can enable the selective capture of one or more payloads at the transplanted organ. In an aspect, a disclosed payload can comprise a therapeutic payload. In an aspect, a disclosed payload can comprise a DBCO modification, an ODIBO modification, a DIBO modification, or a BCN modification. In an aspect, a disclosed payload can comprise a therapeutic payload having a DBCO modification, an ODIBO modification, a DIBO modification, or a BCN modification. In an aspect, a disclosed method can enable the selective capture of one or more molecules at the transplanted organ. In an aspect, a disclosed molecule can comprise a therapeutic molecule. In an aspect, a disclosed molecule can comprise a DBCO modification, an ODIBO modification, a DIBO modification, or a BCN modification. In an aspect, a disclosed molecule can comprise a therapeutic molecule having a DBCO modification, an ODIBO modification, a DIBO modification, or a BCN modification.

[0208] In an aspect, a disclosed payload can comprise a combination of therapeutic payloads. In an aspect, a disclosed combination of therapeutic payloads can comprise a DBCO modification, an ODIBO modification, a DIBO modification, or a BCN modification.

[0209] In an aspect, a disclosed combination of therapeutic payloads can each have a DBCO modification, an ODIBO modification, a DIBO modification, or a BCN modification. Modifications can be the same or can be different.

[0210] In an aspect, a disclosed combination of therapeutic payloads can comprise payloads belonging to a similar class of pay loads (e.g., one or more antibodies) or belonging to a different class of payloads (e.g., one or more antibodies and one or more non-antibodies). In an aspect, a disclosed molecule can comprise a combination of therapeutic molecules. In an aspect, a disclosed combination of therapeutic molecules can comprise a DBCO modification, an ODIBO modification, a DIBO modification, or a BCN modification. In an aspect, a disclosed combination of therapeutic molecules can each a DBCO modification, an ODIBO modification, a DIBO modification, or a BCN modification. In an aspect, modifications can be the same or can be different.

[0211] In an aspect, a disclosed combination of therapeutic molecules can comprise molecules belonging to a similar class of molecules (e.g., one or more antibodies) or belonging to a different class of molecules (e.g., one or more antibodies and one or more non-antibodies). In an aspect of a disclosed method, a disclosed therapeutic payload can comprise a reactive group that is complementary to the handle or the tether on the functionalized and / or engineered donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells. In an aspect of a disclosed method, a disclosed therapeutic molecule can comprise a reactive group that is complementary to the handle or the tether on the functionalized and / or engineered donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells.

[0212] In an aspect of a disclosed method, a disclosed therapeutic payload can selectively ligate to the handle or the tether on the functionalized and / or engineered donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells via SPAAC. In an aspect of a disclosed method, a disclosed therapeutic molecule can selectively ligate to the handle or the tether on the functionalized and / or engineered donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells via SPAAC. In an aspect, SPAAC can occur independently of an endogenous receptor system.

[0213] In an aspect of a disclosed method, a disclosed therapeutic payload can selectively ligate to the handle or the tether on the functionalized and / or engineered donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells via a disclosed bioorthogonal reaction (such as, for example, a CuAAC reaction, a IEDDA reaction, or a SPAAC reaction). In an aspect of a disclosed method, a disclosed therapeutic payload can selectively ligate to the handle or the tether on the functionalized and / or engineered donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells via any bioorthogonal reaction known to the skilled person in the art. In an aspect of a disclosed method, a disclosed therapeutic molecule can selectively ligate to the handle or the tether on the functionalized and / or engineered donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells via a disclosed bioorthogonal reaction (such as, for example, a CuAAC reaction, a IEDDA reaction, or a SPAAC reaction). In an aspect, a disclosed bioorthogonal reaction can occur independently of an endogenous receptor system. In an aspect of a disclosed method, a disclosed therapeutic molecule can selectively ligate to the handle or the tether on the functionalized and / or engineered donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells via any bioorthogonal reaction known to the skilled person in the art.

[0214] In an aspect of a disclosed method, a disclosed therapeutic payload can selectively ligate to the handle or the tether on the functionalized and / or engineered donor organ or a portion thereof,donor target tissue, donor population of cells, or donor connective tissue via a CuAAC reaction. In an aspect of a disclosed method, a disclosed therapeutic molecule can selectively ligate to the handle or the tether on the functionalized and / or engineered donor organ or a portion thereof, donor target tissue, donor population of cells, or donor connective tissue via a CuAAC reaction. In an aspect of a disclosed method, a disclosed therapeutic payload can selectively ligate to the handle or the tether on the functionalized and / or engineered donor organ or a portion thereof, donor target tissue, donor population of cells, or donor connective tissue via an IEDDA reaction. In an aspect of a disclosed method, a disclosed therapeutic molecule can selectively ligate to the handle or the tether on the functionalized and / or engineered donor organ or a portion thereof, donor target tissue, donor population of cells, or donor connective tissue via an IEDDA reaction. In an aspect of a disclosed method, a disclosed therapeutic payload can selectively ligate to the handle or the tether on the functionalized and / or engineered donor organ or a portion thereof, donor target tissue, donor population of cells, or donor connective tissue via a SPAAC reaction). In an aspect of a disclosed method, a disclosed therapeutic molecule can selectively ligate to the handle or the tether on the functionalized and / or engineered donor organ or a portion thereof, donor target tissue, donor population of cells, or donor connective tissue via a SPAAC reaction.

[0215] In an aspect, a disclosed payload or a disclosed molecule can be delivered to a disclosed target organ (or portion thereof), a disclosed target tissue, a disclosed population of cells, or a disclosed connective tissue one or more times using one or more disclosed bioorthogonal reactions. In an aspect, a disclosed payload or a disclosed molecule can be delivered to a disclosed target organ (or portion thereof), a disclosed target tissue, a disclosed population of cells, or a disclosed connective tissue one or more times using one or more bioorthogonal reactions known to the person skilled in the art.

[0216] In an aspect, a disclosed payload can comprise a one or more diagnostic probes, one or more imaging agents, one or more biosensors, or any combination thereof. In an aspect, a disclosed molecule can comprise a one or more diagnostic probes, one or more imaging agents, one or more biosensors, or any combination thereof. In an aspect, a disclosed payload or a disclosed molecule can comprise a singular payload or a singular molecule, or can comprise a combination of components that constitute a payload or a molecule. In an aspect, a disclosed payload or a disclosed molecule can further comprise an agent that enables a diagnostic assay, a imaging assay or imaging procedure, or a biosensory event or activity to be monitored.

[0217] In an aspect, a disclosed therapeutic payload can comprise one or more agents, each with a reactive group that is complementary to the handle or the tether on the functionalized and / or engineered donor organ, portion of a donor organ, donor tissue, connective tissue, or populationof cells. In an aspect, a disclosed therapeutic molecule can comprise one or more molecules, each with a reactive group that is complementary to the handle or the tether on the functionalized and / or engineered donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells.

[0218] In an aspect, a disclosed therapeutic payload can comprise one or more agents, each with a DBCO modification, an ODIBO modification, a DIBO modification, or a BCN modification. In an aspect, a disclosed therapeutic molecule can comprise one or more molecules, each with a DBCO modification, an ODIBO modification, a DIBO modification, or a BCN modification. In an aspect, a disclosed therapeutic molecule can comprise a fusion product with a DBCO modification, an ODIBO modification, a DIBO modification, or a BCN modification.

[0219] In an aspect, a disclosed therapeutic payload can selectively and covalently ligate to the tether or handle on the functionalized and / or engineered donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells via SPAAC. In an aspect, a disclosed therapeutic molecule can selectively and covalently ligate to the tether or handle on the functionalized and / or engineered donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells via SPAAC.

[0220] In an aspect, a disclosed method can be organ agnostic. In an aspect, a disclosed donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells can comprise (in whole or in part) a kidney, the liver, the heart, a lung, a pancreas, the intestines, the stomach, the uterus, a cornea, skin, the face, a hand, an arm, the larynx, the trachea, a thymus, an ovary, or a penis, or cells thereof. In an aspect, a disclosed donor organ can be a kidney.

[0221] In an aspect, a disclosed donor kidney can comprise installed handles or installed tethers in one or more regions. In an aspect, a disclosed region of a donor kidney can comprise the proximal tubule, cortex, medulla, renal column, pyramid, renal pelvis, major calyx, minor calyx, papillae, or ureter. In an aspect, disclosed tethers or disclosed handles are installed across endothelial, epithelial, tubular, glomerular, and parenchymal compartments.

[0222] In an aspect, following administration of a disclosed therapeutic payload or a disclosed therapeutic molecule, a disclosed method can reduce systemic exposure and off-target toxicity.

[0223] In an aspect, a disclosed method can meet one or more functional design criteria for clinical application. In an aspect of a disclosed method, (i) installation of disclosed handles or disclosed tethers can be compatible with standard organ preservation workflows; (ii) installation of disclosed handles or disclosed tethers can avoid compromising graft viabi li ty; (iii) disclosed handles or disclosed tethers can be stable after transplantation of the donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells into a recipient; (iv) disclosedhandles or disclosed tethers can accumulate circulating therapeutic payloads and / or therapeutic molecules through chemistry-driven ligation rather than passive deposition; or (v) any combination thereof.

[0224] In an aspect, a disclosed method can further comprise validating the installation of the disclosed tethers and / or the disclosed handles. In an aspect of a disclosed method, validating the installation of the disclosed tethers and / or disclosed handles can comprise one or more invasive and / or non-invasive techniques. In an aspect, techniques can comprise macroscopic imaging and / or molecular confirmation. In an aspect of a disclosed method, validating the installation of the disclosed tethers and / or disclosed handles can comprise measuring and / or visualizing one or more biological and / or chemical reactions. In an aspect, for example, measuring and / or visualizing a disclosed biological and / or chemical reaction can comprise a change in color and / or a change in pH. In an aspect, for example, measuring and / or visualizing a disclosed biological and / or chemical reaction can comprise a change that can be measured by ELISA.

[0225] In an aspect, a disclosed method can further comprise quantifying and / or measuring rejection kinetics through longitudinal analyses. In an aspect, a disclosed longitudinal analysis can be performed using a disclosed payload or a disclosed molecule that can be quantified or measured in an invasive or non-invasive manner.

[0226] In an aspect, a disclosed method can effect selective accumulation of a disclosed payload or a disclosed molecule in a transplanted donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells. In an aspect, a disclosed method can effect selective accumulation of a disclosed payload or a disclosed molecule in a transplanted donor kidney.

[0227] In an aspect, upon transplantation, a disclosed method can convert a functionalized donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells into a depot for selectively captured payloads or molecules. In an aspect, upon transplantation, a disclosed method can convert a functionalized donor kidney into a depot for selectively captured payloads or molecules.

[0228] In an aspect, a disclosed method can preserve the functionality of a disclosed functionalized organ, portion of a donor organ, donor tissue, connective tissue, or population of cells. In an aspect, a disclosed method can preserve the functionality of a disclosed functionalized kidney. In an aspect, a disclosed method can preserve the functionality of a disclosed functionalized organ, portion of a donor organ, donor tissue, connective tissue, or population of cells despite immune filtration. In an aspect, a disclosed method can preserve the functionality of a disclosed functionalized kidney despite immune filtration.

[0229] In an aspect, introducing to a donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells a disclosed azide solution can be replaced with a step that comprises a metabolic administration. For example, in an aspect, a solution / compound / formulation comprising azide tethers or azide handles can be administered to a donor prior to procurement of a donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells. In an aspect, metabolic administration can introduce to a donor a solution / compound / formulation comprising azide tethers or azide handles and can rely on the donor’s natural metabolism to incorporate the azide tethers or azide handles into the donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells. In an aspect, the azide tethers or the azide handles can be linked to a sugar, an amino acid, a lipid, or a nucleotide. In an aspect, a sugar, an amino acid, a lipid, or a nucleotide can be modified by the addition of the azide tethers or the azide handles and then incorporated into a solution / compound / formulation for administration to a donor.

[0230] In an aspect, introducing to a donor kidney a disclosed azide solution can be replaced with a step that comprises a metabolic administration. For example, in an aspect, a solution / compound / formulation comprising azide tethers or azide handles can be administered to a donor prior to procurement of a donor kidney. In an aspect, metabolic administration can introduce to a donor a solution / compound / formulation comprising azide tethers or azide handles and can rely on the donor's natural metabolism to incorporate the azide tethers or azide handles into the donor kidney. In an aspect, the azide tethers or the azide handles can be linked to a sugar, an amino acid, a lipid, or anucleotide. In an aspect, a sugar, an amino acid, a lipid, or a nucleotide can be modified by the addition of the azide tethers or the azide handles and then incorporated into a solution / compound / formulation for administration to a donor.

[0231] In an aspect, a disclosed method can further comprise monitoring the recipient posttransplantation. In an aspect, a disclosed method can further comprise providing to the recipient one or more post-operative care regimens (e.g., analgesia, fluid management, etc.). In an aspect, post-transplantation monitoring can include measuring or tracking indicia of rejection (including, for example, levels of BUN, creatinine, electrolytes, etc.). For example, in an aspect of a disclosed method, the level of one or more biomarkers in a biological sample obtained from the recipient can be detected and quantified and / or measured to develop or identify a pattern or trend for each biomarker prior to and following transplantation of a disclosed functionalized donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells or a disclosed functionalized donor kidney . A disclosed pattern or trend for each biomarker can be providedover a number of intervals (such as, e.g., days, weeks, months, or years). In an aspect, the pattern or trend for each biomarker can be characterized by one or more histopathological marker.

[0232] In an aspect of a disclosed method, the period from procurement of the one or more solid organs, portion of a donor organ, donor tissue, connective tissue, or population of cells from the donor to implantation in the recipient can comprise about 1 hour to about 36 hours. Organ harvesting techniques and protocols are known to the skilled person in the art. See, for example, the webpage for United Network for Organ Sharing (UNOS). In an aspect of a disclosed method, the period from procurement to implantation of one or two kidneys can comprise less than 36 hours and preferably less than 24 hours. In an aspect of a disclosed method, the period from procurement to implantation of the heart or one or two lungs can comprise less than 8 hours and preferably less than 4 hours. In an aspect of a disclosed method, the period from procurement to implantation of the liver can comprise less than 12 hours and preferably less than 8 hours. In an aspect of a disclosed method, the period from procurement to implantation of the pancreas can comprise less than 18 hours and preferably less than 12 hours.

[0233] In an aspect, flushing a donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells can comprise flushing via arteries and / or veins, contacting, immersing, bathing, drenching, submersing, and / or coating a donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells with PlasmaLyte or an analogous physiologically compatible saline substitute, PBS, a Belzer UW solution, standard preservation solutions, any disclosed storage and / or preservation solution, or any combination thereof.

[0234] In an aspect, a disclosed method can further comprise treating the recipient with an immunosuppressive regimen. In an aspect, a disclosed immunosuppressive regimen can comprise administering a calcineurin inhibitor, an inosine monophosphate dehydrogenase inhibitor, an antithymocyte globulin, or any combination thereof. In an aspect, a disclosed immunosuppressive regimen can comprise administering cyclosporine, tacrolimus, methotrexate, mycophenolate mofetil, corticosteroids, azathioprine or antithymocyte globulin (ATG), monoclonal antibodies (e.g., anti-CD3, anti-CD5, and anti-IL-2 antibodies), or any combination thereof. In an aspect, a disclosed immunosuppressive regimen can comprise administering mycophenolate mofetil, Alemtuzumab, Antithymocyte globulin (ATG), Sirolimus, Tacrolimus, Thalidomide, Daclizumab, Infliximab, Clofazimine, denileukin diftitox, defibrotide, budesonide, beclomethasone dipropionate, pentostatin, or any combination thereof.

[0235] In an aspect, a disclosed immunosuppressive regimen can comprise administering tacrolimus and mycophenolate mofetil. In an aspect, a disclosed inosine monophosphate dehydrogenase inhibitor can comprise mycophenolate mofetil. In an aspect, mycophenolatemofetil can be administered intravenously. In an aspect, a therapeutically effective dose of my cophenolate mofetil can comprise about 1 mg / kg to about 100 mg / kg. In an aspect, a therapeutically effective does of mycophenolate mofetil can comprise about 1 mg / kg to about 10 mg / kg, about 10 mg / kg to about 20 mg / kg, about 20 mg / kg to about 30 mg / kg, about 30 mg / kg to about 40 mg / kg, about 40 mg / kg to about 50 mg / kg, about 50 mg / kg to about 60 mg / kg, about 60 mg / kg to about 70 mg / kg, about 70 mg / kg to about 80 mg / kg, about 80 mg / kg to about 90 mg / kg, or about 90 mg / kg to about 100 mg / kg. In an aspect, a therapeutically effective does of mycophenolate mofetil can comprise more than 100 mg / kg. In an aspect, a therapeutically effective dose of mycophenolate mofetil can be administer at least 1 time per day, at least 2 times per day, at least 3 times per day. at least 4 times per day, or about 5 times per day. In an aspect, a therapeutically effective dose of mycophenolate mofetil can be about 1500 mg. In an aspect, a therapeutically effective dose of mycophenolate mofetil can be 15 mg / kg - 25 mg / kg administered intravenously and / or orally and administered every 12 hours.

[0236] In an aspect, a therapeutically effective dose of tacrolimus can be about 0.1 mg / kg to about 10.0 mg / kg. In an aspect, a therapeutically effective dose of tacrolimus can be about 0.1 mg / kg to about 1.0 mg / kg, about 1.0 mg / kg to about 2.0 mg / kg, about 2.0 mg / kg to about 3.0 mg / kg, about 3.0 mg / kg to about 4.0 mg / kg, about 4.0 mg / kg to about 5.0 mg / kg, about 5.0 mg / kg to about 6.0 mg / kg, about 6.0 mg / kg to about 7.0 mg / kg, about 7.0 mg / kg to about 8.0 mg / kg, about 8.0 mg / kg to about 9.0 mg / kg. about 9.0 mg / kg to about 10.0 mg / kg, or more than 10.0 mg / kg. In an aspect, a therapeutically effective amount of tacrolimus can be administered about every 8 hours to 12 hours. Generally, a therapeutically effective dose delivered intravenously can be about 1 / 3 of a therapeutically effective dose delivered orally. In an aspect, a disclosed method can employ one or more immunosuppressive agents listed in Table 1. In an aspect, Table 1 provides a listing of clinically acceptable forms of immunosuppression including the agent, the indication, the mechanism of action, the signal disruption, and the adverse effects.Table 1 - Clinically Accepted Forms of Immunosuppression.Immunosuppressive Agent Indication Mechanism of Action Affects production of several Corticosteroids Induction, inflammatory mediators and (Methylprednisolone, Maintenance, and multiple cytokines (IL1, IL2, Prednisone) Rejection IL3, IL6, TNFa, IFN -gamma, PGs, leukotrienes)Interferes with DNA synthesis AntimetabolitesMaintenance by preventing de novo purine (mycophenolate mofetil)synthesisImmunosuppressive Agent Indication Mechanism of Action Blocks protein transcription in Calcineurin Inhibitors (CNI)Maintenance response to IL-2 and prevents (tacrolimus, cyclosporine A)cellular proliferation Inhibitors of mammalian target of rapamycin (mTOR) mTOR InhibtorsMaintenance activation, resulting in cell cycle (Sirolimus, Everolimus)arrest and blockade of T-cell proliferationBiologic agentsAnti-CD3 leads to lysis of (polyclonal antibodies - Induction or rejectionlymphocytesATGAM, Thymoglobulin)Varies Basiliximab'. blockers of T Monoclonal antibodies Rituximab'. - antibody- lymphocyte activation (Muromonab, Daclizumab, mediated rejection Rituzimab is an anti-CD20 (B Basiliximab, Rituximab, Alemtuzumab', chronic cell); Alemtuzumab is an anti- Alemtuzumab) rejection CD52 on nucleated cells of bone Basiliximab'. Induction marrowCostimulation blockade Induction or Blocks CD80 co-stimulation (Belatacept) maintenance ligandTable 1 (continued) - Clinically Accepted Forms of Immunosuppression.Immunosuppressive Agent Signal Disrupted Main Adverse Effect Corticosteroids diabetes, hypertension, (Methylprednisolone. Broad suppression osteoporosis, hirsutism, weight Prednisone) gainAntimetabolites Pancytopenia, Abdominal Proliferation(mycophenolate mofetil) discomfortCalcineurin Inhibitors (CNI) Neurotoxicity, Nephrotoxicity,Signal 3(tacrolimus, cyclosporine A) DiabetogenicmTOR Inhibtors Dow nstream of Signal Hyperlipidemia, Pedal edema, (Sirolimus, Everolimus) 2 and 3 Oral ulcersBiologic agents Anaphylaxis, Post-transplant (polyclonal antibodies - Depletional lymphoproliferatie disorder ATGAM, Thymoglobulin) (PTLD)Monoclonal antibodies Varies,Mixed;(Muromonab, Daclizumab, Rituximab'. Reactivation of TB Signal 3Basiliximab, Rituximab, Alemtuzumab'. Hirsutism, PTLD DepletionalAlemtuzumab) Basiliximab'. Hypersensitivity Costimulation blockadeSignal 2 PTLD. Early rejection(Belatacept)

[0237] In an aspect, a disclosed method can further comprise weaning the recipient off a disclosed immunosuppressive regimen. In an aspect, for example, a skilled clinician can review data generated by testing the recipient's T-cell levels and / or T-cell response (e.g.. MLR) and can modify the immunosuppressive regimen based on that data. In an aspect, for example, a skilled clinician can review data generated obtained by testing one or more biological parameters of the recipient and can modify the immunosuppressive regimen based on that data. In an aspect of a disclosed method, a skilled clinician can use data to guide subsequent steps of treating and / or caring for the recipient.

[0238] In an aspect, a recipient can be maintained on the immunosuppressive regimen based on the generated data. For example, in an aspect, a skilled clinical can review the data and decide to continue administering one or more aspects of the immunosuppressive regimen to the recipient. In an aspect, a disclosed immunosuppressive regimen can be modified based on the generated data. In an aspect, a recipient can be maintained on a modified immunosuppressive regimen based on the generated data. For example, in an aspect, a skilled clinical can review the data and decide to modify7one or more aspects of the immunosuppressive regimen to the recipient. In an aspect, a recipient can be maintained on a modified immunosuppressive regimen based on the generated data. In an aspect, a recipient can be removed from a disclosed immunosuppressive regimen based on the generated data. For example, in an aspect, a skilled clinical can review the data and decide to remove or withdraw one or more aspects of the immunosuppressive regimen

[0239] In an aspect, a disclosed method can comprise biopsying the transplanted donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells or transplanted donor kidney. In an aspect, a disclosed biopsy can occur about 1 month to about 2 months after implant, about 2 months to about 3 months after implant, about 3 months to about 4 months after implant, about 4 months to about 5 months after implant, about 5 months to about 6 months after implant, about 6 months to about 7 months after implant, about 7 months to about 8 months after implant, about 8 months to about 9 months after implant, about 9 months to about 10 months after implant, about 10 months to about 11 months after implant, about 11 moths to about 12 months after implant, or more. In an aspect, a disclosed biopsy can occur about 1 year to about 2 years after implant, about 2 years to about 3 years after implant, about 3 years to about 4 years after implant, about 4 years to about 5 years after implant, about 5 years to about 6 years after implant, about 6 years to about 7 years after implant, about 7 years to about 8 years after implant, about 8 years to about 9 years after implant, about 9 years to about 10 years after implant, or more.

[0240] In an aspect of a disclosed method, a recipient can be in need a solid organ transplant or one or more solid organ transplants. For example, in an aspect, a disclosed solid organ transplantcan comprise a heart, one or two lungs, a liver or portion thereof, one or two kidneys, a pancreas, the intestines or a portion thereof, the small bowel or a portion thereof, or any combination thereof.

[0241] In an aspect, at the time of transplantation, a recipient can be an adult, an adolescent, a child, a toddler, or an infant.

[0242] In an aspect, a disclosed method can further comprise monitoring the recipient for the development of adverse effects. In an aspect, in the absence of adverse effects, a disclosed method can comprise continuing to administer a disclosed immunosuppressive agent and / or a disclosed therapeutic agent. In an aspect, in the presence of adverse effects, a disclosed method can comprise modifying one or more steps of a disclosed method. In an aspect, a disclosed method can further comprise modifying an aspect of the method. In an aspect, modifying an aspect of a disclosed method can comprise changing the amount of a disclosed immunosuppressive agent and / or a disclosed therapeutic agent administered to the recipient, changing the frequency of administration of a disclosed immunosuppressive agent and / or a disclosed therapeutic agent to the recipient, changing the duration of time that a disclosed immunosuppressive agent and / or a disclosed therapeutic agent is administered to a recipient, or any combination thereof.

[0243] In an aspect, a disclosed method can be performed without an increased risk of clotting and / or without an increased risk of thrombosis.

[0244] In an aspect, a disclosed method can be performed without genetic modification of the recipient's cells, tissues, and / or organs. In an aspect, a disclosed method can be performed without genetic modification of the cells and / or tissues of the donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells.

[0245] In an aspect of a disclosed method, a fluorophore can be added to a disclosed payload or a disclosed molecule.

[0246] In an aspect, a disclosed method can decrease and / or minimize the severity of a rejection event of the one or more transplanted organs. In an aspect, a disclosed method can prevent the rejection of the one or more transplanted organs. In an aspect, a disclosed rejection event can be classified a hyperacute rejection event, an acute rejection event, or a chronic rejection event. In an aspect of a disclosed method, the one or more transplanted organs are not rejected by the subject. In an aspect, a disclosed method can improve and / or increase the viability of one or more transplanted organs. In an aspect of a disclosed method, the functionality of one or more transplanted organs can be improved and / or increased. In an aspect of a disclosed method, the functionality of one or more transplanted organs is not decreased and / or diminished.

[0247] Disclosed herein is a donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells functionalized by the ORGANIC protocol. Disclosed herein is a donor kidney functionalized by the ORGANIC protocol.D. Methods of Preparing a Donor Organ (STEALTH)

[0248] Disclosed herein is a method of preparing a donor organ for transplantation, the method comprising subjecting the donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells to the Surface Tethered Engineered Alloprotective Ligands for Transplant Health (STEALTH) protocol.

[0249] Disclosed herein is a method of preparing a donor organ for transplantation, the method comprising functionalizing a donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells ex vivo by installing reactive groups on the donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells; and using the installed reactive groups to immobilize one or more immunomodulatory ligands.

[0250] Disclosed herein is a method of preparing a donor organ for transplantation, the method comprising functionalizing a donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells by installing azide tethers or azide handles on the donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells; and using the installed azide tethers or azide handles to immobilize one or more immunomodulatory' ligands.

[0251] Disclosed herein is a method of preparing a donor organ for transplantation, the method comprising installing reactive groups on a donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells ex vivo, thereby functionalizing the donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells for subsequent capture of circulating therapeutic payloads or therapeutic molecules; and using the installed reactive groups to immobilize one or more immunomodulatory ligands.

[0252] Disclosed herein is a method of preparing a donor organ for transplantation, the method comprising installing azide tethers or azide handles on a donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells, thereby functionalizing the donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells for subsequent capture of circulating therapeutic payloads or therapeutic molecules; and using the installed azide tethers or azide handles to immobilize one or more immunomodulatory' ligands.

[0253] Disclosed herein is a method of preparing a donor organ for transplantation, the method comprising installing reactive groups on a donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells ex vivo, thereby functionalizing the donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells for subsequent capture ofcirculating payloads or circulating molecules; and using the installed reactive groups to immobilize one or more immunomodulatory ligands.

[0254] Disclosed herein is a method of preparing a donor organ for transplantation, the method comprising installing azide tethers or azide handles on a donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells, thereby functionalizing the donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells for subsequent capture of circulating payloads or circulating molecules; and using the installed azide tethers or azide handles to immobilize one or more immunomodulatory ligands.

[0255] Disclosed herein is a method of preparing a donor organ for transplantation, the method comprising procuring an organ, portion of a donor organ, donor tissue, connective tissue, or population of cells from a donor; and subjecting the donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells to the Surface Tethered Engineered Alloprotective Ligands for Transplant Health (STEALTH) protocol.

[0256] Disclosed herein is a method of preparing a donor organ for transplantation, the method comprising procuring an organ, portion of a donor organ, donor tissue, connective tissue, or population of cells from a donor; functionalizing a donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells ex vivo by installing reactive groups on the donor organ; and using the installed reactive groups to immobilize one or more immunomodulatory ligands.

[0257] Disclosed herein is a method of preparing a donor organ for transplantation, the method comprising procuring an organ, portion of a donor organ, donor tissue, connective tissue, or population of cells from a donor; functionalizing a donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells by installing azide tethers or azide handles on the donor organ; and using the installed azide tethers or azide handles to immobilize one or more immunomodulatory ligands.

[0258] Disclosed herein is a method of preparing a donor organ for transplantation, the method comprising procuring an organ, portion of a donor organ, donor tissue, connective tissue, or population of cells from a donor; and installing reactive groups on a donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells ex vivo, thereby functionalizing the donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells for subsequent capture of circulating therapeutic payloads or therapeutic molecules; and using the installed reactive groups to immobilize one or more immunomodulatory ligands.

[0259] Disclosed herein is a method of preparing a donor organ for transplantation, the method comprising procuring an organ, portion of a donor organ, donor tissue, connective tissue, or population of cells from a donor; and installing azide tethers or azide handles on a donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells, thereby functionalizing the donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells for subsequent capture of circulating therapeutic payloads or therapeutic molecules; and using the installed azide tethers or azide handles to immobilize one or more immunomodulatory ligands.

[0260] Disclosed herein is a method of preparing a donor organ for transplantation, the method comprising procuring an organ, portion of a donor organ, donor tissue, connective tissue, or population of cells from a donor; installing reactive groups on a donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells ex vivo, thereby functionalizing the donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells for subsequent capture of circulating payloads or circulating molecules; and using the installed reactive groups to immobilize one or more immunomodulatory ligands.

[0261] Disclosed herein is a method of preparing a donor organ for transplantation, the method comprising procuring an organ, portion of a donor organ, donor tissue, connective tissue, or population of cells from a donor; installing azide tethers or azide handles on a donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells, thereby functionalizing the donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells for subsequent capture of circulating payloads or circulating molecules; and using the installed azide tethers or azide handles to immobilize one or more immunomodulatory ligands.

[0262] Disclosed herein is a method of preparing a donor organ for transplantation, the method comprising procuring an organ, portion of a donor organ, donor tissue, connective tissue, or population of cells from a donor; subjecting the donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells to the Surface Tethered Engineered Alloprotective Ligands for Transplant Health (STEALTH) protocol; and transplanting into a recipient a disclosed functionalized donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells.

[0263] Disclosed herein is a method of preparing a donor organ for transplantation, the method comprising procuring an organ, portion of a donor organ, donor tissue, connective tissue, or population of cells from a donor; functionalizing a donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells ex vivo by installing reactive groups on the donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells; using theinstalled reactive groups to immobilize one or more immunomodulatory ligands; and transplanting into a recipient a disclosed functionalized donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells.

[0264] Disclosed herein is a method of preparing a donor organ for transplantation, the method comprising procuring an organ, portion of a donor organ, donor tissue, connective tissue, or population of cells from a donor; functionalizing a donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells by installing azide tethers or azide handles on the donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells; using the installed azide tethers or azide handles to immobilize one or more immunomodulatory ligands; and transplanting into a recipient a disclosed functionalized donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells.

[0265] Disclosed herein is a method of preparing a donor organ for transplantation, the method comprising procuring an organ, portion of a donor organ, donor tissue, connective tissue, or population of cells from a donor; installing reactive groups on a donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells ex vivo, thereby functionalizing the donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells for subsequent capture of circulating therapeutic payloads or therapeutic molecules; using the installed reactive groups to immobilize one or more immunomodulatory ligands; and transplanting into a recipient a disclosed functionalized donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells.

[0266] Disclosed herein is a method of preparing a donor organ for transplantation, the method comprising procuring an organ, portion of a donor organ, donor tissue, connective tissue, or population of cells from a donor; installing azide tethers or azide handles on a donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells, thereby functionalizing the donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells for subsequent capture of circulating therapeutic payloads or therapeutic molecules; using the installed azide tethers or azide handles to immobilize one or more immunomodulatory ligands; and transplanting into a recipient a disclosed functionalized donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells.

[0267] Disclosed herein is a method of preparing a donor organ for transplantation, the method comprising procuring an organ, portion of a donor organ, donor tissue, connective tissue, or population of cells from a donor; installing reactive groups on a donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells ex vivo, thereby functionalizing the donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells forsubsequent capture of circulating payloads or circulating molecules; using the installed reactive groups to immobilize one or more immunomodulatory ligands; and transplanting into a recipient a disclosed functionalized donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells.

[0268] Disclosed herein is a method of preparing a donor organ for transplantation, the method comprising procuring an organ, portion of a donor organ, donor tissue, connective tissue, or population of cells from a donor; installing azide tethers or azide handles on a donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells, thereby functionalizing the donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells for subsequent capture of circulating payloads or circulating molecules; using the installed azide tethers or azide handles to immobilize one or more immunomodulatory ligands; and transplanting into a recipient a disclosed functionalized donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells.

[0269] In an aspect, ORGANIC can comprise installing tethers or handles onto the donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells during standard preservation workflows. In an aspect, a disclosed method can transform the donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells itself into a chemically programmable interface. In an aspect, a disclosed method can establish the donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells itself as a reloadable platform for targeted drug delivery following transplantation. In an aspect, disclosed tethers or disclosed handles can be conjugated to primary amines belonging to proteins on the cell surface. This conjugation can be covalent. This conjugation can be NHS-ester-mediated. Following the NHS-ester-mediated conjugation, a disclosed tether or a disclosed handle can be used for subsequent click-based capture of a cyclooctyne-modified payload or cyclooctyne-modified molecule.

[0270] In an aspect, disclosed connective tissue can comprise fascia, tendons, ligaments, or any type of connective tissue known to the art.

[0271] In an aspect, a disclosed functionalized donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells can comprise surface-exposed azide handles or surface-exposed azide tethers capable of participating in SPAAC reactions. In an aspect, a disclosed engineered donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells can comprise surface-exposed azide handles or tethers capable of participating in SPAAC reactions. In an aspect, a disclosed method can incorporate principles of bioorthogonal chemistry.

[0272] In an aspect, the installation of azide tethers or azide handles can comprise steps of the process set forth in FIG. 5E.

[0273] In an aspect, installing azide tethers or azide handles can comprise use of a bioorthogonal reaction. In an aspect, bioorthogonal reactions can comprise a Staudinger ligation (in which azides and phosphines are biocompatible and which stable amide linkages are produced), a CuAAC reaction (which is a fast reaction with well-established chemistry and good regioselectivity), a SPAAC reaction (which does not use copper catalysts), a tetrazine ligation (which has very fast reactions with tunable kinetics / stability tunable), a metal-catalyzed biorthogonal reactions, a native chemical ligation, an oxime and hydrazone ligation, a light-catalyzed biorthogonal reaction, and an IEDDA reaction. In an aspect, a disclosed bioorthogonal reaction can comprise an oximehydrazone ligation. In an aspect, oximes and hydrazones can be formed through the condensation of carbonyl groups with alkoxy amines and hydrazines, respectively. In an aspect, a disclosed Staudinger ligation reaction can comprise azide and triphenylphosphine. In an aspect, a disclosed CuAAC reaction, Cu(I) can react with the sulfhydryl group in the organism. In an aspect, a disclosed Staudinger ligation can comprise an in vivo formation of amide bonds. In an aspect, a disclosed photoinducible bioorthogonal chemistry can comprise spatio-temporal control with light. In an aspect, a disclosed oxime and hydrazone ligation can be enabled by ketone and aldehyde tags. In an aspect, a disclosed strain-promoted [3+2] cycloaddition can comprise copper-free coupling with 1,3-dipoles. In an aspect, a disclosed tetrazine ligation can comprise exceptionally rapid kinetics. In an aspect, a disclosed palladium and ruthenium-catalyzed coupling can comprise unique tags for biomolecule modification. In an aspect, a disclosed copper-catalyzed azide-alkyne cycloaddition can comprise minimal size, can be readily accessible, and can be broadly useful. In an aspect, a disclosed native chemical ligation can comprise protein synthesis from synthetic or expressed fragments.

[0274] In an aspect, the attachment of DBCO modified-PD-Ll attachment to azide tethers or azide handles can comprise steps of the process set forth in FIG. 11B, FIG. 12A - FIG. 12C. In an aspect, the installation of azide tethers or azide handles can comprise steps of the process set forth in FIG. 5E. In an aspect, the attachment of DBCO modified-CTLA-4 attachment to azide tethers or azide handles can comprise steps of the process set forth in FIG. 11B, FIG. 12A - FIG. 12C.

[0275] In an aspect, STEALTH can be defined as building upon ORGANIC. In other words, STEALTH can comprise installing azide tethers or azide handles on the surface of a donor organ or a donor kidney, and then attaching PD-L1 to the azide tethers or azide handles. In an aspect, STEALTH can incorporate ORGANIC and then can add the covalent attachment of PD-L1. Inan aspect, STEALTH can comprise (i) azide tether or handle installation, and (ii) DBCO-PD-L1 surface ligation or attachment.

[0276] In an aspect, a disclosed DBCO modified-PD-Ll can be generated according to a disclosed process (e.g., the process set forth in FIG. 11B and / or described in Example 2). In an aspect, a disclosed DBCO modification can be substituted with an ODIBO modification, a DIBO modification, or a BCN modification to generate a ODIBO modified-PD-Ll, a DIBO modified-PD-L1 , or a BCN modified-PD-Ll .

[0277] In an aspect, STEALTH can be defined as building upon ORGANIC. In other words, STEALTH can comprise installing azide tethers or azide handles on the surface of a donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells or a donor kidney, and then attaching CTLA-4 to the azide tethers or azide handles. In an aspect, STEALTH can incorporate ORGANIC and then can add the covalent attachment of CTLA-4. In an aspect, STEALTH can comprise (i) azide tether or handle installation, and (ii) DBCO-CTLA-4 surface ligation or attachment.

[0278] In an aspect, a disclosed DBCO modified-CTLA-4 can be generated according to a disclosed process (e.g., the process set forth in FIG. 11B and / or described in Example 2). In an aspect, a disclosed DBCO modification can be substituted with an ODIBO modification, a DIBO modification, or a BCN modification to generate a ODIBO modified-CTLA-4, a DIBO modified-CTLA-4, or a BCN modified-CTLA-4.

[0279] In an aspect, procuring a disclosed donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells and functionalizing a disclosed donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells can be performed in a singular location (e.g., one hospital or clinic). In an aspect, procuring a disclosed donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells and functionalizing a disclosed donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells can be performed in different locations (e.g., two hospitals or clinics). In an aspect, procuring a disclosed donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells, installing azide tethers or azide handles on a donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells and using the installed azide tethers or azide handles to immobilize one or more immunomodulatory ligands can be performed in a singular location (e.g., one hospital or clinic). In an aspect, procuring a disclosed donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells, installing azide tethers or azide handles on a donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells, and using the installed azide tethers or azide handles to immobilize one ormore immunomodulatory ligands can be performed in different locations (e.g., two hospitals or clinics).

[0280] In an aspect, procuring a disclosed donor kidney and functionalizing a disclosed donor kidney can be performed in a singular location (e.g., one hospital or clinic). In an aspect, procuring a disclosed donor kidney and functionalizing a disclosed donor kidney can be performed in different locations (e.g., two hospitals or clinics). In an aspect, procuring a disclosed donor kidney and then installing azide tethers or azide handles on a donor kidney and using the installed azide tethers or azide handles to immobilize one or more immunomodulatory' ligands can be performed in a singular location (e.g., one hospital or clinic). In an aspect, procuring a disclosed donor kidney and then installing azide tethers or azide handles on a donor kidney and using the installed azide tethers or azide handles to immobilize one or more immunomodulatory7ligands can be performed in different locations (e.g., two hospitals or clinics).

[0281] In an aspect, a disclosed method can further comprise procuring an organ, portion of a donor organ, donor tissue, connective tissue, or population of cells from a donor. In an aspect, a donor can be a living donor that has consented to making a live organ donation. In an aspect, a donor can be a donor that has been declared brain dead. In an aspect, a donor can be a donor that has experienced cardiac death. In an aspect, a disclosed method can further comprise transplanting into a recipient a disclosed functionalized donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells.

[0282] In an aspect, following transplantation, PD-L1 can attenuate T cell receptor signaling, can suppress inflammatory cytokine production, can promote regulatory' T cell (Treg) activities, or any combination thereof. In an aspect, following transplantation, PD-L1 can sene to locally restrain alloimmune activation. In an aspect, following transplantation, PD-L1 can establish a localized inhibitory signaling environment in and around the transplanted donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells. In an aspect, following transplantation, PD-L1 can sene to bias antigen presentation and T cell engagement toward regulatory rather than inflammatory outcome. In an aspect, PD-L1 can enable checkpoint signaling to be incorporated into the donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells or donor kidney. In an aspect, PD-L1 can retain functional checkpoint activity' when immobilized. In an aspect, PD-L1 can retain modulate T cell responses. In an aspect, PD-L1 can mitigate organ injury' and / or can preserve organ function. In an aspect, PD-L1 can modulate the intragraft immune landscape, can promote enrichment and activation of regulatory T cells, can restrain alloimmune activation, can limit B cell expansion, or any combination thereof. In an aspect, PD-L1 can suppress immune activation in and around thetransplanted donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells. In an aspect, PD-L1 can promote both the expansion and spatial organization of regulatory T cell populations in and around the transplanted donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells. In an aspect, PD-L1 can preserve the microarchitecture of the transplanted donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells. In an aspect, PD-L1 can delay the onset of or minimize the severity of tissue necrosis and / or architectural collapse of the transplanted donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells. In an aspect, PD-L1 can improve the function of the transplanted donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells despite ischemic stress and / or alloimmune stress.

[0283] In an aspect, a disclosed method can comprise preserving a procured organ, portion of a donor organ, donor tissue, connective tissue, or population of cells; flushing a procured organ, portion of a donor organ, donor tissue, connective tissue, or population of cells to deplete amines; installing azide tethers or azide handles via a perfusion pump or gravity perfusion; flushing the procured organ, portion of a donor organ, donor tissue, connective tissue, or population of cells to remove unreacted azide tethers or azide handles; and using the installed azide tethers or azide handles to immobilize one or more immunomodulatory ligands.

[0284] In an aspect; a disclosed method can comprise preserving a procured organ, portion of a donor organ, donor tissue, connective tissue, or population of cells; flushing a procured organ, portion of a donor organ, donor tissue, connective tissue, or population of cells to deplete amines; installing azide tethers or azide handles via a perfusion pump or gravity perfusion; flushing the procured organ, portion of a donor organ, donor tissue, connective tissue, or population of cells to remove unreacted azide tethers or azide handles; using the installed azide tethers or azide handles to immobilize one or more immunomodulatory ligands; and then transplanting the functionalized donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells.

[0285] In an aspect; a disclosed method can comprise preserving a procured organ, portion of a donor organ, donor tissue, connective tissue, or population of cells; flushing a procured organ, portion of a donor organ, donor tissue, connective tissue, or population of cells to deplete amines; installing azide tethers or azide handles via a perfusion pump or gravity perfusion; flushing the procured organ, portion of a donor organ, donor tissue, connective tissue, or population of cells to remove unreacted azide tethers or azide handles; using the installed azide tethers or azide handles to immobilize one or more immunomodulatory ligands; transplanting the functionalized donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells; and then administering to the recipient one or more payloads or one or more molecules.

[0286] In an aspect; a disclosed method can comprise preserving a procured organ; flushing a procured organ, portion of a donor organ, donor tissue, connective tissue, or population of cells to deplete amines; installing azide tethers or azide handles via a perfusion pump or gravity perfusion; flushing the procured organ, portion of a donor organ, donor tissue, connective tissue, or population of cells to remove unreacted azide tethers or azide handles; using the installed azide tethers or azide handles to immobilize one or more immunomodulatory ligands; transplanting the functionalized donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells; and then administering one or more times to the recipient one or more pay loads or one or more molecules.

[0287] In an aspect; a disclosed method can comprise preserving a procured kidney; flushing a procured kidney to deplete amines; installing azide tethers or azide handles via a perfusion pump or gravity perfusion; flushing the procured kidney to remove unreacted azide tethers or azide handles; and using the installed azide tethers or azide handles to immobilize one or more immunomodulatory ligands

[0288] In an aspect; a disclosed method can compnse preserving a procured kidney; flushing a procured kidney to deplete amines; installing azide tethers or azide handles via a perfusion pump or gravity perfusion; flushing the procured kidney to remove unreacted azide tethers or azide handles; using the installed azide tethers or azide handles to immobilize one or more immunomodulatory ligands; and then transplanting the functionalized donor kidney.

[0289] In an aspect; a disclosed method can comprise preserving a procured kidney; flushing a procured kidney to deplete amines; installing azide tethers or azide handles via a perfusion pump or gravity7perfusion; flushing the procured kidney to remove unreacted azide tethers or azide handles; using the installed azide tethers or azide handles to immobilize one or more immunomodulatory ligands; transplanting the functionalized donor kidney; and then administering to the recipient one or more payloads or one or more molecules.

[0290] In an aspect; a disclosed method can comprise preserving a procured kidney; flushing a procured kidney to deplete amines; installing azide tethers or azide handles via a perfusion pump or gravity perfusion; flushing the procured kidney to remove unreacted azide tethers or azide handles; using the installed azide tethers or azide handles to immobilize one or more immunomodulatory ligands; transplanting the functionalized donor kidney; and then administering one or more times to the recipient one or more payloads or one or more molecules.

[0291] In an aspect; a disclosed method comprising preserving a procured organ, portion of a donor organ, donor tissue, connective tissue, or population of cells; flushing a procured organ, portion of a donor organ, donor tissue, connective tissue, or population of cells to deplete amines;installing azide tethers or azide handles via a perfusion pump or gravity’ perfusion; flushing the procured organ, portion of a donor organ, donor tissue, connective tissue, or population of cells to remove unreacted azide tethers or azide handles; and using the installed azide tethers or azide handles to immobilize one or more immunomodulatory’ ligands can comprise about 45 - 75 minutes.

[0292] In an aspect; a disclosed method comprising preserving a procured organ, portion of a donor organ, donor tissue, connective tissue, or population of cells; flushing a procured organ, portion of a donor organ, donor tissue, connective tissue, or population of cells to deplete amines; installing azide tethers or azide handles via a perfusion pump or gravity' perfusion; flushing the procured organ, portion of a donor organ, donor tissue, connective tissue, or population of cells to remove unreacted azide tethers or azide handles; and using the installed azide tethers or azide handles to immobilize one or more immunomodulatory ligands can comprise about 60 minutes. In an aspect; a disclosed method comprising preserving a procured kidney; flushing a procured kidney to deplete amines; installing azide tethers or azide handles via a perfusion pump or gravity perfusion; flushing the procured kidney to remove unreacted azide tethers or azide handles; and using the installed azide tethers or azide handles to immobilize one or more immuno-modulatory ligands can comprise about 45 - 75 minutes. In an aspect; a disclosed method comprising preserving a procured kidney; flushing a procured kidney to deplete amines; installing azide tethers or azide handles via a perfusion pump or gravity perfusion; flushing the procured kidney to remove unreacted azide tethers or azide handles; and using the installed azide tethers or azide handles to immobilize one or more immunomodulatory’ ligands can comprise about 60 minutes.

[0293] In an aspect, a disclosed method can comprise preserving a procured organ; flushing a procured organ to deplete amines; installing azide tethers or azide handles via a perfusion pump or gravity perfusion; flushing the procured organ to remove unreacted azide tethers or azide handles; and using the installed azide tethers or azide handles to immobilize PD-L1.

[0294] In an aspect; a disclosed method can comprise preserving a procured organ, portion of a donor organ, donor tissue, connective tissue, or population of cells; flushing a procured organ, portion of a donor organ, donor tissue, connective tissue, or population of cells to deplete amines; installing azide tethers or azide handles via a perfusion pump or gravity' perfusion; flushing the procured organ, portion of a donor organ, donor tissue, connective tissue, or population of cells to remove unreacted azide tethers or azide handles; using the installed azide tethers or azide handles to immobilize PD-L1; and then transplanting the functionalized donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells.

[0295] In an aspect; a disclosed method can comprise preserving a procured organ, portion of a donor organ, donor tissue, connective tissue, or population of cells; flushing a procured organ, portion of a donor organ, donor tissue, connective tissue, or population of cells to deplete amines; installing azide tethers or azide handles via a perfusion pump or gravity perfusion; flushing the procured organ, portion of a donor organ, donor tissue, connective tissue, or population of cells to remove unreacted azide tethers or azide handles; using the installed azide tethers or azide handles to immobilize PD-L1 ; transplanting the functionalized donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells; and then administering to the recipient one or more payloads or one or more molecules.

[0296] In an aspect; a disclosed method can comprise preserving a procured organ, portion of a donor organ, donor tissue, connective tissue, or population of cells; flushing a procured organ, portion of a donor organ, donor tissue, connective tissue, or population of cells to deplete amines; installing azide tethers or azide handles via a perfusion pump or gravity perfusion; flushing the procured organ, portion of a donor organ, donor tissue, connective tissue, or population of cells to remove unreacted azide tethers or azide handles; using the installed azide tethers or azide handles to immobilize PD-L1; transplanting the functionalized donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells; and then administering one or more times to the recipient one or more pay loads or one or more molecules.

[0297] In an aspect; a disclosed method can comprise preserving a procured kidney; flushing a procured kidney to deplete amines; installing azide tethers or azide handles via a perfusion pump or gravity perfusion; flushing the procured kidney to remove unreacted azide tethers or azide handles; and using the installed azide tethers or azide handles to immobilize PD-L1

[0298] In an aspect; a disclosed method can comprise preserving a procured kidney; flushing a procured kidney to deplete amines; installing azide tethers or azide handles via a perfusion pump or gravity perfusion; flushing the procured kidney to remove unreacted azide tethers or azide handles; using the installed azide tethers or azide handles to immobilize PD-L1; and then transplanting the functionalized donor kidney.

[0299] In an aspect; a disclosed method can comprise preserving a procured kidney; flushing a procured kidney to deplete amines; installing azide tethers or azide handles via a perfusion pump or gravity perfusion; flushing the procured kidney to remove unreacted azide tethers or azide handles; using the installed azide tethers or azide handles to immobilize PD-L1; transplanting the functionalized donor kidney; and then administering to the recipient one or more payloads or one or more molecules.

[0300] In an aspect; a disclosed method can comprise preserving a procured kidney; flushing a procured kidney to deplete amines; installing azide tethers or azide handles via a perfusion pump or gravity perfusion; flushing the procured kidney to remove unreacted azide tethers or azide handles; using the installed azide tethers or azide handles to immobilize PD-L1; transplanting the functionalized donor kidney; and then administering one or more times to the recipient one or more payloads or one or more molecules.

[0301] Tn an aspect; a disclosed method comprising preserving a procured organ, portion of a donor organ, donor tissue, connective tissue, or population of cells; flushing a procured organ, portion of a donor organ, donor tissue, connective tissue, or population of cells to deplete amines; installing azide tethers or azide handles via a perfusion pump or gravity’ perfusion; flushing the procured organ, portion of a donor organ, donor tissue, connective tissue, or population of cells to remove unreacted azide tethers or azide handles; and using the installed azide tethers or azide handles to immobilize PD-L1 can comprise about 45 - 75 minutes.

[0302] In an aspect; a disclosed method comprising preserving a procured organ, portion of a donor organ, donor tissue, connective tissue, or population of cells; flushing a procured organ, portion of a donor organ, donor tissue, connective tissue, or population of cells to deplete amines; installing azide tethers or azide handles via a perfusion pump or gravity' perfusion; flushing the procured organ, portion of a donor organ, donor tissue, connective tissue, or population of cells to remove unreacted azide tethers or azide handles; and using the installed azide tethers or azide handles to immobilize PD-L1 can comprise about 60 minutes.

[0303] In an aspect; a disclosed method comprising preserving a procured kidney; flushing a procured kidney to deplete amines; installing azide tethers or azide handles via a perfusion pump or gravity perfusion; flushing the procured kidney to remove unreacted azide tethers or azide handles; and using the installed azide tethers or azide handles to immobilize PD-L1 can comprise about 45 - 75 minutes.

[0304] In an aspect; a disclosed method comprising preserving a procured kidney; flushing a procured kidney to deplete amines; installing azide tethers or azide handles via a perfusion pump or gravity perfusion; flushing the procured kidney to remove unreacted azide tethers or azide handles; and using the installed azide tethers or azide handles to immobilize PD-L1 can comprise about 60 minutes.

[0305] In an aspect, a disclosed method can comprise preserving a procured organ, portion of a donor organ, donor tissue, connective tissue, or population of cells; flushing a procured organ, portion of a donor organ, donor tissue, connective tissue, or population of cells to deplete amines; installing azide tethers or azide handles via a perfusion pump or gravity' perfusion; flushing theprocured organ, portion of a donor organ, donor tissue, connective tissue, or population of cells to remove unreacted azide tethers or azide handles; and using the installed azide tethers or azide handles to immobilize CTLA-4.

[0306] In an aspect; a disclosed method can comprise preserving a procured organ, portion of a donor organ, donor tissue, connective tissue, or population of cells; flushing a procured organ, portion of a donor organ, donor tissue, connective tissue, or population of cells to deplete amines; installing azide tethers or azide handles via a perfusion pump or gravity perfusion; flushing the procured organ, portion of a donor organ, donor tissue, connective tissue, or population of cells to remove unreacted azide tethers or azide handles; using the installed azide tethers or azide handles to immobilize CTLA-4; and then transplanting the functionalized donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells.

[0307] In an aspect; a disclosed method can comprise preserving a procured organ, portion of a donor organ, donor tissue, connective tissue, or population of cells; flushing a procured organ, portion of a donor organ, donor tissue, connective tissue, or population of cells to deplete amines; installing azide tethers or azide handles via a perfusion pump or gravity' perfusion; flushing the procured organ , portion of a donor organ, donor tissue, connective tissue, or population of cells to remove unreacted azide tethers or azide handles; using the installed azide tethers or azide handles to immobilize CTLA-4; transplanting the functionalized donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells; and then administering to the recipient one or more payloads or one or more molecules.

[0308] In an aspect; a disclosed method can comprise preserving a procured organ, portion of a donor organ, donor tissue, connective tissue, or population of cells; flushing a procured organ, portion of a donor organ, donor tissue, connective tissue, or population of cells to deplete amines; installing azide tethers or azide handles via a perfusion pump or gravity' perfusion; flushing the procured organ, portion of a donor organ, donor tissue, connective tissue, or population of cells to remove unreacted azide tethers or azide handles; using the installed azide tethers or azide handles to immobilize CTLA-4; transplanting the functionalized donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells; and then administering one or more times to the recipient one or more payloads or one or more molecules.

[0309] In an aspect; a disclosed method can comprise preserving a procured kidney; flushing a procured kidney to deplete amines; installing azide tethers or azide handles via a perfusion pump or gravity perfusion; flushing the procured kidney to remove unreacted azide tethers or azide handles; and using the installed azide tethers or azide handles to immobilize CTLA-4

[0310] In an aspect; a disclosed method can comprise preserving a procured kidney; flushing a procured kidney to deplete amines; installing azide tethers or azide handles via a perfusion pump or gravity perfusion; flushing the procured kidney to remove unreacted azide tethers or azide handles; using the installed azide tethers or azide handles to immobilize CTLA-4; and then transplanting the functionalized donor kidney.

[0311] In an aspect; a disclosed method can comprise preserving a procured kidney; flushing a procured kidney to deplete amines; installing azide tethers or azide handles via a perfusion pump or gravity perfusion; flushing the procured kidney to remove unreacted azide tethers or azide handles; using the installed azide tethers or azide handles to immobilize CTLA-4; transplanting the functionalized donor kidney; and then administering to the recipient one or more payloads or one or more molecules.

[0312] In an aspect; a disclosed method can comprise preserving a procured kidney; flushing a procured kidney to deplete amines; installing azide tethers or azide handles via a perfusion pump or gravity perfusion; flushing the procured kidney to remove unreacted azide tethers or azide handles; using the installed azide tethers or azide handles to immobilize CTLA-4; transplanting the functionalized donor kidney; and then administering one or more times to the recipient one or more payloads or one or more molecules.

[0313] In an aspect; a disclosed method comprising preserving a procured organ, portion of a donor organ, donor tissue, connective tissue, or population of cells; flushing a procured organ, portion of a donor organ, donor tissue, connective tissue, or population of cells to deplete amines; installing azide tethers or azide handles via a perfusion pump or gravity' perfusion; flushing the procured organ, portion of a donor organ, donor tissue, connective tissue, or population of cells to remove unreacted azide tethers or azide handles; and using the installed azide tethers or azide handles to immobilize CTLA-4 can comprise about 45 - 75 minutes. In an aspect; a disclosed method comprising preserving a procured organ, portion of a donor organ, donor tissue, connective tissue, or population of cells; flushing a procured organ, portion of a donor organ, donor tissue, connective tissue, or population of cells to deplete amines; installing azide tethers or azide handles via a perfusion pump or gravity perfusion; flushing the procured organ, portion of a donor organ, donor tissue, connective tissue, or population of cells to remove unreacted azide tethers or azide handles; and using the installed azide tethers or azide handles to immobilize CTLA-4 can comprise about 60 minutes.

[0314] In an aspect; a disclosed method comprising preserving a procured kidney; flushing a procured kidney to deplete amines; installing azide tethers or azide handles via a perfusion pump or gravity perfusion; flushing the procured kidney to remove unreacted azide tethers or azidehandles; and using the installed azide tethers or azide handles to immobilize CTLA-4 can comprise about 45 - 75 minutes. In an aspect; a disclosed method comprising preserving a procured kidney; flushing a procured kidney to deplete amines; installing azide tethers or azide handles via a perfusion pump or gravity7perfusion; flushing the procured kidney to remove unreacted azide tethers or azide handles; and using the installed azide tethers or azide handles to immobilize CTLA-4 can comprise about 60 minutes.

[0315] Tn an aspect, upon procurement, flushing a procured donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells can ensure that high concentrations of amino acids and other nucleophilic compounds designed to protect cellular metabolism during cold storage (but can also interfere with a disclosed bioorthogonal reaction such as, for example, a CuAAC reaction, a IEDDA reaction, or a SPAAC reaction) are removed from the donor organ. In an aspect, upon procurement, flushing a procured donor kidney can ensure that high concentrations of amino acids and other nucleophilic compounds designed to protect cellular metabolism during cold storage (but can also interfere yvith a disclosed bioorthogonal reaction such as, for example, a CuAAC reaction, a IEDDA reaction, or a SPAAC reaction) are removed from the donor kidney.

[0316] In an aspect, gravity perfusion can be obtained by controlling or modifying the height of the infusion bag relative to the donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells. In an aspect, an arterial pressure of about 60 mmHg can be achieved in a donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells by gravity perfusion. In an aspect, an arterial pressure of about 60 mmHg can be achieved in a donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells by gravity perfusion, wherein the infusion bag is about 70 cm to about 100 cm higher than the donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells. In an aspect, an arterial pressure of about 60 mmHg can be achieved in a donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells by gravity' perfusion, wherein the infusion bag is about 75 cm to about 90 cm higher than the donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells. In an aspect, an arterial pressure of about 60 mmHg can be achieved in a donor organ by gravity perfusion, wherein the infusion bag is about 80 cm to about 85 cm higher than the donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells. In an aspect, a disclosed infusion bag can be mounted on an adjustable IV pole and moved up and down to generate a difference in pressures in the disclosed donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells. In an aspect, gravity perfusion can be obtained by controlling or modifying the height ofthe infusion bag relative to the donor kidney. In an aspect, an arterial pressure of about 60 mmHg can be achieved in a donor kidney by gravity perfusion. In an aspect, an arterial pressure of about 60 mmHg can be achieved in a donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells by gravity perfusion, wherein the infusion bag is about 70 cm to about 100 cm higher than the donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells. In an aspect, an arterial pressure of about 60 mmHg can be achieved in a donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells by gravity perfusion, wherein the infusion bag is about 75 cm to about 90 cm higher than the donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells. In an aspect, an arterial pressure of about 60 mmHg can be achieved in a donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells by gravity' perfusion, wherein the infusion bag is about 80 cm to about 85 cm higher than the donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells. In an aspect, a disclosed infusion bag can be mounted on an adjustable IV pole and moved up and down to generate a difference in pressures in the disclosed donor kidney. In an aspect, using gravity-based perfusion can confer one or more advantages including, for example, simplifying the perfusion setup and / or reducing the risk of pressure-induced vascular injury'. In an aspect, using gravity -based can enable uniform perfusion of a donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells or a donor kidney.

[0317] In an aspect, a disclosed azide tether or a disclosed azide handle can persist longer than a systemically administered payload or systemically administered molecule. In an aspect, a disclosed azide tether or a disclosed azide handle can persist longer than a systemically administered therapeutic payload or systemically administered therapeutic molecule.

[0318] In an aspect, upon procurement, a disclosed procured organ can be transferred to cold preservation for STEALTH modification. In an aspect, upon procurement, a disclosed procured kidney can be transferred to cold preservation for STEALTH modification.

[0319] In an aspect, following procurement, one or more steps of a disclosed method can be performed under cold storage conditions. In an aspect, following procurement, one or more steps of a disclosed method can be performed on ice.

[0320] In an aspect, upon procurement, a disclosed donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells can be flushed with a UW Belzer solution or another standard preservation solution. In an aspect, upon procurement, a disclosed procured kidney can be flushed with a UW Belzer solution or another standard preservation solution. In an aspect, flushing a disclosed donor organ, portion of a donor organ, donor tissue, connective tissue,or population of cells or a disclosed donor kidney can remove residual blood. In an aspect, a disclosed kidney can be flushed with an amine-free solution. In an aspect, a disclosed kidney can be flushed with an amine-free solution via the renal artery. In an aspect, a disclosed kidney can be flushed via the renal artery with cold PBS or cold Belzer University of Wisconsin (UW) solution or another standard preservation solution. In an aspect, following an initial flushing with PBS or UW Belzer or another standard preservation solution, a disclosed organ, portion of a donor organ, donor tissue, connective tissue, or population of cells can be transitioned to PlasmaLyte or an analogous physiologically compatible saline substitute. In an aspect, PlasmaLyte or an analogous physiologically compatible saline substitute can be used to remove preservation solution components and / or endogenous amine-containing species. In an aspect, PlasmaLyte or an analogous physiologically compatible saline substitute can be used prior to chemical modification. In an aspect, PlasmaLyte or an analogous physiologically compatible saline substitute can be used prior to STEALTH modification. In an aspect, PlasmaLyte or an analogous physiologically compatible saline substitute can be used prior to installing the disclosed azide tethers or the disclosed azide handles. In an aspect, PlasmaLyte or an analogous physiologically compatible saline substitute can be used prior to functionalizing the donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells ex vivo. In an aspect, PlasmaLyte or an analogous physiologically compatible saline substitute can be delivered by gravity perfusion on ice.

[0321] In an aspect, upon procurement, a disclosed donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells can be flushed with a UW Belzer solution or another standard preservation solution and transferred to cold preservation for STEALTH modification. In an aspect, upon procurement, a disclosed donor kidney can be flushed with a UW Belzer solution or another standard preservation solution transferred to cold preservation for STEALTH modification.

[0322] As known to the skilled person, Belzer UW solution is a sterile non-pyrogenic solution and comprises Pentafraction (50 g / L); Lactobionic Acid (as Lactone) (35.83 g / L); Potassium Phosphate monobasic (3.4 g / L); Magnesium Sulfate heptahydrate (1.23 g / L); Raffinose pentahydrate (17.83 g / L); Adenosine (1.34 g / L); Allopurinol (0.136 g / L); Total Glutathione (0.922 g / L); Potassium Hydroxide (5.61 g / L); Sodium Hydroxide, 5N (5.0 mL / L); and Water for Injection (q.s.); and with an osmolarity of approximately 320 mOsm; a sodium concentration of approximately 29 mEq / L; a potassium concentration of approximately 125 mEq / L; and a pH of approximately 7.4 at 20 °C.

[0323] In an aspect, another standard preservation solution can be any solution known to the art and used to preserve an organ, portion of a donor organ, donor tissue, connective tissue, or population of cells following procurement from a donor. In an aspect, another standard preservation solution can be one that is commonly used for cold storage (e.g., Celsior Solution, Euro-Collins Solution, Institut Georges Lopez-1 (IGL-1) Solution, Perfadex Solution, Stanford Solution, Collins Solution, SPS-1 (Static Preservation Solution-!), KPS-1 (Kidney Preservation Solution-1), ET-Kyoto Solution, Servator B, Servator H, Servator C, Servator P, Sevartor M, SCOT Solution (Solution de Conservation des Organes et des Tissus), Polysol Solution, Biolasol Solution, Lifor Solution, Unisol Solution, Custodiol-N Solution, Somah Solution, etc.).

[0324] In an aspect, other standard preservation solution can comprise histidine-tryptophan-ketoglutarate solution (HTK).

[0325] In an aspect, another standard preservation solution can comprise CoStorSol (University of Wisconsin). In an aspect, CoStorSol can comprise Pentafraction (50 g / L); Lactobionic Acid (as Lactone) 935.83 g / L); Potassium Phosphate monobasic (3.4 g / L);Magnesium Sulfate heptahydrate (1.23 g / L); Raffinose pentahydrate (17.83 g / L); Adenosine (1.34 g / L); Allopurinol (0.136 g / L); Total Glutathione (0.922 g / L); Potassium Hydroxide (5.61 g / L); Sodium Hydroxide / Hydrochloric Acid (Adjust to pH 7.4); Water for Injection (q.s.).

[0326] In an aspect, another standard preservation solution can comprise Celsior (manufactured by IGL). In an aspect, Celsior can comprise Glutathione (0.921 g (3 mmol)); Mannitol : 10.930 g (60 mmol)); Lactobionic acid : 28.664 g (80 mmol)); Glutamic acid : 2.942 g (20 mmol)); Sodium hydroxide : 4.000 g (100 mmol)); Calcium chloride dihydrate : 0.037 g (0.25 mmol)); Potassium chloride : 1.118 g (15 mmol)); Magnesium chloride hexahydrate (2.642 g (13 mmol)); Histidine (4.650 g (30 mmol)); Water for injection; and Sodium hydroxide (4% (pH adjustment)).

[0327] In an aspect, another standard preservation solution can comprise SPS-1. In an aspect, SPS-1 can comprise Hydroxyethyl Starch (HES) (50 g); Lactobionic Acid (as Lactone) (35.83 g); Potassium Phosphate monobasic (3.4 g); Magnesium Sulfate heptahydrate (1.23 g); Raffinose Pentahydrate (17.83 g); Adenosine (1.34 g); Allopurinol (0.136 g); Glutathione (reduced form) (0.922 g); and Potassium Hydroxide (5.61 g).

[0328] In an aspect, another standard preservation solution can comprise KPS-1. In an aspect, KPS-1 can comprise Calcium chloride (dihydrate) (0.068 g); Sodium hydroxide (0.70 g); HEPES (free acid) (2.38 g); Potassium phosphate (monobasic) (3.4 g); Mannitol (USP) (5.4 g); Glucose, beta D (+) (1.80 g); Sodium gluconate (17.45 g); Magnesium gluconate D (-) gluconic acid, hemimagnesium salt (1.13 g); Ribose, D (-) (0.75 g); Hydroxyethyl Starch (HES) (50.0 g); Glutathione (reduced form) (0.92 g); Adenine (free base) (0.68 g).

[0329] In an aspect, another standard preservation solution can comprise Servator B. In an aspect, Servator B can comprise Pentafraction (50 g / L); Lactobionic Acid (as Lactone) (35.83 g / L); Potassium Phosphate monobasic (3.4 g / L); Magnesium Sulfate heptahydrate (1.23 g / L); Raffinose pentahydrate (17.83 g / L); Adenosine (1.34 g / L); Allopurinol (0.136 g / L); Total Glutathione (0.922 g / L); Potassium Hydroxide (5.61 g / L); and Sodium Hydroxide / Hydrochloric Acid (adjust to pH 7.4). In an aspect, another standard preservation solution can comprise Servator H. In an aspect, Servator H can comprise Sodium Chloride (0.8766 g / L); Potassium Chloride (0.6710 g / L); Magnesium Chloride (0.8132 g / L); Histidine Hydrochloride (3.7733 g / L); Histidine Tryptophan (27.9289 g / L); Mannitol (5.4651 g / L); Calcium Chloride (0.0022 g / L); and Potassium Hydrogen 2-oxopentandioate (0.1842 g / L). In an aspect, another standard preservation solution can comprise Servator C. In an aspect, Servator C can comprise Glutathione (0.922 g / L); Mannitol (10.931 g / L); Lactobionic acid (28.660 g / L); Glutamic acid (2.943 g / L); Sodium hydroxide (4.000 g / L); Calcium chloride (0.037 g / L); Potassium chloride (1.12 g / L); Magnesium chloride (2.645 g / L); Histidine (4.655 g / L); and Water for injection (q.s. to 1000 mL). In an aspect, another standard preservation solution can comprise Servator P. In an aspect, Servator P can comprise Dextran 40 (50 g / L); Glucose Monohydrate (1 g / L); Potassium Chloride (0.4 g / L); Sodium Chloride (8 g / L); Potassium Phosphate monobasic (0.063 g / L); Sodium phosphate dibasic dehydrate or Disodium phosphate (0.0576 g / L); Magnesium Sulphate Heptahydrate or Magnesium Sulphate (0.201 g / L); and Water for injection (q.s. to 1000 ml). In an aspect, another standard preservation solution can comprise Servator M. In an aspect, Servator M can comprise Adenine (free base) (0.68 g / L); Calcium Chloride dihydrate (0.068 g / L); Dextrose (1.80 g / L); Glutathione (reduced) (0.92 g / L); HEPES (free acid) (2.38 g / L); Hydroxy ethyl Starch (50.0 g / L); Magnesium Gluconate (anhydrous) (1.13 g / L); Mannitol (5.4 g / L); Potassium Phosphate (monobasic) (3.4 g / L); Ribose, D-(-) (0.75 g / L); Sodium Gluconate (17.45 g / L); Sodium Hydroxide (0.70 g / L); and Water for injection (q.s. to 1000 mL).

[0330] In an aspect, a disclosed flushing with a UW Belzer solution or another standard preservation solution can be continued for at least 5 minutes, at least 6 minutes, at least 7 minutes, at least 8 minutes, at least 9 minutes, at least 10 minutes, at least 11 minutes, at least 12 minutes, at least 13 minutes, at least 14 minutes, at least 15 minutes, at least 16 minutes, at least 17 minutes, at least 19 minutes, at least 19 minutes, at least 20 minutes, at least 25 minutes, at least 30 minutes, at least 35 minutes, at least 40 minutes, at least 45 minutes, at least 50 minutes, at least 55 minutes, at least 60 minutes, or more than 60 minutes. In an aspect, a disclosed flushing with a UW Belzer solution or another standard preservation solution can be continued for at least 5 minutes to atleast 30 minutes. In an aspect, a disclosed flushing with a UW Belzer solution or another standard preservation solution can be continued for at least 15 minutes to at least 30 minutes.

[0331] In an aspect, a disclosed flushing with a UW Belzer solution or another standard preservation solution can comprise at least 20 mL, at least 30 mL, at least 40 mL, at least 50 mL, at least 60 mL. at least 70 mL. at least 80 mL. at least 90 mL, at least 100 mL, at least 110 mL, at least 120 mL, at least 130 mL. at least 140 mL, at least 150 mL, at least 160 mL. at least 170 mL, at least 180 mL, at least 190 mL, at least 200 mL, at least 210 mL, at least 220 mL, at least 240 mL, at least 250 mL, at least 260 mL, at least 270 mL, at least 280 mL, at least 290 mL, at least 300 mL, at least 310 mL, at least 320 mL, at least 330 mL, at least 340 mL, at least 350 mL, at least 360 mL, at least 370 mL. at least 380 mL, at least 390 mL, at least 400 mL, at least 410 mL, at least 420 mL, at least 430 mL, at least 440 mL, at least 450 mL, at least 460 mL, at least 470 mL, at least 480 mL, at least 490 mL, at least 500 mL, or more than 500 mL. In an aspect, a disclosed flushing can comprise at least 0.1 L, at least 0.2 L, at least 0.3 L, at least 0.4 L, at least 0.5 L, at least 0.6 L, at least 0.7 L, at least 0.8 L, at least 0.9 L, at least 1.0 L, or more than 1.0 L. In an aspect, a disclosed flushing with a UW Belzer solution or another standard preservation solution can comprise about 200 mL to about 500 mL.

[0332] In an aspect, the volume and / or the duration of a flushing with a UW Belzer solution or another standard preservation solution can be modified in view of one or more considerations (including, for example, vascular resistance, flow rate, perfusion pump v. gravity perfusion, etc.) or any combination thereof.

[0333] In an aspect, a disclosed method can comprise (i) flushing the donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells with a first solution; (ii) removing the first solution by flushing a second solution; (iii) infusing the donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells with the azide solution or solution comprising azide tethers or azide handles; and (iv) flushing the donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells with another solution (e.g., the second solution) to remove the unreacted azide solution.

[0334] In an aspect, a disclosed method can comprise (i) flushing the donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells with a UW Belzer solution or another standard preservation solution; (ii) removing the UW Belzer solution or the other standard preservation solution by flushing a PlasmaLyte or an analogous physiologically compatible saline substitute; (iii) infusing the donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells with the azide solution or solution comprising azide tethers or azide handles; and (iv) flushing the donor organ, portion of a donor organ, donor tissue, connective tissue, orpopulation of cells with PlasmaLyte or an analogous physiologically compatible saline substitute to remove the unreacted azide solution.

[0335] In an aspect, upon procurement, a disclosed procured organ, portion of a donor organ, donor tissue, connective tissue, or population of cells can be flushed with cold phosphate buffered saline (PBS) or a UW Belzer solution or another standard preservation solution. In an aspect, a disclosed PBS-flushed or a disclosed UW Belzer solution-flushed or another standard preservation solution-flushed organ, portion of a donor organ, donor tissue, connective tissue, or population of cells can be injected with a solution comprising a disclosed azide handle or a disclosed azide tether. In an aspect, a disclosed PBS-flushed or a disclosed UW Belzer solution-flushed or another standard preservation solution-flushed organ, portion of a donor organ, donor tissue, connective tissue, or population of cells can be injected with a solution comprising NHS-azide. In an aspect, a disclosed PBS-flushed or a disclosed UW Belzer solution-flushed or another standard preservation solution-flushed organ, portion of a donor organ, donor tissue, connective tissue, or population of cells can be injected with a solution comprising NHS-PEG4-azide. In an aspect, a disclosed PBS-flushed or a disclosed U W Belzer solution-flushed or another standard preservation solution-flushed organ, portion of a donor organ, donor tissue, connective tissue, or population of cells can be injected with a solution comprising NHS-azide tethers or handles. In an aspect, a disclosed PBS-flushed or a disclosed UW Belzer solution-flushed or another standard preservation solution-flushed organ, portion of a donor organ, donor tissue, connective tissue, or population of cells can be injected with a solution comprising NHS-PEG4-azide tethers or handles.

[0336] In an aspect, a disclosed PBS-flushed or a disclosed UW Belzer solution-flushed organ, portion of a donor organ, donor tissue, connective tissue, or population of cells can be injected with a solution comprising a disclosed azide handle or a disclosed azide tether via an artery. In an aspect, a disclosed PBS-flushed or a disclosed UW Belzer solution-flushed or another standard preservation solution-flushed organ, portion of a donor organ, donor tissue, connective tissue, or population of cells can be injected with a solution comprising NHS-PEG4-azide an artery. In an aspect, a disclosed solution comprising a disclosed azide handle or a disclosed azide tether can comprise a PBS solution or a UW Belzer solution or another standard preservation solution.

[0337] As known to the skilled person, PlasmaLyte or an analogous physiologically compatible saline substitute comprises sodium chloride (5.26 g / L), potassium chloride (0.37 g / L), magnesium chloride hexahydrate (0.30 g / L), sodium acetate trihydrate (3.68 g / L), sodium gluconate (5.02 g / L) as well as water for injections and sodium hydroxide.

[0338] In an aspect, upon procurement, a disclosed procured kidney can be transferred to cold preservation for STEALTH modification. In an aspect, a disclosed procured kidney can be flushedwith cold phosphate buffered saline (PBS) or a disclosed UW Belzer solution or another standard preservation solution. In an aspect, a disclosed PBS-flushed or a disclosed UW Belzer solutionflushed or another standard preservation solution-flushed kidney can be injected with a solution comprising a disclosed azide handle or a disclosed azide tether. In an aspect, a disclosed PBS-flushed or a disclosed UW Belzer solution-flushed or another standard preservation solution-flushed kidney can be injected with a solution comprising NHS-azide. In an aspect, a disclosed PBS-flushed or a disclosed UW Belzer solution-flushed or another standard preservation solutionflushed kidney can be injected with a solution comprising NHS-PEG4-azide. In an aspect, a disclosed PBS-flushed or a disclosed UW Belzer solution-flushed or another standard preservation solution-flushed kidney can be injected with a solution comprising NHS-azide tethers or handles. In an aspect, a disclosed PBS-flushed or a disclosed UW Belzer solution-flushed or another standard preservation solution-flushed kidney can be injected with a solution comprising NHS-PEG4-azide tethers or handles.

[0339] In an aspect, a disclosed PBS-flushed or a disclosed UW Belzer solution-flushed or another standard preservation solution-flushed kidney can be injected with a solution comprising a disclosed azide handle or a disclosed azide tether via the renal artery. In an aspect, a disclosed PBS-flushed or a disclosed UW Belzer solution-flushed or another standard preservation solution-flushed kidney can be injected with a solution comprising NHS-PEGi-azide via the renal artery. In an aspect, a disclosed solution comprising a disclosed azide handle or a disclosed azide tether can comprise a PBS solution or a disclosed UW Belzer solution or another disclsoed standard preservation solution.

[0340] In an aspect of a disclosed method, a disclosed solution can be introduced in a donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells via an artery’. In an aspect of a disclosed method, a disclosed solution can be introduced in a donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells via an artery while one or more veins in the donor organ are clamped or occluded. In an aspect of a disclosed method, the clamping or occlusion of the veins in the organ donor, portion of a donor organ, donor tissue, connective tissue, or population of cells can facilitate the interaction between the tethers or handles and the cells and / or tissues of the organ donor. In an aspect of a disclosed method, the interaction between the NHS esters and accessible primary' amines of proteins in the cells and / or tissue can be facilitated.

[0341] In an aspect of a disclosed method, a disclosed solution can be introduced in a donor kidney via the renal artery. In an aspect of a disclosed method, a disclosed solution can be introduced in a donor kidney via the renal artery while renal vein in the donor kidney is clamped or occluded.In an aspect of a disclosed method, the clamping or occlusion of the renal vein in the donor kidney can facilitate the interaction between the tethers or handles and the cells and / or tissues of the donor kidney. In an aspect of a disclosed method, the interaction between the NHS esters and accessible primary amines of proteins in kidney cells and / or kidney tissue can be facilitated.

[0342] In an aspect of a disclosed method, perfusion of a disclosed donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells can be performed using gravity-driven flow. In an aspect of a disclosed method, perfusion of a disclosed donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells can be performed using a pump or a perfusion pump.

[0343] In an aspect of a disclosed method, following the injection of a disclosed azide solution, the donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells can be stored and / or incubated on ice for at least 5 minutes, at least 6 minutes, at least 7 minutes, at least 8 minutes, at least 9 minutes, at least 10 minutes, at least 11 minutes, at least 12 minutes, at least 13 minutes, at least 14 minutes, at least 15 minutes, at least 16 minutes, at least 17 minutes, at least 19 minutes, at least 19 minutes, at least 20 minutes, at least 25 minutes, at least 30 minutes, at least 35 minutes, at least 40 minutes, at least 45 minutes, at least 50 minutes, at least 55 minutes, at least 60 minutes, or more than 60 minutes. In an aspect of a disclosed method, following the injection of a disclosed azide solution, the donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells can be stored and / or incubated on ice for at least 1 hour, at least 1.5 hours, at least 2 hours, at least 2.5 hours, at least 3 hours, at least 3.5 hours, at least 4 hours, at least 4.5 hours, or at least 5 hours.

[0344] In an aspect of a disclosed method, following the injection of a disclosed azide solution, the donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells can be stored and / or incubated on ice for between 10 minutes and 20 minutes pnor to a flush to remove the unreacted azide. In an aspect of a disclosed method, following the injection of a disclosed azide solution, the donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells can be stored and / or incubated on ice for between 30 min and 60 min prior to a flush to remove the unreacted azide.

[0345] In an aspect, the volume of a disclosed azide solution delivered to a disclosed donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells can comprise at least 5 rnL, at least 10 mL, at least 15 rnL, at least 20 mL, at least 25 rnL, at least 30 mL, at least 35 mL, at least 40 mL, at least 45 mL, at least 50 mL, at least 55 mL, at least 60 mL, at least 65 mL, at least 70 rnL, at least 75 mL, at least 80 mL, at least 85 mL, at least 90 mL, at least 95 mL, at least 100 mL, or more than at least 100 mL. In an aspect, the volume of a disclosed azidesolution delivered to a disclosed donor kidney can comprise at least 5 mL, at least 10 mL, at least 15 mL, at least 20 mL, at least 25 mL, at least 30 mL, at least 35 mL, at least 40 mL, at least 45 mL, at least 50 mL, at least 55 mL, at least 60 mL, at least 65 mL, at least 70 mL, at least 75 mL, at least 80 mL, at least 85 mL, at least 90 mL, at least 95 mL, at least 100 mL, or more than at least 100 mL.

[0346] In an aspect, a disclosed solution can comprise at least 50 pM azide, at least 60 pM azide, at least 70 pM azide, at least 80 pM azide, at least 90 pM azide, at least 100 pM azide, at least 110 pM azide, at least 120 pM azide, at least 130 pM azide, at least 140 pM azide, at least 150 pM azide, at least 160 pM azide, at least 170 pM azide, at least 180 pM azide, at least 190 pM azide, at least 200 pM azide, at least 210 pM azide, at least 220 pM azide, at least 230 pM azide, at least 240 pM azide, at least 250 pM azide, at least 260 pM azide, at least 270 pM azide, at least 280 pM azide, at least 290 pM azide, at least 300 pM azide, at least 310 pM azide, at least 320 pM azide, at least 330 pM azide, at least 340 pM azide, at least 350 pM azide, at least 360 pM azide, at least 370 pM azide, at least 380 pM azide, at least 390 pM azide, at least 400 pM azide, at least 410 pM azide, at least 420 pM azide, at least 430 pM azide, at least 440 pM azide, at least 450 pM azide, at least 460 pM azide, at least 470 pM azide, at least 480 pM azide, at least 490 pM azide, at least 500 pM azide, or more than 500 pM azide.

[0347] In an aspect, after being stored and / or incubated, a disclosed functionalized donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells can be flushed one or more times with PBS or PlasmaLyte or an analogous physiologically compatible saline substitute prior to the introduction and immobilization of one or more immunomodulatory ligands.

[0348] In an aspect of a disclosed method, after being stored and / or incubated, unreacted reagent can be removed with one or more PBS flushes or one or more or PlasmaLyte or an analogous physiologically compatible saline substitute flushes prior to the introduction and immobilization of one or more immunomodulatory ligands. In an aspect, after being stored and / or incubated, a disclosed donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells can be flushed one or more times with PlasmaLyte or an analogous physiologically compatible saline substitute prior to the introduction and immobilization of one or more immunomodulatory ligands. In an aspect of a disclosed method, after being stored and / or incubated, unreacted reagent can be removed with one or more PlasmaLyte or an analogous physiologically compatible saline substitute flushes prior to the introduction and immobilization of one or more immunomodulatory ligands. In an aspect, after being stored and / or incubated, a disclosed functionalized donor kidney can be flushed one or more times with PBS prior to the introduction and immobilization of one or more immunomodulatory ligands. In an aspect of adisclosed method, after being stored and / or incubated, unreacted reagent can be removed with one or more PBS flushes prior to the introduction and immobilization of one or more immunomodulatory ligands. In an aspect, after being stored and / or incubated, a disclosed functionalized donor kidney can be flushed one or more times with PlasmaLyte or an analogous physiologically compatible saline substitute prior to the introduction and immobilization of one or more immunomodulatory ligands. In an aspect of a disclosed method, after being stored and / or incubated, unreacted reagent can be removed with one or more PlasmaLyte or an analogous physiologically compatible saline substitute flushes prior to the introduction and immobilization of one or more immunomodulatory ligands.

[0349] In an aspect, after being stored and / or incubated, a disclosed functionalized donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells can be flushed one or more times with an appropriate solution prior to the introduction and immobilization of one or more immunomodulatory ligands. In an aspect of a disclosed method, after being stored and / or incubated, unreacted reagent can be removed from the functionalized donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells with one or more flushes with an appropriate solution prior to the introduction and immobilization of one or more immunomodulatory ligands. In an aspect, after being stored and / or incubated, a disclosed functionalized kidney organ can be flushed one or more times with an appropriate solution prior to the introduction and immobilization of one or more immunomodulatory ligands. In an aspect of a disclosed method, after being stored and / or incubated, unreacted reagent can be removed from the functionalized donor kidney with one or more flushes with an appropriate solution prior to the introduction and immobilization of one or more immunomodulatory ligands.

[0350] In an aspect, a concentration of one or more disclosed immunomodulatory ligands can comprise about 0.1 pg per organ to about 10 mg per organ, about 0.1 pg per organ to about 1 mg per organ, about 1 pg per organ to about 5 mg per organ, about 5 pg per organ to about 1 mg per organ, or about 1.0 mg per organ to about 10 mg per organ. In an aspect, a concentration of one or more disclosed immunomodulatory ligands can comprise about 1.0 mg per organ, about 2.0 mg per organ, about 3.0 mg per organ, about 4.0 mg per organ, about 5.0 mg per organ, about 6.0 mg per organ, about 7.0 mg per organ, about 8.0 mg per organ, about 9.0 mg, or about 10 mg per organ. In an aspect, a concentration of one or more disclosed immunomodulatory ligands can be defined and / or determined relative to tissue mass, surface area, or perfusion volume of a disclosed donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells.

[0351] In an aspect, a disclosed handle or a disclosed tether having an immobilized immunomodulatory ligand can withstand cold storage ex vivo, reperfusion on implantation, postimplantation vascular shear stress, early immune remodeling, or any combination thereof.

[0352] In an aspect, a disclosed handle or a disclosed tether having an immobilized immunomodulatory ligand can support durable post-transplant therapeutic capture. In an aspect, one or more steps of a disclosed method can be conducted and / or performed under sterile conditions using clinically relevant preservation solutions. In an aspect, a disclosed donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells can be maintained under static cold storage unless otherwise specified.

[0353] In an aspect, a disclosed donor kidney can be maintained under static cold storage unless otherwise specified. In an aspect, a disclosed method can minimize supraphysiologic stress and / or can preserve kidney tissue integrity. In an aspect of a disclosed method, perfusion and / or flushing of a disclosed donor kidney can be performed using gravity-driven flow. In an aspect of a disclosed method, perfusion and / or flushing of a disclosed donor kidney can be performed using a pump or a perfusion pump. In an aspect, a disclosed perfusion can achieve uniform delivery throughout a disclosed donor organ, portion of a donor organ, donor tissue, connective tissue, or population of cells. In an aspect, a disclosed perfusion can achieve uniform delivery throughout distal cortical cells of a disclosed donor kidney.

[0354] In an aspect, a disclosed flushing can be continued for a pre-determined time. In an aspect, a disclosed flushing with a disclosed solution can be continued for at least 5 minutes, at least 6 minutes, at least 7 minutes, at least 8 minutes, at least 9 minutes, at least 10 minutes, at least 11 minutes, at least 12 minutes, at least 13 minutes, at least 14 minutes, at least 15 minutes, at least 16 minutes, at least 17 minutes, at least 19 minutes, at least 19 minutes, at least 20 minutes, at least 25 minutes, at least 30 minutes, at least 35 minutes, at least 40 minutes, at least 45 minutes, at least 50 minutes, at least 55 minutes, at least 60 minutes, or more than 60 minutes.

[0355] In an aspect, a disclosed flushing with a disclosed solution can comprise at least 20 mL, at least 30 mL, at least 40 mL, at least 50 mL, at least 60 mL, at least 70 mL, at least 80 mL, at least 90 mL, at least 100 mL, at least 110 mL. at least 120 mL, at least 130 mL. at least 140 mL, at least 150 mL, at least 160 mL, at least 170 mL, at least 180 mL, at least 190 mL, at least 200 mL, at least 210 mL, at least 220 mL, at least 240 mL, at least 250 mL, at least 260 mL, at least 270 mL, at least 280 mL, at least 290 mL, at least 300 mL, at least 310 mL, at least 320 mL, at least 330 mL, at least 340 mL, at least 350 mL. at least 360 mL, at least 370 mL, at least 380 mL, at least 390 mL, at least 400 mL, at least 410 mL, at least 420 mL, at least 430 mL, at least 440 mL, at least 450 mL, at least 460 mL, at least 470 mL, at least 480 mL, at least 490 mL, at least 500 mL,or more than 500 mL. In an aspect a disclosed flushing can comprise at least 0.1 L, at least 0.2 L, at least 0.3 L, at least 0.4 L, at least 0.5 L, at least 0.6 L, at least 0.7 L, at least 0.8 L, at least 0.9 L, at least 1.0 L, or more than 1.0 L. In an aspect, a disclosed flushing can comprise about 200 mL to about 500 mL.

[0356] In an aspect, a disclosed PlasmaLyte flushing or flushing with an analogous physiologically compatible saline substitute can be continued for at least 5 minutes, at least 6 minutes, at least 7 minutes, at least 8 minutes, at least 9 minutes, at least 10 minutes, at least 1 1 minutes, at least 12 minutes, at least 13 minutes, at least 14 minutes, at least 15 minutes, at least 16 minutes, at least 17 minutes, at least 19 minutes, at least 19 minutes, at least 20 minutes, at least 25 minutes, at least 30 minutes, at least 35 minutes, at least 40 minutes, at least 45 minutes, at least 50 minutes, at least 55 minutes, at least 60 minutes, or more than 60 minutes.

[0357] In an aspect, a disclosed PlasmaLyte flushing or flushing with an analogous physiologically compatible saline substitute can comprise at least 20 mL, at least 30 mL, at least 40 mL, at least 50 mL, at least 60 mL, at least 70 mL, at least 80 mL, at least 90 mL, at least 100 mL, at least 110 mL, at least 120 mL. at least 130 mL, at least 140 mL, at least 150 mL, at least 160 mL, at least 170 mL, at least 180 mL, at least 190 mL, at least 200 mL, at least 210 mL, at least 220 mL, at least 240 mL, at least 250 mL, at least 260 mL, at least 270 mL, at least 280 mL, at least 290 mL, at least 300 mL, at least 310 mL, at least 320 mL, at least 330 mL, at least 340 mL, at least 350 mL, at least 360 mL. at least 370 mL. at least 380 mL, at least 390 mL, at least 400 mL, at least 410 mL, at least 420 mL, at least 430 mL, at least 440 mL, at least 450 mL, at least 460 mL, at least 470 mL, at least 480 mL, at least 490 mL, at least 500 mL, or more than 500 mL. In an aspect, a disclosed PlasmaLyte flushing or flushing with an analogous physiologically compatible saline ...

Claims

VII. CLAIMSWhat is claimed is:

1. A method of preparing donor biological tissue for transplantation, the method comprising: functionalizing procured donor biological tissue ex vivo by installing reactive groups on a surface of the tissue,wherein the reactive groups are configured to covalently bind a complementary reactive group associated with a therapeutic payload or an immunomodulatory ligand.

2. The method of Claim 1, wherein the donor biological tissue comprises an organ or a portion of an organ.

3. The method of Claim 1, wherein the donor biological tissue comprises a population of cells.

4. The method of Claim 3, wherein the population of cells comprises endothelial cells.

5. The method of Claim 1, wherein the donor biological tissue comprises a connective tissue.

6. The method of Claim 1, wherein the reactive groups comprise azide tethers or azide handles.

7. The method of Claim 1, wherein installing the reactive groups comprises flushing the donor biological tissue with a preservation solution; flushing the donor biological tissue with an amine-depleting solution; introducing an azide-containing linker; and removing unreacted linker.

8. The method of Claim 7. wherein the preservation solution comprises Belzer University of Wisconsin (UW) solution or another standard preservation solution.

9. The method of Claim 7, wherein the amine-depleting solution comprises PlasmaLyte or an analogous physiologically compatible saline substitute.

10. The method of Claim 7, wherein the introducing step comprises perfusion via gravity -driven flow.

11. The method of Claim 10, wherein the gravity-driven flow achieves physiologic arterial pressure.

12. The method of Claim 1, further comprising immobilizing an immunomodulatory ligand on the donor biological tissue.

13. The method of Claim 12, wherein the immunomodulatory ligand comprises PD-L1 or CTLA- 4.

14. The method of Claim 12 or Claim 13, wherein the immunomodulatory ligand is covalently attached to the azide tethers or azide handles via bioorthogonal chemistry.

15. The method of any one of Claims 12 - 13, further comprising implanting into a recipient the functionalized donor biological tissue.

16. The method of Claim 15, wherein following transplantation the functionalized donor biological tissue exhibits localized immunomodulatory activity.

17. The method of Claim 16, wherein the localized immunomodulatory activity comprises attenuation of T cell activation, reduction of inflammatory signaling, promotion of regulatory T cell activity, or any combination thereof.

18. The method of Claim 1. wherein following transplantation the reactive groups persist on the donor biological tissue following transplantation.

19. The method of Claim 1, wherein the reactive groups on the donor biological tissue enable repeated covalent capture of subsequently administered therapeutic payloads comprising a complementary reactive group.

20. The method of Claim 18, further comprising administering to the recipient a therapeutic payload comprising a complementary reactive group.

21. The method of Claim 20, wherein the complementary reactive group comprises a cyclooctyne group.

22. The method of Claim 21, wherein the cyclooctyne group comprises DBCO, DIBO, BCN, or ODIBO23. The method of Claim 20, wherein administering the therapeutic payload comprises systemic administration.

24. The method of Claim 23, wherein following systemic administration, the therapeutic payload selectively accumulates at the donor biological tissue.

25. The method of any preceding claim, further comprising treating the recipient with an immunosuppressive regimen.

26. The method of Claim 25, wherein the immunosuppressive regimen comprises cyclosporine, tacrolimus, methotrexate, mycophenolate mofetil, cyclosporine, or any combination thereof.

27. The method of Claim 1, further comprising procuring an organ from a donor.

28. The method of Claim 27, wherein the donor has been declared brain dead or has experienced cardiac death.

29. The method of Claim 27, wherein procuring a disclosed donor organ and functionalizing a procured donor organ are performed in a singular location.

30. The method of Claim 27, wherein procuring a disclosed donor organ and functionalizing a procured donor organ are performed in different locations.